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ABSTRACT     
Organisms across Archaea, Bacteria and Eukarya possess a series of mechanisms to 
protect the integrity of the deoxyribonucleic acid (DNA) from the constant attack of 
internal and external factors that modify the structure of the double helix, potentially 
causing an increase in mutagenesis. The Nucleotide Excision Repair (NER) pathway 
removes bulky lesions in the DNA caused by ultraviolet (UV) radiation and other sources 
that can introduce a strong distortion in the double helix. A key element in this repair 
mechanism is the transcription factor IIH (TFIIH), a ten-subunit complex which opens 
and extends the DNA bubble originated at the damaged site to allow the subsequent 
repair factors access to the lesion, so the insult can be removed. Mutations in TFIIH 
subunits xeroderma pigmentosum group B (XPB), xeroderma pigmentosum group D 
(XPD) or p8 can cause a series of autosomal recessive disorders with symptoms that 
include mild-to-extreme photosensitivity, progeria, physical and neurological 
abnormalities, and in some cases an increased susceptibility to cancer.  
 
This thesis describes the processes of cloning, expression and purification followed to 
obtain damage-detector heterodimer XPC-HR23B, the 7-subunit TFIIH Core sub-
complex and the 10-subunit TFIIH complex by means of a powerful baculoviral 
expression vector (BEV) called MultiBacTM, a tool specifically conceived for the obtaining 
of multi-subunit eukaryotic complexes. The biochemical characterization of TFIIH Core 
showed that the sub-complex can bind a series of double-stranded DNA (dsDNA) 
substrates with an affinity in the nM range, and the presence of a bubble or damage at 
the duplex does not change TFIIH Core’s binding affinity significantly. The study of TFIIH 
Core’s unwinding ability confirmed that the sub-complex can open a series of dsDNA 
substrates only when a 5’ overhang end is available, and this activity can be stalled by a 
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1. Introduction  
1.1. DNA damage and repair pathways 
The integrity of the deoxyribonucleic acid (DNA) is constantly threatened by internal and 
external factors (e.g. metabolic products, ultraviolet (UV) radiation), with a human cell 
typically suffering more than 105 lesions in a single day (Tomkinson et al., 2006). These 
distortions introduced in the double helix can potentially lead to an increase in 
mutagenesis, which in turn may result in a higher risk of cancer. As damaged DNA 
cannot be replaced, cells depend on different repair systems to maintain its integrity.  
 
DNA repair mechanisms (figure 1) can be classified into three different groups: (1) direct 
repair, (2) recombinational repair and (3) excision repair, with each one including many 
sub-classes, although some overlapping between mechanisms frequently occurs (Eisen 




Figure 1: DNA repair pathways.  
Summary of the most frequent lesions encountered in the DNA and the different types of repair 
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Figure 1. Schematic of DNA damage causes, consequences and repair pathways. Further details are found in the main text.
by the Ishino lab (Ishino et al. 2016). This advance, described in
detail below, has the potential to answer one of the major out-
standing questions of the archaeal DNA repair field.
This is a field in transition. Much of the early work on DNA
replication and repair in the archaea arose from a desire to
study simpler model systems of eukaryal (ultimately, human)
processes. This approach led to many notable successes. How-
ever, as the need formodel systems has faded, there is a growing
realisation that the archaea are not a niche player in the bio-
sphere but rather a major, significant component that deserves
study in their own right. Their cellular and molecular biology is
often distinct from those of the bacteria and eukarya, and this
is certainly true for their DNA repair pathways.
DNA repair and the origin of the eukarya
Although still not universally agreed, the recent discovery of new
archaeal lineages known collectively as the ‘ASGARD’ archaea,
which includes the species Lokiarchaeota and Thorarchaeota, has
caused a reassessment of the relationship between the archaeal
and eukaryal domains (reviewed in Eme et al. 2017). The large
number of gene families previously thought to be specific to the
eukarya that are found in ASGARD genomes has led to the sug-
gestion that Eukarya arose from an archaeal species related to
the ASGARD archaea. Other experts however disagree with this
interpretation of the data (Da Cunha et al. 2017). What can the
distribution of DNA repair genes across the archaea add to this
hot topic (Fig. 2)? If we take the example of the XPF nuclease,
it comes in two ‘flavours’ in archaea. The short version con-
sists only of a nuclease domain, which interacts with PCNA, and
is found only in the TACK superphylum (Rouillon and White
2011). The long version has a nuclease fused to a helicase do-
main matching eukaryal XPF. This is present predominantly in
the Euryarchaea, but also in the ASGARD archaea. Similarly, a
eukaryal-type replication proteinA (RPA, a single-strandedDNA-
binding protein) is present in most archaea with the exception
of the Crenarchaea and Thermoplasma, which have a short ver-
sion (Rouillon and White 2011). Focussing on the two examples
of ASGARD archaea in Fig. 2, it is apparent that Lokiarchaea
and Thorarchaea have the complement of eukaryal-type repair
proteins one would expect for an ancestor of the eukarya. This
includes copies of the bacterial-type MMR proteins MutS and
MutL, which are also present throughout the eukaryal lineage.
Intriguingly, the ASGARD archaea have also picked up the bac-
terial UvrABC NER system. Overall, the distribution pattern of
DNA repair genes in the arch ea, and the ASGARD lineage in
particular, is consistent with the hypothesis that the latter gave
rise to the eukaryal domain of life.
MISMATCH REPAIR
The canonical MutL-MutS pathway
MMR is the process by which bases incorporated in error by
the DNA replication machinery are detected and corrected. The
MutL-MutS MMR pathway first characterised in Escherichia coli is
present in most bacteria (with the notable exception of the Acti-
nobacteria) and in the eukarya, but is the exception rather than
the rule in the archaea (Kelman and White 2005). Most archaea
lack plausible MutS and MutL homologues, and those that have
them tend to be temperaturemesophiles such as halophiles and
methanogens that most likely captured these genes by lateral
gene transfer from bacteria (Fig. 2). The mode of inheritance of
a bacterial-type MMR pathway from bacteria to the eukarya is a
matter of conjecture. One possibility is that endosymbiotic event
that led to the evolution of the mitochondrion from an Alpha-
proteobacterium allowed the bacterial genes forMMR to become
established in the early eukaryal genome. An alternative possi-
bility is that the eukarya inherited the bacterial MMRmachinery
via their archaeal lineage. It is notable that the ASGARD archaea
including Lokiarchaeum and Thorarchaeum, which have been
proposed as the most closely related extant archaea to the pro-
genitor of the eukarya (Eme et al. 2017), possess clear MutS and
MutL homologues.
The emerging role of EndoMS
The lack of canonical MMR in most archaea is not reflected in
highmutation rates (Grogan 2004), and deletion of MutS-MutL in
Halobacterium salinarum did not give rise to a hypermutation phe-
notype (Busch and DiRuggiero 2010). These observations sug-
gest that alternative pathways exist to detect and remove mis-
matches post DNA replication.
Downloaded from https://academic.oup.com/femsre/advance-article-abstract/doi/10.1093/femsre/fuy020/4993143
by University of Dundee user




The major pathways included in each group are briefly described below: 
 
• Direct repair:  
o Photoreactivation (PHR): PHR refers to the process of reversing the toxic 
effects of UV radiation (particularly cyclobutane pyrimidine dimers (CPDs) 
and 6–4 pyrimidine–pyrimidone photoproducts (6–4PPs)) in a reaction 
that depends on visible light and a flavin adenine dinucleotide (FAD) 
cofactor, performed by an enzyme called photolyase. Photolyases can be 
found in Bacteria, Archaea and Eukarya, although homologues 
presenting PHR activity have not been found in placental mammals 
(Weber, 2005). 
o DNA ligation: the joining of separated DNA strands is an essential, 
universal mechanism required in the replication, excision repair and 
recombination processes; additionally, a ligation reaction performed to fix 
a break in the DNA can be considered a form of direct repair. Several 
classes of adenosine triphosphate (ATP)- and nicotinamide adenine 
dinucleotide (NAD)-dependent ligases have been identified, frequently 
involved in repair mechanisms such as excision repair (ligases I and III) 
(Tomkinson et al., 2001) and recombinational repair (ligase IV) 
(Grawunder et al., 1998). 
o Alkylation reversal: alkylation of the DNA (both by external and internal 
factors) leads to lesions that can block replication, cause mutations and 
even cell death (Sedgwick, 2004). Although guanine bases are the most 
susceptible to damage by alkylating agents (Mishina et al., 2006), the N7-
methylguanine lesion is frequently removed spontaneously, leaving an 
abasic site that will be repaired through a different pathway (Wilson & 
Barsky, 2001). The vast majority of alkylation-induced lesions can be 
solved by one of three different enzymatic activities: O6-methylguanine-
DNA-methyltransferases like the E. coli protein Ada (Sedgwick et al., 
1988), with no homologues found in eukaryotes so far (Mishina et al., 
2006); methyladenil-DNA glycosylases like AlkA (Labahn et al., 1996); 
and the iron (II)-dependent dioxygenase AlkB (Trewick et al., 2002). 
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• Recombinational repair 
o Homologous recombination (HR): HR is the preferred pathway to repair 
double-strand breaks (DSBs) in Archaea, Bacteria, and Eukarya. Intra-
strand crosslinks and post-replication daughter strand gaps (DSGs) are 
also repaired by HR. The process comprises four steps: creation of a 3’ 
single-stranded DNA (ssDNA) substrate (checkpoint for the resolution of 
the DSB by HR or by non-homologous end-joining (NHEJ) (Kass & Jasin, 
2010) capable of invading an undamaged homologous duplex that can 
act as a template, repair synthesis, branch migration (Jasin & Rothstein, 
2013) and resolution of the Holliday junction by the combined action of 
helicases and structure-specific endonucleases (Mimitou & Symington, 
2009).  
o Non-homologous end-joining (NHEJ): NHEJ is mostly a eukaryotic 
pathway, with only one group of Archaea possessing all the factors 
required for a complete NHEJ complex (Bartlett et al., 2013). It is also 
present in some species of Bacteria, where the system is especially 
helpful at the stationary phase, when only one copy of the genome is 
available (Matthews & Simmons, 2014). Contrary to HR, NHEJ permits 
the repair of DSBs without a template strand, and so frequent deletion or 
addition of nucleotides can happen at the repaired site. Although this 
flexibility can seem undesired in a repair system, the benefit of NHEJ 
restoring chromosomal integrity far outweighs the inconvenience of these 
smaller changes in the DNA (Lieber, 2008). 
 
• Excision repair   
o Base excision repair (BER): the highly conserved BER pathway 
eliminates single- to a few nucleotide lesions caused by oxidative damage 
or alkylating agents, among others. The BER reaction occurs in four 
steps: first, the altered base is detected and removed by a DNA 
glycosylase. The type of damage will determine which glycosylase carries 
out the removal of the lesion, which in turn will define the type of BER 
required (short BER if only one nucleotide has to be resynthesized, long 




1999). Second, the glycosylase will cleave the N-glycosylic bond between 
the base affected by the lesion and the deoxyribose sugar, releasing the 
damaged base and leaving an apurinic / apyrimidinic site (Krokan et al., 
1997).  Next, the DNA backbone is nicked by an endonuclease, and a 
copy to repair the abasic site is subsequently synthesized by a 
polymerase, with a ligase finally sealing the gap to complete the reaction 
(Robertson et al., 2009).  
o Mismatch repair (MMR): as mismatched bases often occur naturally 
during DNA replication, MMR is not only a system to repair lesions, but a 
mechanism to ensure the fidelity of the copy generated. MMR is highly 
conserved in Bacteria and Eukarya (Eisen & Hanawalt, 1999), with the 
majority of Archaea lacking an obvious Mutator S - Mutator L (MutS-MutL) 
system (Kelman & White, 2005). In the MMR pathway, best described in 
E. coli, the MutS homodimer recognizes the lesion in the DNA and 
interacts with protein MutL, which enhances this damage recognition role 
and recruits the endonuclease Mutator H (MutH), which will excise the 
damaged fragment. Finally, the single-stranded gap will be filled by DNA 
polymerase III, and a ligase will bind the new fragment to the  repaired 
strand to end the reaction  (Li, 2008). Recently, an archaeal 
endonuclease mismatch specific (EndoMS, originally named NucS) has 
been reported to cleave a range of mismatches on both strands, leaving 
a DSB and thus connecting the MMR and HR pathways (Ishino et al., 
2016).  
o Nucleotide excision repair (NER): NER is a complex system that removes 
bulky adducts in the DNA caused by sources such as UV radiation or 
genotoxical agents. While the three defining steps of the NER mechanism 
(damage recognition, unwinding of the DNA duplex around the distortion 
and removal of the lesion) that lead to the restoration of the double helix 
are common to Bacteria, Archaea and Eukarya, the systems that perform 
the reaction are very different in all three (Sugasawa, 2016). This pathway 
will be discussed at length in the following sections. 
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1.2. The nucleotide excision repair pathway 
The highly conserved NER pathway is a defense mechanism that protects cells from 
mutagenic and carcinogenic processes by removing an extensive range of bulky adducts 
and lesions that introduce a signficant distortion in the double helix. In Bacteria and 
Eukarya NER is divided in two sub-pathways, according to the location of the damage: 
the global genome repair (GGR) pathway removes lesions present anywhere in the 
genome (Kisker et al., 2013) (Compe & Egly, 2012), while the transcription-coupled 
repair (TCR) pathway removes alterations occurring in an actively-transcribed DNA 
strand (Hanawalt & Spivak, 2008), typically in a faster manner than removal of damage 
in a strand that is not being transcribed (Mellon et al., 1987).  
 
1.2.1. Nucleotide excision repair in Bacteria  
The NER process in Bacteria requires only a handful of proteins, as opposed to 
eukaryotic NER, where the repairosome includes more than twenty different proteins (de 
Laat et al., 1999). Moreover, although bacteria and eukaryotes share the basic steps 
comprising the repair mechanism (damage detection, DNA unwinding and removal of 
the lesion), the genes that perform these steps show no homology whatsoever, 
suggesting different origins for the two systems (Eisen & Hanawalt, 1999). However, the 
high degree of conservation observed for the Uvr group of proteins suggests a common 
NER mechanism for most bacterial species (Peng et al., 2011). 
 
The UvrABC system responsible for the NER pathway in Bacteria (figure 2) was first 
described in 1983 (Sancar & Rupp, 1983), and its efficiency seems to be directly related 
to its ability to detect alterations in the double helix rather than specific lesions, as 
demonstrated by the wide range of substrates repaired by it (Van Houten et al., 2005). 
 
The homodimer UvrA is the first element to detect and bind to the damaged site in the 
GGR pathway, forming a short-lived complex before passing the DNA to UvrB in an ATP-
dependent manner (Stracy et al., 2016). UvrB is a central player in the bacterial NER 
process, as it interacts with all Uvr proteins. Association with UvrA and the damaged 




also induces a conformational change in UvrB that will facilitate the insertion of a b-
hairpin between the two strands to open the DNA (Theis et al., 2000). A model in which 
UvrA2-bound UvrB is actually a dimer has been proposed: this transient UvrA2B2 complex 
now translocates along the undamaged strand, opening the duplex in this way rather 
than unwinding it. At the same time, it searches for the cause of the distortion:  if no 
actual damage is present, the complex is disbanded, but upon finding the lesion, UvrB 
promotes the removal of UvrA2 and a stable UvrB2-DNA complex is formed (Kisker et al., 
2013).  
 
In the next step in the repair process, UvrB recruits the dual endonuclease UvrC to the 
damaged site, where it will make an incision on both sides of the lesion, removing a 
fragment of about 13 nucleotides (Verhoeven et al., 2000). The recruitment of UvrC is 
accompanied by the release of one of the UvrB molecules (Verhoeven et al., 2002). 
 
UvrB also recruits the 3’ to 5’ helicase UvrD to the incised site. The helicase will unwind 
the incised fragment, causing the excision of the fragment containing the lesion and the 
release of UvrC from the UvrBC complex, while UvrB remains attached to the 
undamaged strand (Ahn, 2000). Next, DNA polymerase (DNApol) I synthesises a new 
copy of the DNA, using the undamaged strand as a template, and finally causing the 
removal of UvrB from the now repaired site (Theis et al., 2000). The reaction is finalized 
when a ligase seals the newly synthesized and the old strands together (Tomkinson et 
al., 2006).  
 
Bacteria also possess a TCR-NER pathway (figure 2). Here, the mutation frequency 
decline (Mfd) protein promotes the ATP-dependent release of the RNApol after it 
becomes stalled when encountering the lesion (Selby & Sancar, 1993). Mfd 
subsequently recruits UvrA2 to the damaged site, which will recruit UvrB. Mfd is released 
together with UvrA2, leaving the UvrB-DNA complex  to complete the following steps as 
previously described for the GGR pathway (Selby & Sancar, 1993).  More recently an 
alternative, Mfd-independent TCR pathway has been reported, in which helicase UvrD 
forces the backtracking of the lesion-stalled RNApol, thus exposing the alteration in the 
DNA and allowing access of the subsequent NER factors to the damaged site (Epshtein 
et al., 2014). 
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Figure 2: Representation of the GGR and TCR pathways in Bacteria.  
Damage is identified by homodimer UvrA (GGR) or by an RNA polymerase (RNApol) (TCR), with 
the subsequent steps (damage verification, incision, removal of the damaged fragment, repair 
synthesis and ligation) shared by both pathways. Adapted from (Kisker et al., 2013). 
 
1.2.2. Nucleotide excision repair in Eukarya 
The eukaryotic NER pathway can effectively remove an impressive range of lesions in 
the DNA, such as damage caused by the UV-light to the pyrimidine bases (CPDs, 6-
4PPs), or damage caused by chemically reactive agents (cis-diaminodichloroplatinum 

































































Figure 1. Schematic representation of the prokaryotic NER pathways. In global genome repair (GGR), the
genome is scanned by the heterotetrameric UvrA2 –UvrB2 complex in search for damaged nucleotides causing
large conformational changes. In transcription-coupled repair, the repair process is initiated by a stalled RNA
polymerase on an actively transcribed gene through the interaction of the RNA polymerase with Mfd, which
recruits the UvrA dimer or a UvrA2 –UvrB heterotrimer to the site of the lesion. Both mechanisms converge into
the same pathway and proceed with damage verification by UvrB followed by 30 and 50 incisions catalyzed
through UvrC. The helicase activity of UvrD is required for the removal of UvrC. The incised strand is excised
and repair is completed after the repair patch is synthesized by DNA polymerase I and DNA ligase seals the nick.
All protein structures in this figure, with the exception of UvrB, are shown with a transparent surface and in
ribbon presentation. UvrB is shown with its surface in orange for domains 1 to 3, and the b-hairpin is shown in
cyan. C-ter, Carboxy terminal; N-ter, amino terminal.
Prokaryotic Nucleotide Excision Repair
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lesions can be explained by the ability of damage-recognition protein xeroderma 
pigmentosum complementation group C (XPC) to identify a distortion in the double helix, 
rather than the actual lesion  (Dip et al., 2004) (Maillard et al., 2007) (Naegeli & 
Sugasawa, 2011).  
 
1.2.2.1. Damage recognition and verification 
The eukaryotic GGR pathway is initiated with the identification of the lesion by damage-
detector XPC, which recognizes a structural perturbation in the double helix (Sugasawa 
et al., 2001) and introduces a further distortion in the DNA at the impaired site (Janićijević 
et al., 2003) (figure 3). Although it was first suggested that XPC is stabilized and its 
binding capacity stimulated by protein HR23B upon recognition of the lesion (Xie et al., 
2004), recent studies propose a model in which the heterodimer XPC-HR23B is the 
actual damage sensor, with HR23B safely delivering XPC to the lesion and then quickly 
dissociating from it as the protein is stabilized by binding to the damaged site (Bergink 
et al., 2012).  
 
It has been observed that CPDs are very poorly recognized by XPC, as the distortion 
they introduce in the double helix is minimal (Kusumoto et al., 2001). The identification 
of this particular lesion is additionally supported by the heterodimer DNA damage-
binding protein 1 / xeroderma pigmentosum complementation group E (DDB1/XPE) 
(Scrima et al., 2008), which stably binds to CPDs  and provides a platform at the lesion 
for XPC to access the damaged site so the NER reaction can progress normally (Moser 
et al., 2005). 
            
This recognition mechanism makes evident the need for a lesion-verification step further 
down the repair process. Xeroderma pigmentosum complementation group A (XPA) and 
transcription factor IIH (TFIIH) subunit xeroderma pigmentosum complementation group 
D (XPD) have both been proposed as candidates to carry out this function, based on the 
observations that XPD is stalled by bulky adducts in both the translocating  and, to a 
lesser extent, the non-translocating strands (Mathieu et al., 2010) (Buechner et al., 
2014). A model in which a ternary XPC-TFIIH-XPA complex translocates along the DNA 
until it becomes stalled by the lesion was proposed (Sugasawa et al., 2009) and later 
reinforced by the work of the Yang group, which confirmed that the presence of XPA 
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enhances the inhibitory nature of these bulky lesions (Li et al., 2015).  
 
 
Figure 3: Damage recognition in the eukaryotic GGR and TCR sub-pathways.  
The lesion is identified by the XPC-HR23B-Centrin 2 complex (GGR) or by the stalled RNApol 
(TCR). The subsequent steps until completion of NER (damage verification, incision, removal of 
the damaged fragment, repair synthesis and ligation) are common to both GGR and TCR. Protein 
Centrin 2 (CETN2) will be discussed in chapter 5. Adapted from (Marteijn et al., 2014). 
 
The correct positioning of XPC at the site of the distortion will determine the recruitment 
and positioning of all subsequent NER factors, and by extension, the success of the 
repair reaction itself. The next repair factor, the 10-subunit TFIIH complex, joins the 
damaged site through interactions between XPC’s C-terminal module and subunits p62 
and xeroderma pigmentosum complementation group B (XPB) within the THFIIH 
complex (Yokoi et al., 2000) (Uchida et al., 2002) (Bernardes de Jesus et al., 2008).  
 





during the transcription of a gene  (Hanawalt & Spivak, 2008). A link between 
transcription and DNA repair was proposed by the Hanawalt group based on their 
observations that damage in an actively-transcribed strand was repaired considerably 
faster than a lesion located in a non-transcribed strand (Hanawalt, 1987). Years later, 
the Egly group determined that that link was the TFIIH complex, which is essential for 
both the transcription and DNA repair processes (Schaeffer et al., 1993). In this sub-
pathway of NER, it’s the stalled RNApol II itself that acts as a damage sensor with the 
aid of the Cockayne Syndrome complementation group B (CSB) protein, a DNA-
dependent ATPase with a loose interaction with the RNApol (Selby & Sancar, 1997) that 
will be strengthened following transcription arrest (Van Gool et al., 1997). The next factor 
to join the repair bubble is the TFIIH complex, recruited to the damaged site by the UV 
stimulated scaffold A (UVSSA) coupling factor, which interacts with subunit p62 in a 
remarkably similar manner as GGR damage-detection protein XPC (Okuda et al., 2017) 
(figure 3). The subsequent steps ensuing the verification of the distortion in the DNA and 
removal of the damage following recruitment of TFIIH are common to both GGR and 
TCR (Compe & Egly, 2012) (Compe & Egly, 2016) (Hanawalt & Spivak, 2008). 
 
1.2.2.2. Opening of the repair bubble 
The 10-subunit TFIIH complex (composed of sub-complexes TFIIH Core and cyclin-
dependent kinase (CDK)-activating kinase (CAK)) is recruited to the damaged site to 
open the double helix around the lesion. Our understanding of how this mechanism 
occurs has been aided by the studies of the structures and mechanisms of action of 
several archaeal homologues of helicases XPB (Fan et al., 2006) and XPD (Liu et al., 
2008) (Wolski et al., 2008) (Fan et al., 2008).  
 
The coordinated actions of XPB and XPD will open and extend the repair bubble to allow 
the following repair factors access to the damaged site (figure 4). An initial model for the 
opening was proposed in which a DNA-stimulated, ATP-dependent conformational 
change in XPB would anchor TFIIH to the DNA and facilitate the separation of the two 
strands, allowing XPD to unwind the duplex (Oksenych et al., 2009). The fact that only 
XPB’s ATPase activity is essential for NER (Coin et al., 2007) (Oksenych et al., 2009) 
and that archaeal XPB is able to open DNA substrates by translocating along the 
undamaged strand rather than unwinding it (Rouillon & White, 2010) support the more 
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recent proposal that eukaryal XPB also acts as a translocase rather than displaying a 
traditional helicase activity (He et al., 2016) (Schilbach et al., 2017). The ATPase activity 
of XPB is regulated by damage sensor XPC (Bernardes de Jesus et al., 2008), and TFIIH 




Figure 4: The TFIIH complex opens the DNA around the damaged site.  
ATP-dependent 3’ to 5’ helicase XPB will open the DNA as it translocates through the duplex, 
allowing ATP-dependent 5’ to 3’ helicase XPD to unwind the DNA, thus extending the repair 
bubble.  
 
As opposed to XPB, XPD’s helicase activity is fundamental for NER, as evidenced by 
the fact that mutations affecting its helicase motifs or its region of interaction with 
regulatory subunit p44 impair the ability of TFIIH to unwind the DNA (Coin et al., 1998) 
(Dubaele et al., 2003). The initial mechanism proposed for unwinding of the DNA by XPD 
postulated that the helicase domain 1 (HD1), the Arch domain and the 4FeS cluster in 
the helicase form a ring that translocates ssDNA in an ATP-dependent manner through 
the channel left by the structure (Liu et al., 2008) (Wolski et al., 2008) (Fan et al., 2008) 
(Kuper et al., 2012). A more recent study proposes an update on this mechanism, with 
ssDNA stably interacting with the helicase domain 2 (HD2) and the Arch domain and 
4FeS cluster opening transitorily at their interface, to allow passage of the ssDNA 
through the pore and posterior binding to HD1 (Constantinescu-Aruxandei et al., 2016) 
(figure 5). XPD also plays a structural role within TFIIH, as it anchors the CAK sub-




(Adamczewski et al., 1996) (Schultz et al., 2000) (Abdulrahman et al., 2013). A third role 
for the helicase as a damage-verification factor has also been suggested  (Sugasawa et 
al., 2009) (Kuper et al., 2012) (Li et al., 2015), but not verified up to date. XPD’s helicase 
activity is stimulated by interaction with subunits p34 and p44 (Coin et al., 1998) (Schmitt 




Figure 5: Structure of the TFIIH 5’ to 3’ helicase XPD.  
Structure of the Sulfolobus tokodaii archaeal XPD, showing helicase domains 1 and 2 and the 
Arch domain. The 4FeS domain area is delimited by the green spheres (A) (adapted from (Liu et 
al., 2008)). The Arch domain, 4Fe4S cluster and HD1 (not shown in the figure) form a channel 
that translocates ssDNA after opening of the interface between the Arch and the 4FeS domains 
(B)  (Constantinescu-Aruxandei et al., 2016) (XPD structure from (Greber et al., 2017). 
 
Subunit p62 was thought to have a merely structural role, and although a recent study 
further supports this role by describing a new region in the protein that interacts with XPD 
and binds the helicase to the Core sub-complex (Luo et al., 2015), p62 is also 
responsible for an extended network of contacts with other transcription factors and 
proteins, particularly with damage-detectors XPC in GGR (Okuda et al., 2015) and 
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UVSSA in TCR (Okuda et al., 2017), as this binding will recruit complex TFIIH to the 
repair bubble.  
       
Figure 6: Damage verification and DNA unwinding in eukaryotic NER.  
The GGR and TCR sub-pathways converge after the detection of the lesion. The TFIIH complex 
is recruited to open the DNA duplex; next, factors RPA and XPA are recruited to protect the 
ssDNA from degradation, and to promote the release of the CAK sub-complex and recruit 
endonucleases XPG and XPF/ERRC1, respectivelygb . Factors in this figure are not drawn to 
scale. Adapted from (Marteijn et al., 2014). 
 
The heterotrimeric replication protein A (RPA) and XPA proteins are now recruited 
together to the XPC-TFIIH-DNA complex (Krasikova et al., 2010), promoted by TFIIH 
subunit p8 through stimulation of the ATPase activity of XPB (Coin et al., 2006), which 
will displace XPC and reorganize the bubble for the arrival of subsequent factors (Tapias 
et al., 2004). RPA binds to ssDNA to protect it from degradation (Krasikova et al., 2010), 
while XPA promotes the ATP-dependent removal of the CAK sub-complex from TFIIH in 
a reaction that is essential for the successful progress of NER (Svejstrup et al., 1995) 
(Coin et al., 2008), as the sub-complex reportedly regulates negatively the helicase 




be released but not degraded, making the sub-complex available to bind to TFIIH Core 
again once transcription is resumed (Coin et al., 2008). The asymmetrical binding of XPA 
to the 5’ end of the repair bubble will also determine the recruitment of endonucleases 
xeroderma pigmentosum complementation group G (XPG) and xeroderma 
pigmentosum complementation group F / excision repair cross-complementation group 
1 (XPF/ERCC1) (Krasikova et al., 2010) (figure 6). 
 
1.2.2.3. Removal of the damaged fragment 
The recruited endonucleases will carry out nearly simultaneous but independent 
incisions at the 3’ (XPG) and the 5’ (XPF/ERCC1) sides of the lesion (Evans et al., 1997). 
These incisions are asymmetrical, as XPG cuts the DNA 4-8 nucleotides away from the 
damage site while the XPF/ERCC1 incision occurs 15-24 nucleotides away from the 
lesion (Peng et al., 2011) (figure 7). Incision by XPF/ERCC1 requires the recruitment 
(but not the catalytic activity) of XPG (Tapias et al., 2004), whose binding promotes the 
release and recycling of heterodimer XPC/HR23B (Riedl et al., 2003). Repair factors 
TFIIH and XPA will also be released from the repair complex soon after XPF/ERCC1 
excises the DNA at the 5’ end, while RPA remains to protect the ssDNA portion of the 
bubble (Riedl et al., 2003). XPG and RPA now promote the recruitment of repair factors 
proliferating cell nuclear antigen (PCNA) (Gary et al., 1997) and replication factor C 
(RFC) (Yuzhakov et al., 1999) to support and ensure the correct synthesis of the new 
DNA fragment; this recruitment will also trigger the release of XPF/ERCC1 (Staresincic 
et al., 2009). 
 
1.2.2.4. Synthesis and ligation of the new fragment 
Repair synthesis can be detected as soon as XPF/ERCC1 excises the DNA at the 5’ end 
(Staresincic et al., 2009). At this stage the repair complex provides a platform for a 
DNApol ε, or a DNApol δ and κ acting together, to join the repair process and start the 
synthesis of a new fragment, using the undamaged strand as a template (Ogi et al., 
2010) (figure 7). Finally, endonuclease XPG excises the 3’ of the damaged strand, and 
as a result a damaged fragment of about 30 nucleotides (Gillet & Schärer, 2006) and 
repair factors XPG and RPA are released from the complex (Mocquet et al., 2008). Once 
the DNA synthesis is completed, a DNA ligase III (for DNApol δ) or a ligase I (for DNApol 
ε) is recruited to seal the new fragment (Moser et al., 2007) (figure 7) as RFC and the 
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DNApol are released (Mocquet et al., 2008). Repair factor PCNA still remains at the 
repair bubble, acting as a bridge between the synthesis and ligation processes (Gary et 
al., 1997). Finally, as soon as the NER reaction is complete the chromatin structure is 
restored to its original packed state (Gaillard et al., 1996) (Polo et al., 2006). 
 
           
Figure 7: Excision and repair synthesis in NER.  
XPA promotes the release of the CAK sub-complex so the combined action of the XPB and XPD 
helicases can open the DNA duplex at the damaged site. Endonucleases XPF/ERCC1 and XPG 
will excise both sides of the damaged fragment, releasing a fragment of about 30 nucleotides as 
a DNApol synthesizes a new fragment and a ligase seals the nicks. The reaction concludes with 
the restoration of the chromatin structure. Factors in this figure are not drawn to scale. Adapted 











































































DNA damage verification. Binding of XPC to lesions 
provides a substrate for the association of the TFIIH 
(transcription initiation factor IIH) complex18–20, which 
is a transcription initiation and repair factor consisting 
of ten protein subunits. Its two DNA helicases, the two 
TFIIH basal transcription factor complex helicase sub-
units XPB and XPD (encoded by ERCC3 and ERCC2, 
respectively), have opposite polarities and extend 
the open DNA configuration around the lesion21,22, 
which probably verifies the presence of a lesion (FIG. 1). 
Whereas the ATPase activity of XPB, rather than its heli-
case activity, is implicated in recruiting TFIIH to DNA 
damage23,24, the 5ʹ–3ʹ unwinding activity of XPD seems 
to be indispensable for NER25. In vitro experiments 
clearly showed that TFIIH itself (assisted by XPA; see 
below), when loaded by XPC onto a bubble DNA sub-
strate, scans the DNA in a 5ʹ–3ʹ direction for helicase-
blocking lesions26, suggesting that the XPD helicase 
is mainly required for damage verification. Structural 
analysis of archaeal XPD orthologues further suggests 
that the Arch and Fe-S cluster domains of XPD form 
an internal channel through which undamaged ssDNA 
can probably pass but damaged DNA cannot27–31. 
When the XPD helicase does not detect any damage, 
the repair reaction may be aborted27–31. Damage veri-
fication also probably involves the XPA protein, which 
detects nucleotides with altered chemical structures in 
ssDNA32. TFIIH was originally identified as an essential 
transcription initiation factor, but it can switch between 
functions in transcription and in NER22,33. The trimeric 
CAK subcomplex (CDK-activating kinase subcomplex) 
of TFIIH is essential for transcription initiation, but it 
is not required for its repair function. Upon binding 
of TFIIH to DNA-bound XPC, the CAK subcomplex 
dissociates34. Conversely, the 8 kD TFIIH basal trans-
cription factor complex TTDA subunit (also known 
as GTF2H5) seems to be important for the role of 
TFIIH in NER, but it is dispensable for its t ranscription 
activity35,36.
Dual incision and gap filling. The highly dynamic multi-
step strategy of lesion detection and verification contains 
several reversible steps before the actual removal of 
lesions by dual (5ʹ and 3ʹ) incision, presumably to pre-
vent the formation of undesirable and irreversible DNA 
modifications37,38. However, the next step is strand inci-
sion, after which a ‘point of no return’ is reached (FIG. 1) 
and the reaction must be efficiently concluded to avoid 
leaving potentially dangerous intermediates. Lesion exci-
sion is catalysed by the structure-specific endo nucleases 
XPF–ERCC1 and XPG (encoded by ERCC5), which 
incise the damaged strand at short distances 5ʹ and 3ʹ 
from the lesion, respectively39 (FIG. 1). The excision leaves 
a single-strand gap of 22–30 nucleotides, which prob-
ably triggers a DNA-damage-signalling reaction (BOX 2). 
Increased damage signalling and genomic instability 
are indeed observed if the dual incision is improp-
erly co ordinated40. Accurate co ordination of incision 
involves the assembly of XPA, XPG and replication pro-
tein A (RPA) at NER lesions that are marked by XPC and 
verified by TFIIH.
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1.2.2.5. Recessive disorders associated with NER 
Mutations affecting the different factors involved in NER are responsible for a variety of 
serious, sometimes fatal genetic syndromes that present a remarkable heterogeneity in 
their genetic make-up and clinical manifestations. Table 1 summarises these disorders 
and their most prominent features. The seven XP complementation groups (XP-A to XP-
G) present defects in NER, with all of them showing the characteristic photosensitivity 
and increased susceptibility to cancer associated to DNA repair defects (Peng et al., 
2011). By contrast, CS and TTD patients do not suffer a higher frequency of cancer, but 
they present an extended variety of mental and physical developmental defects 
(Lehmann, 2003) that match defects in transcription rather than impairment of the repair 
process (Dubaele et al., 2003) (Bootsma & Hoeijmakers, 1993).  
 
Table 1: Autosomal recessive disorders caused by mutations in NER factors  






UV Sensitivity  
Syndrome (UVSS) 
Photosensitivity 
Mild skin abnormalities 
No CSB 
Cockayne syndrome  
(CS)  
















Dry, parchment-like skin 
Neurological abnormalities 
 
Yes XPA - G 
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XPA – G 
 
A wide variety of non-lethal mutations have been described for helicase XPD, while only 
a few have been reported in relation to XPB, consistent with its essential role in 
transcription (Tirode et al., 1999). The great majority of the pathological mutations 
affecting XPD are localized in its C-terminal end, affecting either XPD’s binding to p44 
or the helicase motifs, thus reducing its helicase activity dramatically (Dubaele et al., 
2003). 
 
The majority of the mutations affecting TFIIH subunits XPB, XPD and p8 that cause TTD 
result in a drastic reduction of TFIIH’s cellular levels (Botta et al., 2002), which paired 
with the enormous variability in the severity of the pathological characteristics presented 
by these patients led to conclude that these mutations had to not only affect the steady-
state levels of TFIIH, but also the complex’s stability (Giglia-Mari et al., 2006) and its role 





1.2.2.6. The NER pathway as a drug target 
The ability of repair pathways to remove DNA damage caused by chemotherapeutical 
agents have turned them into a target for novel cancer treatments, as the use of repair 
inhibitors would potentially improve the efficiency of the current strategies, burdened by 
the growing resistance to anti-cancer drugs (Helleday et al., 2008). 
 
These novel strategies have placed particular focus on NER, and more specifically on 
the TFIIH complex (figure 8), as it is involved in the removal of bulky adducts on the DNA 
caused not only by UV radiation, but also by chemicals like the widely-used 
chemotherapeutic drug cisplatin (Rosenberg et al., 1969) (Fuertes et al., 2003) (Rabik & 
Dolan, 2007). The fact that cisplatin-induced DNA damage is processed and eliminated 
by NER was confirmed by a study showing that increased levels of the TFIIH subunit 
XPB are connected to resistance to cisplatin in primary ovarian cancer (Dabholkar et al., 
2000). The involvement of NER in resistance to cisplatin treatments was further 
confirmed by the presence of low levels of both XPA and XPF-ERCC1 in testicular 
cancer, a form of the disease particularly responsive to treatment with cisplatin (Welsh 
et al., 2004). 
 
Although the recent publication of a study that successfully overcame resistance to the 
anti-cancer drug melphalan by inhibiting TFIIH helicase XPB in multiple myeloma 
cancerous cells (Szalat et al., 2017) confirms that  the use of DNA repair inhibitors (in 
combination with classical approaches or as monotherapy alternatives) as agents in 
cancer treatment is a real possibility (Helleday et al., 2008) (Zurita & Cruz-Becerra, 2016) 
(Berico & Coin, 2017) (Desai et al., 2018), the need for drugs that selectively target 
tumorous cells is a setback that cannot be ignored. Although there’s an argument that 
overlapping between repair pathways could compensate the activity of the inhibited 
pathway in non-cancerous cells, that same crosstalk could result in resistance to the new 
treatment. For now, alternative cancer therapies using DNA repair inhibitors remains a 
challenging field.  
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Figure 8: The TFIIH complex as a target for chemotherapeutic drugs.  
Inhibitors whose effectiveness has already been described are indicated in red, while potential 
targets for alternative therapeutic drugs are indicated in black. Adapted from (Zurita & Cruz-
Becerra, 2016) (Berico & Coin, 2017) (Titov et al., 2011) (Chung et al., 2012) (Alekseev et al., 
2014) (Szalat et al., 2017) (Kwiatkowski et al., 2014). 
 
1.2.3. Nucleotide excision repair in Archaea  
The NER pathway in archaea is often confusing, with species presenting bacterial-like 
genes, eukaryal-like ones or a mixture of both (Rouillon & White, 2011).  
 
Although initial studies proposed a bacterial-like repair system for Archaea (Ögrünç et 
al., 1998), only a small group (mesophilic methanogens and halophiles) actually possess 
the UvrABC genes, while most of them present clear orthologues for the eukaryotic NER 
proteins XPB, XPD, XPG and XPF (figure 9) (White, 2003). Furthermore, the recent 
description of the ASGARD archaeal lineages (Eme et al., 2017), which present the 
eukaryotic DNA repair orthologues one would expect in an ancestor, support an 
evolutionary pattern in which Eukarya emerged from this branch of the Archaea (White 




Although no orthologues of XPC or XPA have been described for Archaea, the single-
stranded DNA binding protein (SSB) from Sulfolobus solfataricus was reportedly able to 
identify destabilizations in the double helix caused by a series of lesions, including 
substrates repaired by NER (figure 9), and a model in which SsoSSB could potentially 
detect the damage and recruit the subsequent repair factors through interaction with its 
C-terminal tail has been proposed  (Cubeddu & White, 2005).  
 
Archaeal XPD is a monomer in solution, with no reported partners. The helicase presents 
a 4FeS cluster (Rudolf et al., 2006), coordinated by four highly conserved cysteine 
residues, that has an essential structural and functional role, as evidenced by the 
pathological phenotypes resulting from mutations in the enzyme (White & Dillingham, 
2012). The available structures of different archaeal XPDs (Liu et al., 2008) (Wolski et 
al., 2008) (Fan et al., 2008) have helped enormously in the understanding of the 
eukaryotic XP, CS and TTD phenotypes, as they have allowed the mapping of these 
mutations to regions that are essential for the function of the helicase. 
 
  
Figure 9: The NER pathway in Archaea.  
Structures of putative archaeal NER orthologues PCNA (Sulfolobus solfataricus), XPF 
(Aeropyrum pernix), XPD (Thermoplasma acidophilum), SSB (Sulfolobus solfataricus) and XPB 
(Archaeoglobus fulgidus) (structure of Bax1 yet unknown). The star at the bubble represents a 
lesion in the DNA. Adapted from (Rouillon & White, 2011). 
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The archaeal monomeric, weak helicase XPB (Fan et al., 2006) is often found in a 
complex with endonuclease Bax1, a potential equivalent to eukaryotic XPG, working 
together towards the extending of the repair bubble and the excision of the damaged 
fragment (figure 9) (Rouillon & White, 2010). The mechanism of action of the archaeal 
XPB supports recent findings that report a role of the helicase in NER as a double-strand 
DNA (dsDNA) translocase rather than the helicase function first assumed (He et al., 
2016). 
 
Several studies have shown that deletion of the XPB and XPD genes have little to no 
effect on the phenotype of the archaea, suggesting that, contrary to what happens in 
eukaryotes, these genes are not essential for archaeal NER, raising the question of 
which alternative function they might have in this group, or whether there are multiple, 
overlapping pathways for NER (White & Allers, 2018).  
 
Although an RNApol has been reported to be stalled by damage in the DNA, the lack of 
a Mfd orthologue or any other factors coupling the transcription and DNA repair 
processes make difficult to define a TCR pathway in archaea (White & Allers, 2018). 
 
1.3. TFIIH: a dual transcription and DNA repair factor 
TFIIH is a ten-subunit complex with a dual role in NER and RNApol II-mediated 
transcription initiation (Flores et al., 1992) (Feaver et al., 1993). Despite their differences, 
TFIIH carries out the same basic role in the two processes: unwinding the DNA to allow 
other transcription or NER factors access to the double helix (Holstege et al., 1996) 
(Kuper et al., 2014). The central role of TFIIH in both processes is evidenced by the 
pathological phenotypes caused by mutations in the XPB, XPD or p8 subunits, with 
symptoms that range from mild photosensitivity to a 2000-fold increased susceptibility to 
cancer (Bootsma & Hoeijmakers, 1993). The role of TFIIH as a DNA repair factor has 
been extensively discussed in section 1.2.2.2, so this analysis will focus on its function 






1.3.1. Structural study of TFIIH 
The first published structure of TFIIH revealed a complex with two distinctive regions: a 
Core sub-complex that included subunits XPB, p62, p52, p44 and p34, and a CAK sub-
complex comprising subunits cyclin-dependent kinase 7 (cdk7), cyclin H and ménage-à-
trois 1 (MAT1), with subunit XPD positioned at the interface of both sub-complexes 
(Schultz et al., 2000) (Abdulrahman et al., 2013) (figure 10). This structure lacked any 
mention to subunit p8, which was not described until 2004 (Giglia-Mari et al., 2004). The 
recent publication of the electron cryomicroscopy (cryoEM) structure of human TFIIH 
confirmed the previously described ring-like disposition of the Core sub-complex with the 
CAK sub-complex protruding from this Core, allowing the unambiguous allocation of 
most subunits (except p62) and XPD within the ring (Greber et al., 2017). 
 
TFIIH adopts different dispositions for its distinct roles: while the complete ten-subunit 
complex participates in transcription, only the Core sub-complex is required to carry out 
the repair reaction (Svejstrup et al., 1995) (Tirode et al., 1999). The Core sub-complex 
presents two enzymatic subunits. The activity of both ATP-dependent helicases XPB (3’ 
to 5’ polarity) and XPD (5’ to 3’ polarity) is essential for NER (Coin et al., 1998) (Oksenych 
et al., 2009). Interestingly, the helicase activity of XPD is not required during 
transcription, although its role in anchoring the CAK sub-complex to TFIIH Core is 
necessary for an optimal reaction (Tirode et al., 1999) (Kuper et al., 2014) . The third 
enzymatic activity of TFIIH is in the CAK sub-complex: subunit cdk7 phosphorylates the 
C-terminal domain (CTD) of Rpb1, the largest subunit of RNApol II, to facilitate promoter 
escape in a reaction that is fundamental to move onto the elongation phase of 
transcription (Lu et al., 1992) (Roy et al., 1994) (Wong et al., 2014). CAK also acts as a 
down-regulator of XPD’s helicase activity (Sandrock & Egly, 2001) (Abdulrahman et al., 
2013); because of this, the sub-complex is removed from TFIIH at an early stage when 
the complex participates in NER (Svejstrup et al., 1995)  (Coin et al., 2008). The 
remaining TFIIH subunits seem to have a structural or regulatory function.  
 
Subunit p8 was described as recently as 2004. Due to its small size, p8 was typically run 
off the bottom of SDS-PAGE gels, and it was only “discovered” in response to the search 
for a TFIIH component responsible for a form of TTD not caused by mutations in the XPB 
or XPD genes (Giglia-Mari et al., 2004). The role of p8 within TFIIH is two-fold: it 
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regulates the cellular levels of TFIIH (either by estabilising the complex or by protecting 
it from degradation) (Giglia-Mari et al., 2004) and it stimulates XPB’s ATPase activity, 
probably through interaction with subunit p52  (Coin et al., 2006). XPB’s ATPase activity 




Figure 10: Structure of the 10-subunit complex TFIIH.  
Cartoon view showing the CAK and Core sub-complexes that integrate TFIIH (A), highlighting its 
three enzymatic activities: ckd7 (kinase), XPB (3’ to 5’ helicase) and XPD (5’ to 3’ helicase). 
CryoEM structure of the TFIIH Core sub-complex plus CAK subunit MAT1 (B). The grey density 
has not been assigned, although it is thought  to represent subunit p62 (Greber et al., 2017).  
 
Subunit p44 has been shown to stimulate the helicase activity of XPD (Coin et al., 1998), 
possibly in collaboration with subunit p34, as hinted by their tight interaction (Schmitt et 
al., 2014). Protein Ssl1 (the yeast homologue of p44) has been identified as an E3 
ubiquitin ligase, reportedly stimulated by protein Tfb4 (the yeast homologue of human 
p34), but this function has not been confirmed for their human counterparts to date 
(Takagi et al., 2005).  
 
Subunit p62 is another multi-function component of TFIIH. During NER, p62 is 
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The cryo-electron microscopy structure of human 
transcription factor IIH
Basil J. Greber1,2, Thi Hoang Duong Nguyen1,2,3, Jie Fang4, Pavel V. Afonine2, Paul D. Adams2,5 & Eva Nogales1,2,4,6
Human transcription factor IIH (TFIIH) is part of the general 
transcriptional machinery required by RNA polymerase II for 
the initiation of eukaryotic gene transcription1. Composed of ten 
subunits that add up to a molecular mass of about 500 kDa, TFIIH 
is also essential for nucleotide excision repair1. The seven-subunit 
TFIIH core complex formed by XPB, XPD, p62, p52, p44, p34, and 
p8 is competent for DNA repair2, while the CDK-activating kinase 
subcomplex, which includes the kinase activity of CDK7 as well 
as the cyclin H and MAT1 subunits, is additionally required for 
transcription initiation1,2. Mutations in the TFIIH subunits XPB, 
XPD, and p8 lead to severe premature ageing and cancer propensity 
in the genetic diseases xeroderma pigmentosum, Cockayne 
syndrome, and trichothiodystrophy, highlighting the importance 
of TFIIH for cellular physiology3. Here we present the cryo-electron 
microscopy structure of human TFIIH at 4.4 Å resolution. The 
structure reveals the molecular architecture of the TFIIH core 
complex, the detailed structures of its constituent XPB and XPD 
ATPases, and how the core and kinase subcomplexes of TFIIH are 
connected. Additionally, our structure provides insight into the 
conformational dynamics of TFIIH and the regulation of its activity.
We collected cryo-electron microscopy (cryo-EM) data of human 
TFIIH, immuno-purified from HeLa cells, and obtained a reconstruc-
tion at an overall resolution of 4.4 Å (see Methods and Extended Data 
Figs 1 and 2). The reconstruction (Fig. 1a) shows a horseshoe-shaped 
assembly corresponding to the TFIIH core complex, in agreement 
with previous lower-resolution reconstructio s of huma  TFIIH 
in  isolation4 and in the context of the RNA polymerase II (Pol II) 
transcription preinitiation complex (PIC) (hereafter, Pol II-PIC)5,6. 
Secondary structure elements are resolved throughout (Extended Data 
Fig. 3a–c), and large amino-acid side chains are visible in the best- 
resolved areas of the map (better than 4 Å; Extended Data Figs 2b and 
3d–f). Because the resolution of our cryo-EM map was not sufficient for 
chain tracing and assignment of the sequence register in several areas, 
we combined docking and rebuilding of homology models with the 
placement of secondary structure elements for previously structurally 
uncharacterized components to generate an atomic model of the TFIIH 
core–MAT1 complex (Fig. 1b and Extended Data Table 1). This atomic 
model was refined against the map and fully validated (Extended Data 
Fig. 3g–i). All protein subunits of the TFIIH core complex except p62, 
as well as the CDK-activating kinase (CAK) component MAT1, could 
be unambiguously assigned in our cryo-EM map, while the remainder 
of the CAK subcomplex is highly flexible and its CDK7 and cyclin H 
subunits are not resolved (Fig. 1a, b). The architecture of TFIIH is 
dominated by its ATPase/helicase subunits XPD and XPB, which are 
situated next to each other at the open end of the horseshoe-shaped 
structure (green and blue, respectively, in Fig. 1a, b). The arc-like con-
nection betwe n them includes the von Willebrand factor A-like folds 
of p44 and p34 and the helical domain of p52 (red, magenta, and yellow, 
respectively, in Fig. 1a, b; domain architectures are shown in Extended 
Data Fig. 4). Even though p62 could not be unambiguously assigned in 
our cryo-EM map, data from chemical crosslinking-mass spectrometry 
(CX-MS) experiments7 suggest that several secondary structure 
 elements built into unassigned density may correspond to parts of p62 
(Fig. 1c, Extended Data Fig. 5 and Supplementary Discussion). These 
α -helical regions and the linkers that seem to connect them localize to 
distant parts of TFIIH, suggesting that p62 may act as a molecular glue 
to stabilize the overall assembly of TFIIH.
The structures of XPD and XPB (Fig. 2) show that both ATPases are in 
the apo-state, with unoccupied nucleotide-binding pockets. Human XPD 
shares its overall architecture with homologous archaeal  helicases8–10, 
with two RecA-like domains (RecA1 and RecA2)  harbouring the struc-
turally conserved helicase motifs, and 4FeS and ARCH domain insertions 
within RecA1 (Fig. 2a and Extended Data Fig. 4). The 4Fe4S cluster is 
clearly visualized in the cryo-EM map as a strong density peak within the 
4FeS domain8,10 (Extended Data Fig. 6a–c). The 4FeS domain is adjacent 
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Figure 1 | Cryo-EM reconstruction of human TFIIH. a, Cryo-EM map 
of TFIIH, colour coded and labelled according to constituent subunits; 
unassigned density is grey. b, Front and back views of the molecular 
structure of TFIIH. Protein subunits are labelled. Unassigned secondary 
structure elements attributed to XPB and p52 are light blue and pale yellow, 
respectively; remaining unassigned elements, grey. c, Unassigned secondary 
structure elements and remaining unassigned density in the p34–p44 
hinge region (teal) may correspond to p62 and the zinc-binding domains 
of p34 and p44. Positions of crosslinks between p62 and other TFIIH core 
proteins7 shown by spheres coloured according to the crosslinked partner; 
crosslinks from studies of yeast TFIIH indicated by ‘Y’.





interaction with lesion-recognition protein XPC (Okuda et al., 2015). The work of Luo et 
al. described a new region in p62 that extensively interacts with XPD, which led them to 
propose a further role of the subunit as an extra anchor point between the helicase and 
the Core sub-complex (Luo et al., 2015). Moreover, p62 is responsible for the interaction 
between TFIIH and transcription factor IIE (TFIIE) (Okuda et al., 2008), and it’s also the 
target of several viral proteins (this role will be further discussed in section 1.3.4). 
 
1.3.1.1. XPD takes part in three different complexes 
XPD is an extremely versatile protein, as proven by its multiple roles (figure 11). Bound 
to the TFIIH Core sub-complex, it has an essential role in NER (Kuper et al., 2014), and 
also possesses a structural role as the element that anchors sub-complex CAK to TFIIH 
Core, providing a platform for the cdk7 subunit to play its fundamental role in transcription 
together with subunit XPB (Abdulrahman et al., 2013).  
 
            
 
 
Figure 11: Different roles associated to helicase XPD.  
XPD participates in NER and transcription as part of the TFIIH complex, in cell cycle regulation 
when bound to the TFIIH-independent CAK complex and in chromosome segregation as part of 
the MMXD complex. Adapted from (Ito et al., 2010). 
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The CAK sub-complex is not a mere partner of TFIIH Core. As an independent complex, 
its cdk7 subunit phosphorylates a plethora of other kinases, triggering vital changes for 
the progression of the cell cycle (Morgan, 1995). In this context, XPD has been reported 
to regulate both the cell’s entrance into mitosis and basal transcription by sequestering 
or releasing the CAK sub-complex from TFIIH, thus determining the role that cdk7 will 
play (Chen et al., 2003). 
 
XPD also has an additional function as part of the mitotic spindle-associated MMS19-
MIP18-XPD (MMXD) complex (Van Houten et al., 2016). The human homologue of the 
Saccharomyces cerevisiae protein MMS19 reportedly interacts with helicases XPB and 
XPD, and a tentative regulatory or structural role of the protein in relation to the TFIIH 
complex was initially proposed (Seroz et al., 2000). A decade later, it was found that 
XPD actually forms a separate, TFIIH-independent complex that also includes proteins 
MMS19, MMS19-Interacting Protein of 18 kDa (MIP18), cytosolic iron-sulfur assembly 
component 1 (CIAO1) and adenine nucleotide translocase 2 (ANT2) (Ito et al., 2010). 
The MMXD complex has a reported role in chromosome segregation, as knockdown of 
the MMS19, MIP18 or XPD proteins caused severe alterations of the mitotic spindle (Ito 
et al., 2010). Interestingly, the MMS19 knocked-down cells present hypersensitivity to 
UV radiation, suggesting a possible interaction with XPD in the repair process (Ito et al., 
2010). The MMS19, MIP18 and CIAO1 proteins also form a cytoplasmic iron-sulfur 
cluster assembly (CIA) complex, involved in the integration of an 4FeS cluster into XPD 
prior to its incorporation to the TFIIH complex (Vashisht et al., 2015). 
 
1.3.2. Role of TFIIH in transcription  
The transcription process starts with the formation of the pre-initiation complex (PIC) at 
the promoter (Schilbach et al., 2017). The sequential assembly of the PIC begins with 
the binding of transcription factor IID (TFIID) to the DNA, stabilized by the subsequent 
recruitment of transcription factor IIA (TFIIA) and transcription factor IIB (TFIIB). TFIIB 
promotes now the recruitment of a pre-formed complex RNApol II - transcription factor 
IIF (TFIIF). Transcription factor IIE (TFIIE) will be recruited to this stable complex by 
direct interactions with RNApol II. Lastly, TFIIE will mediate the recruitment of TFIIH to 





As in NER, TFIIH plays a central role in transcription as the factor responsible for melting 
the promoter: the ATPase activity of XPB will be employed to open the DNA around the 
promoter upstream of the starting site, allowing the RNApol access to the template strand 
(Holstege et al., 1996). Recent studies propose that XPB actually melts the promoter by 
acting as a translocase, separating the duplex as it threads the DNA towards RNApol II 




Figure 12: Sequential assembly of the PIC.  
TFIID is the first factor to bind the promoter, stabilized by TFIIA and TFIIB. TFIIB recruits a pre-
formed RNApol II – TFIIF complex, and the RNApol will interact with TFIIE, which finally will 
mediate the recruitment of TFIIH to complete the PIC. Adapted from (Orphanides et al., 1996). 
 
TFIIH subunit cdk7 also has a fundamental role in the process as the kinase is 
responsible for the phosphorylation of the CTD of Rbp1, the largest subunit of RNApol 
II, thus enabling promoter escape (Lu et al., 1992) (Roy et al., 1994) (Wong et al., 2014). 
The CTD of RNApol II comprises a number of repetitions (26 in yeast, 52 in mammals) 
of the peptide YSPTSPS, reported to be a major target for several kinases (Ossipow et 
al., 1995), including cdk7, which phosphorylates the CTD at the Ser5 position exclusively 
(Roy et al., 1994) (Wong et al., 2014). The RNApol II enzyme can be found in vivo in a 
non-phosphorylated state (IIA), which is the form recruited to the PIC, or a highly 
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phosphorylated one (IIO), which carries out the elongation phase (Lu et al., 1992).  
 
The regulation mechanisms of the helicase activity of XPB and the kinase activity of cdk7 
can potentially act as control checkpoints for transcription. TFIIE stimulates the ATPase 
activity of XPB up to 5-fold, promoting the start of the transcription reaction (Ohkuma & 
Roeder, 1994). In the case of cdk7, the cdk8 kinase, together with the cyclin C protein, 
phosphorylate cdk7’s partner cyclin H, hindering cdk7’s kinase activity and thus inhibiting 
transcription initiation (Akoulitchev et al., 2000). The cdk8/cyclin C complex can also stop 
transcription initiation through phosphorylation of the CTD of Rpb1 before being recruited 
to the PIC, thus preventing its assembly (Akoulitchev et al., 2000).  
 
1.3.3. Evolutionary conservation 
The three defining steps of the NER process (damage recognition, DNA unwinding and 
removal of the lesion) are essentially conserved in all domains of life, but the systems 
that are responsible for the actual repair reaction are completely different, as previously 
covered in this chapter. Most of the proteins involved in eukaryotic NER can only be 
found in this group, and the genes involved in bacterial and eukaryotic DNA repair show 
no homology, hinting at different origins for the two systems (Eisen & Hanawalt, 1999). 
On the contrary, many archaeal species present clear homologs of the TFIIH helicases 
XPB and XPD (White, 2003), although these proteins always appear as independent 
subunits, without forming a complex like their eukaryotic counterparts. Moreover, no 
homologs of the remaining TFIIH subunits have been found in archaea (Rouillon & White, 
2011).  
 
An exhaustive analysis carried out by Bedez and co-workers showed that the TFIIH Core 
sub-complex is universally present and highly conserved in Eukarya: helicases XPB and 
XPD and subunit p44 were present in all 63 species included in their study. Subunit p52 
is absent in only one species, while p34 was not detected in Euglenozoa. Finally, p8 and 
p62 were absent only in a few unicellular species (Bedez et al., 2013). A second study 
in teleost fish found orthologues of all 10 TFIIH subunits in all the species analysed, 
showing an impressive 80-90% sequence identity, particularly for subunits XPB, XPD 
and cdk7 (Silva et al., 2014). This study also reported a higher conservation of the Core 




relevant role of the 7-subunit sub-complex to functioning TFIIH (Hirsh & Fraser, 2001). 
 
1.3.4. TFIIH as a viral target 
As mentioned before, subunit p62 provides the TFIIH complex with an extensive network 
of contacts with many different proteins. Surprisingly, some of these interactions involve 
viral proteins that target p62 as a means to affect the transcription process (Lyles, 2000). 
 
The non-structural (NSs) protein of the Rift Valley fever virus (RVFV) (responsible for a 
type of haemorrhagic fever in humans and high rates of miscarriage in  livestock (Boshra 
et al., 2011) was first proposed to reduce the host’s transcription levels by sequestering 
free subunits p44 and XPB, making them unavailable for incorporation into TFIIH and 
thus reducing the cellular concentration of the de novo synthesized complex (Le May et 
al., 2010). Later, a more efficient mechanism was observed in which protein NSs 
promotes the degradation of TFIIH subunit p62 (Kalveram et al., 2011) soon after 
infection by directing it to the E3 ubiquitin ligase system (Kainulainen et al., 2014), 
drastically reducing TFIIH levels in the cell. 
 
Subunit p62 is also a target of the transactivator herpes simplex virion protein 16 (VP16) 
(Xiao et al., 1994). The herpes virus is a common human pathogen that presents an 
enormous variety of clinical manifestations, from mild lesions of the mucosal membranes 
to life-threatening symptoms such as encephalitis (Whitley & Roizman, 2001). VP16 
stimulates the expression of immediate-early genes in infected cells, triggering a lytic 
cycle rather than a latent infection (Wysocka & Herr, 2003). In this case, the herpes virus 
hijacks the host’s transcriptional machinery for its own purposes, and binding of VP16 to 
TFIIH subunit p62 will stimulate both the initiation and elongation stages of transcription 
(Blau et al., 1996) (Langlois et al., 2008). 
 
Another transactivation factor that stimulates both host and viral transcription through 
interaction with p62 is the Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) (Chabot 
et al., 2014). EBV is a widely spread virus affecting humans with a predominantly latent 
cycle (Mckenzie & El-guindy, 2015).  The reactivation of the lytic cycle is of particular 
importance in immunocompromised patients and it has been associated to several types 
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of cancer, in particular Hodgkin’s and Burkitt’s lymphoma and nasopharyngeal 
carcinoma (Mckenzie & El-guindy, 2015). 
 
1.4. The MultiBacTM system 
1.4.1. Impact of baculovirus expression systems  
The first paper describing the expression of a heterologous protein in insect cells was 
published by the Summers group in 1983  (Smith et al., 1983): they exploited the 
polyhedrin promoter in the Autographa californica multiple nucleopolyhedrovirus 
(AcMNPV), a baculovirus with a circular, double-stranded DNA genome of about 134 kb 
that infects species of the order Lepidoptera (Hawtin et al., 1997), to overexpress human 
interferon-b.  
 
The development of baculoviral expression vectors (BEVs) was potentiated by several 
helpful characteristics of the AcMNPV: it’s easy to manipulate, and the rod-shape of the 
baculovirus permits the encapsidation of large DNA fragments besides the viral genome. 
As well as having a strong promoter, the polyhedrin gene encodes for a protein that is 
not required for viral replication in cell culture, and its absence in infected cells can be 
used as a marker for selection of recombinant viruses. Lastly, baculoviruses cannot 
replicate in vertebrates, so its use as a protein expression system is completely safe 
(Smith et al., 1983) (Van Oers et al., 2015). 
 
Protein expression using BEVs offers a series of features not available in the more 
traditional E. coli expression system. Frequently, eukaryotic complexes contain subunits 
that are too large for E. coli’s protein production machinery. Insect cells not only don’t 
present this problem, but they also provide post-translational modifications and a folding 
machinery similar to mammalian cells, and while expression of heterologous protein in 
insect cells takes a longer time compared to E. coli, it also offers a higher yield and better 
sample quality (Bieniossek et al., 2012) (Assenberg et al., 2013).  
 
Despite its many advantages, it was not until the system was widely available 
commercially that BEVs became a routinely used tool in laboratories. Although they are 




applications for BEVs are numerous (figure 13), and their efficacy as gene-transfer 
agents in gene therapy and as a system to produce human vaccine components has 
already been reported (Airenne et al., 2013). 
 
                
 
Figure 13: Applications of BEVS in biotechnology. 
Adapted from (Airenne et al., 2013). 
 
1.4.2. The MultiBacTM system: a powerful cloning tool 
1.4.2.1. Heterologous protein expression using MultiBacTM  
Three features make MultiBacTM stand out among the many BEVs options commercially 
available today: (1) a set of small, easy to manipulate vectors that contain a multiplication 
module that allows the creation of multi-gene expression cassettes, (2) a LoxP site for 
creation of multi-gene constructs via recombination in a single, quick step, and (3) a 
baculoviral genome engineered for improved recombinant protein expression 
(Bieniossek et al., 2013). 
 
MultiBacTM includes a set of five small plasmids (figure 14): acceptors pACEBac1 and 
pACEBac2, carrying a gentamycin resistance marker, and donors pIDC, pIDS and pIDK, 
carrying resistance markers for chloramphenicol, spectinomycin and kanamycin, 
respectively. All five plasmids present a multiplication module, consisting of a restriction 
site for a homing endonuclease (I-CeuI for acceptors and PI-SceI for donors) and a 
second restriction site for the BstXI enzyme, that allows the cloning of multiple genes 
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into a single plasmid. Both acceptors and donors also carry a LoxP site that permits the 
obtaining of multi-gene constructs in a single step via recombination with a Cre 
recombinase. Only acceptors present the transposition elements Tn7R and Tn7L that 
will allow transposition into the baculoviral genome at a later stage in the process of 
expressing an heterologous protein, so while any combination of donors can be 
employed, the use of at least one acceptor plasmid is indispensable (Bieniossek et al., 
2013). 
 
              
 
Figure 14: MultiBacTM is a powerful cloning tool.  
Cartoon representation of the acceptor (top panel) and donor (bottom panel) plasmids composing 
the MultiBacTM system. The representation highlights their most important features: homing 
endonuclease / BstXI multiplication module, LoxP recombination site, resistance markers, and 
transposition elements that permit the cloning and expression of multi-subunit eukaryotic 
complexes. Adapted from (Bieniossek et al., 2013). 
 
The multi-gene construct, previously obtained in a regular E. coli strain, will be 
transposed into the baculoviral genome present in strain DH10 MultiBacTM, which also 
contains a transposase encoded in a helper plasmid (Bieniossek et al., 2013). This 




modified for enhanced production of heterologous protein by disruption of the genes V-
CATH and chiA (Bieniossek et al., 2012), which are responsible for the liquefaction of 
the infected larvae to facilitate the dissemination of the new viral particles (Hawtin et al., 
1997).  This modification results in minimization of the proteolytic activity of the virus, 
thus reducing cell lysis and improving protein production (Berger et al., 2004). 
 
Finally, the obtained bacmid – the name given to the recombinant baculovirus - will be 
transfected into insect cells, and the recovered P0 virus will be used for infection of a 
scaled-up insect cell culture for high-yield expression of heterologous protein 
(Bieniossek et al., 2012). 
 
1.4.2.2. MultiBacTM allows expression of multi-protein complexes 
Very rarely proteins carry out their function on their own: they tend to act as complexes 
with other proteins and molecules such as nucleic acids, performing essential reactions 
in fundamental processes like DNA replication or transcription. The research of these 
complexes has been very limited due to the high quality and quantity of the sample 
required for their study, rarely achievable with the cloning and expression tools available 
until recently (Bieniossek et al., 2012), and integrative methods were the best option to 
approach the study of these macromolecular machines (Robinson et al., 2007). With this 
in mind, the MultiBacTM system was specifically conceived as a production tool for 
eukaryotic multi-protein complexes (Berger et al., 2004). 
 
This expression tool solves two problems typically associated with the production of 
multi-protein complexes: it efficiently handles large, multiple genes, and it allows the 
quick modification of the complex if a subunit needs to be altered (e. g. a new purification 
tag needs to be introduced) by replacing the original plasmid with one containing the 
desired modification, without needing to clone the whole complex again (Bieniossek et 
al., 2012).  
 
Structures as big as the anaphase promoting complex (APC/C) (a 1.1 MDa, 13-subunit 
complex that participates in cell cycle regulation) and transcription factor’s Mediator head 
module (223 kDa, 7 subunits), among many others, have been reported after expression 
using the MultiBacTM system. However, the system still presents room for improvement, 
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and issues as undesired post-translational modifications and instability of the infecting 
viral stocks remain to be tackled (Bieniossek et al., 2012).  
 
1.5. Aims and objectives 
The TFIIH complex has been the subject of extensive research since its description in 
1992 (Flores et al., 1992) due to its essential functions in both transcription and DNA 
repair. This PhD project aimed to study the role of the complex, and particularly that of 
the TFIIH Core sub-complex (subunits XPB, XPD, p62, p52, p44, p34 and p8) as a NER 
factor. The objective of our research was to try to understand the reactions taking place 
at the repair bubble that lead to the removal and repair of the damaged fragment, as a 
lot of questions still remain unanswered despite the intensive focus placed on TFIIH: 
 
• How does the complex fit into the repair bubble? Does it bind to the damaged 
strand, the undamaged strand, or both?  
• Does XPD really verify the lesion in the DNA? Does the 4FeS cluster play a role 
in this verification? 
• How do XPB and XPD carry out their roles inside the bubble? And the other 
subunits? How do they interact with DNA, and with each other? Do they undergo 
any conformational changes to bind to the damaged site? 
 
Chapter 3 characterises the binding of XPC (responsible for identifying a lesion in the 
DNA and the first repair factor to bind the damaged site (Sugasawa et al., 1998)) to a 
series of double stranded substrates, confirming it’s preference for mispaired sites rather 
than actual lesions. Chapter 4 describes the process of cloning and expressing both the 
10-subunit complex and the 7-subunit TFIIH Core sub-complex using the MultiBacTM 
cloning system and expressing the complex in Sf9 insect cells, which allowed us to obtain 
up to 1 mg of pure complex from a 2 L culture (such a high yield has only been achieved 
by the Yang group up to date (Li et al., 2015)). Chapter 5 characterizes the binding of 
TFIIH to a series of double-stranded substrates and the unwinding of both damaged and 
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2. Materials and methods 
2.1. Cloning using the MultiBacTM system  
2.1.1. Engineered genes. 2A Sequences  
Synthetic genes (not codon-optimized) for all ten TFIIH subunits, XPC and HR23B were 
ordered from Integrated DNA Technologies (IDT) (see appendix A for full sequences). 
Uniprot accession codes for the protein isoforms employed are indicated in table 2.  
 
Table 2: UniProt accession numbers for the proteins included in this study. 













    
 
Genes for Core subunits p44-p34, p52-p8 and CAK subunits cdk7-cyclin H were 
designed as a single unit, with each pair of genes separated by an autocleavable 2A-like 
encoding sequence (figure 15). 
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Figure 15: TFIIH genes engineered with 2A autocleavable sequences.  
Cartoon representation showing constructs p52-V5-F2A-p8 and p44-T2A-p34 from the Core 
TFIIH sub-complex, and cdk7-T2A-cyclin H from the CAK sub-complex. 
 
These F2A and T2A peptides are variations of the 2A auto-cleavable sequence encoded 
by the genome of the Foot-and-Mouth Disease Virus (FMDV). The 2A sequence causes 
the ribosome to stall during translation, releasing the nascent protein by self-cleaving at 
the NPG’P site and remaining attached to the C-terminal end of the newly translated 
protein without affecting is function or expression (Luke et al., 2009). The ribosome will 
now translocate to the next in-frame starting position, where it will resume translation. 
 
2.1.2. Purification tags 
A six-residue polyhistidine tag was initially designed to be attached to one or several of 
the TFIIH subunits for purification purposes. The tag also included a TEV cleavage site 
(for removal of the tag) and a V5 epitope for protein detection in a Western blot (figure 
16). These two elements are common to all the tags designed for this project. 
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Figure 16: 6xHis-V5-TEV purification tag. 
 
This tag was later modified by introducing a nine-residue spacer between the V5 epitope 
and TEV cleavage sites (figure 17) and the new tag-encoding sequence was cloned not 
only into several TFIIH Core subunits, but also into the XPC and HR23B proteins. Both 
tag-encoding sequences were ordered from IDT as a gBlock (small synthetic DNA 
fragment designed for easy modification of genes) and cloned at the N-terminal end of 
the chosen subunits using restriction enzymes NcoI and XmaI (New England Biolabs) 
following the manufacturer’s instructions. 
 
 
Figure 17: 8xHis-V5-spacer-TEV purification tag.  
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Two additional tags were specifically designed for the purification of subunit XPD. First, 
a ten-residue polyhistidine tag including the TEV cleavage site and the V5 epitope was 
attached to the C-terminal end of the helicase (figure 18):  
 
Figure 18: TEV-10xHis-V5 purification tag.  
 
A sequence encoding a Twin-Strep-tag® streptavidin tag was later cloned also at the C-
terminal end of XPD (figure 19): 
 
Figure 19: Twin-Strep-tag® purification tag. 
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Both tags were ordered from IDT as gBlocks and cloned using restriction enzymes ScaI 
and KpnI (New England Biolabs) as indicated by the manufacturer. 
 
2.1.3. Tetracysteine (TCP) tag 
A sequence encoding a tetracysteine peptide (TCP) (CCGPCC) was cloned at the N-
terminal end of XPC (figure 20 (A)). The tag was ordered from IDT as an oligonucleotide 
and cloned into XPC using the NcoI restriction enzyme (Thermo Fisher Scientific). The 
XPC synthetic gene had previously been cloned into a pACEBac2 plasmid containing an 
8xHis-V5-spacer-TEV purification tag. The presence of the TCP tag was verified by 
sequencing (GATC Biotech). 
 
The same TCP tag-encoding sequence was also cloned at the N-terminal end of TFIIH 
Core subunit XPB, whose gene had been previously cloned into a pACEBac2 plasmid 
using restriction enzymes NcoI and KpnI (figure 20 (B)). The successful cloning of the 
tag was also verified by sequencing. The sequence encoding the TCP-tagged XPB was 
later cloned into the TFIIH Core sub-complex. 
 
 
Figure 20: TCP-tagged XPC and XPB.  
A TCP tag was cloned at the N-terminal end of both XPC (A) and TFIIH Core subunit XPB (B). In 
the case of XPC, the full tag included 8xHis-V5-spacer-TEV-TCP. 
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2.1.4. Cloning using the MultiBac TM multiplication module  
The ten-subunit TFIIH complex and the heterodimer XPC-HR23B were cloned using the 
MultiBacTM baculovirus expression system (Geneva Biotech). As previously mentioned 
in chapter 1, section 1.4.2.1, the MultiBacTM system includes a set of five plasmids: two 
acceptors and three donors, but as we cloned all of our genes using the homing 
endonuclease / BstXI multiplication module, only the acceptor plasmids pACEBac1 
(2904bp) and pACEBac2 (2761bp) (figure 21) were used. Both plasmids carry a 
gentamycin resistance marker, the Tn7R / Tn7L elements necessary for later 
transposition of our TFIIH or XPC-HR23B construct, and a multiplication module defined 
here by the homing endonuclease I-CeuI and the restriction enzyme BstXI. This module 
also encompasses a promoter and a polyadenylation sequence (Bieniossek et al., 2013). 
 
 
Figure 21: pACEBac1 and pACEBac2 vector maps  
(Bieniossek et al., 2013). 
 
In a first step each TFIIH gene, plus XPC and HR23B, was cloned into either pACEBac1 
or pACEBac2 using restriction enzymes BamHI/SalI and NcoI/KpnI (Fermentas), 
respectively, following the manufacturer’s instructions. Afterwards genes were cloned, 
one at a time, into a single plasmid using the multiplication module I-CeuI/BstXI (New 
England Biolabs), as shown in figure 22, until the desired combination was 
accomplished. Several recombinant multi-gene plasmids were created following this 
method: one encoding all seven Core subunits (XPD, XPB, p62, p52-F2A-p8 and p44-
T2A-p34), another one encoding the three CAK subunits (cdk7-T2A-cyclin H and MAT1), 
and a final multi-gene plasmid encoding the heterodimer XPC- HR23B. A list containing 
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all the plasmids generated in the course of this study can be found in appendix B, table 





Figure 22: Cloning using MultiBacTM’s multiplication module.  
In the first reaction (blue box) a plasmid containing one of our genes is linearized with the homing 
endonuclease I-CeuI, which leaves a cohesive end compatible with the one created by BstXI 
when a second gene, located in a different plasmid, is excised with both enzymes. Both the 
linearized vector and excised insert are now ligated as in a regular cloning procedure. This means 
that every time a new gene is cloned into the plasmid a hybrid, non-functional I-CeuI/BstXI site is 
created, and the original BstXI site is restored. In a second reaction (grey box) the plasmid that 
now contains two genes is linearized with I-CeuI as before, and a third gene, located again in a 
different plasmid, is excised with the homing endonuclease and BstXI, etc.  This method 
theoretically allows the cloning of as many expression cassettes as desired (Bieniossek et al., 
2009). 
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Intermediate constructs were verified by restriction with the appropriate combinations of 
different enzymes, such as NcoI, KpnI, BamHI, HindIII, etc. (Fermentas) following the 
manufacturer’s instructions. Final TFIIH Core constructs were further analyzed by PCR 
using the MyTaqTM DNA Polymerase (Bioline) and primers listed in appendix C, 
according to the reaction shown in table 3. All final constructs (TFIIH Core, CAK sub-
complex and heterodimer XPC-HR23B) were ultimately verified by sequencing (GATC 
Biotech) each gene.  
 
Table 3: PCR reaction for verification of intermediate TFIIH Core constructs. 
Cycles 1 30 1 
Temperature 95 °C 95 °C 45 – 50 °C 72 °C 72 °C 
Time 5 minutes 30 seconds 30 seconds 1 minute 10 minutes 
 
 
2.1.5. Tn7 Transposition and bacmid purification 
The recombinant plasmids carrying the TFIIH Core, CAK or XPC-HR23B genes were 
transposed into chemically competent DH10 MultiBacTM cells containing an engineered 
baculoviral genome derived from the AcMNPV virus (Bieniossek et al., 2012) and a 
helper plasmid containing a Tn7 transposase, provided with the MultiBacTM kit. A full list 
of the bacmids generated for this project can be found in appendix B, table B2. The multi-
gene construct is transposed into a Tn7 site, causing the disruption of the lacZ gene, 
which will allow for blue/white colony selection (figure 23).  
 
The transposition protocol was adapted for each construct according to its size: 
 
• Incubation on ice varied from 30 minutes for smaller constructs to 2 hours for the 
seven-gene Core construct. 
• Heat shock went from 60 to 90 seconds for the bigger constructs.  
• Chilling on ice was extended from 5 minutes up to 20 minutes. 
• Finally, the recovery step varied from 6 to 24 hours at 37 °C with shaking as the 
construct grew bigger. 
  MATERIALS AND METHODS 
   43 
Each culture was then plated into LB agar containing 50 µg/ml kanamycin, 7 µg/ml 
gentamycin, 10 µg/ml tetracycline, 100 µg/ml ampicillin, 40 µg/ml isopropyl β-D-1-
thiogalactopyranoside (IPTG) and 20 µg/ml X- gal and incubated at 37 °C for 2-3 days.  
 
                                         
Figure 23: Transposition of a multi-gene construct into the baculoviral genome.  
Positive transpositions will appear as white colonies amid a background of blue unsuccessful 
ones when plated in LB agar containing 50 µg/ml kanamycin, 7 µg/ml gentamycin, 10 µg/ml 
tetracycline, 100 µg/ml ampicillin, 40 µg/ml IPTG and 20 µg/ml X-gal (Bieniossek et al., 2013).  
 
A minimum of two recombinant white colonies per construct were picked and re-streaked 
to confirm their white phenotype. These colonies were also used to start 3 ml Luria-
Bertani (LB) broth cultures containing 50 µg/ml kanamycin and 7 µg/ml gentamycin. The 
cultures were incubated at 37 °C, 200 rpm overnight, then centrifuged at 15000 rpm for 
1 minute at room temperature (centrifuge 5424, Eppendorf).  Pellet was resuspended in 
buffer P1, then buffer P2 and finally buffer N3 from a QIAprep Spin Miniprep Kit (Qiagen). 
The suspension was centrifuged at 15000 rpm for 10 minutes at room temperature, and 
supernatant was transferred to a fresh tube. The baculoviral DNA present in the 
supernatant was precipitated with isopropanol and washed twice with ethanol 70%. All 
work following the second washing step was performed in a sterile S@feflow 1.2 hood 
(Bioair Instruments). Ethanol was removed from the tube, and sterile bacmids were 
finally resuspended in 30 µl deionized water and kept at 4 °C until transfected.  
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2.2. Insect cell culture techniques 
2.2.1. Routine maintenance of insect cell cultures 
A running stock of Spodoptera frugiperda (Sf9) cells (Thermo Scientific) is kept in the 
form of monolayers cultured in T75 flasks (Greiner Bio-One) (figure 24), incubated at 27 
°C in a MaxQ 6000 incubator (Thermo Scientific). Monolayers are sub-cultured every 
five to six days in sterile conditions in a S@feflow 1.2 hood (Bioair Instruments), with 
Sf900TM III serum-free medium (SFM) (Gibco). 
 
The cells were adapted from monolayer to suspension conditions before every infection. 
A starter 25 ml Sf900TM III SFM medium suspension culture with an initial cell density of 
1x106 cells/ml was initiated in 125 ml disposable shaker flasks (Corning) and incubated 
at 27 °C with 110 rpm orbital shaking. The suspension was sub-cultured back to 1x106 




Figure 24: Summary of Sf9 culture techniques. 
  MATERIALS AND METHODS 
   45 
2.2.2. Insect cell transfection  
Recombinant bacmids were transfected into a monolayer of Sf9 cells using X- 
tremeGENE HP DNA Transfection Reagent (Roche). 1x106 Cells were seeded to each 
well in a 6-well plate (Greiner Bio-One), and volume was topped up to 3 ml with fresh 
Sf900TM III SFM medium. The plate was incubated at 27 °C for a minimum of 2 hours to 
allow cells to attach to the surface of the well. Meanwhile, each bacmid to be transfected 
was resuspended in 200 µl Sf900TM III SFM medium. A mixture of 100 µl Sf900TM III SFM 
medium and 10 µl transfection reagent was added to each bacmid, and tubes were 
incubated at room temperature for 30 minutes. Afterwards, the bacmid/transfection 
reagent mixture was added to the Sf9 cell monolayer (2 wells for every bacmid to be 
transfected), and plates were incubated at 27 °C for 60 hours before recovering a P0 
viral stock (figure 24).  
 
2.2.3. Insect cell infection  
Infections were carried out in a Sf9 suspension culture with a starting cell density of 1x106 
cells/ml in a total volume of 25 ml Sf900TM III SFM medium. This suspension was infected 
with 3 ml of a passage 0 (P0) viral stock and incubated for 60 hours in a shaker flask at 
27 °C with 110 rpm orbital shaking (figure 24). Afterwards, cell pellet and medium 
containing viral stock P1 were collected by centrifugation (CF20 centrifuge, Awel) at 
1000 rpm for 5 minutes and kept at -80 °C until tested. Once expression levels had been 
evaluated, the volume of the Sf9 suspension was scaled up appropriately for TFIIH Core, 
CAK or XPC-HR23B overexpression. Infections are always performed using 3 ml virus 
for every 25 ml cell suspension, generally utilizing viral stocks obtained from cultures that 
have been passaged one (P1) or two (P2) times.   
 
2.2.4. Insect cell co-infection 
A co-infection experiment was carried out to obtain the 10-subunit TFIIH complex. For 
this test, a 25 ml Sf9 suspension with a starting cell density of 1x106 cells/ml was infected 
with 1 ml of a P3 TFIIH Core viral stock and 3 ml of a P0 CAK viral stock. The suspension 
was incubated for 60 hours at 27 °C with 110 rpm orbital shaking, and after that time the 
pellet and medium containing a viral stock P1 that included all ten TFIIH subunits were 
harvested as described for our regular infection experiments. After evaluation of the 
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expression levels, the volume of the Sf9 suspension was scaled up, and co-infections 
were performed with 3 ml of a P1, P2 or P3 10-subunit TFIIH viral stock for every 25 ml 
cell suspension.   
 
2.3. Purification of the TFIIH complex 
2.3.1. TFIIH Extraction and BioSprint expression tests  
Expression levels for the different TFIIH complexes obtained were checked from a 25 ml 
Sf9 suspension culture infected with 3 ml of a P0 viral stock as described in section 2.2.3. 
Cell pellet was harvested by centrifugation and resuspended in 5 ml lysis buffer 
(phosphate-buffered saline (PBS), 300 mM NaCl, 0.1% Triton, plus 10 units/ml DNAseI 
(Sigma) and a protease inhibitor cocktail (Roche)) per gram of pellet. The resuspended 
cells were subsequently lysed with a dounce homogenizer (Fisher Scientific) (20 strokes 
with a tight pestle, performed on ice) and centrifuged at 13000 rpm for 30 minutes at 4 
°C (centrifuge 5415, Eppendorf). The cleared supernatant was then transferred to a fresh 
tube and analyzed in a BioSprint station (Qiagen): 500 µl supernatant and 10 µl magnetic 
Ni-NTA beads (Promega) were loaded into the first column of the BioSprint sample tray. 
After binding, the beads were washed twice with 500 µl buffer PBS, 300 mM NaCl, 30 
mM imidazole, and bound proteins were eluted in 50 µl buffer PBS, 300 mM NaCl, 300 
mM imidazole.  
 
2.3.1.1. BioSprint expression test in anaerobic conditions 
Pellet was harvested by centrifugation from a 25 ml Sf9 suspension culture infected with 
3 ml of a P0 viral stock and resuspended in 5 ml lysis buffer per gram of pellet, previously 
degassed with nitrogen for 20 minutes. Extraction of the recombinant TFIIH Core sub-
complex was performed in a glove box in an anaerobic atmosphere following the method 
described in the previous section. The cleared supernatant was transferred to a fresh 
tube and the sub-complex was purified by performing the same steps included in the 
BioSprint process manually: 1 ml supernatant was added to a tube containing 30 µl 
magnetic Ni-NTA beads (Promega) and incubated for 15 minutes, mixing frequently. The 
supernatant was separated with the help of a magnetic rack, and the beads were washed 
twice with 1 ml degassed wash buffer. The TFIIH Core sub-complex was finally eluted 
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from the beads with 100 µl degassed elution buffer after a 10-minute incubation period. 
Beads were finally resuspended in 100 µl wash buffer and a sample was loaded into a 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel to verify that 
the complex had been successfully eluted.   
 
2.3.1.2. SDS-PAGE analysis  
The different fractions obtained from the BioSprint purification test were verified by SDS-
PAGE analysis. Loading buffer (NuPAGE™ LDS Sample Buffer (4X) 1 mM dithiothreitol 
(DTT) (Thermo Scientific)) was added to samples prior to heating them at 90 °C for 2 
minutes. Afterwards, samples were loaded into a NuPAGE™ 4-12% Bis-Tris Protein Gel 
(Thermo Scientific) and run at 200 V for 35 minutes in 1X NuPAGE™ MES SDS Running 
Buffer (Thermo Scientific). Gels were finally stained with InstantBlueTM Protein Stain 
(Expedeon) for 20-30 minutes approximately and rinsed with water before analysis. 
 
2.3.1.3. Western blotting analysis 
Sometimes expression levels for certain constructs were too low to be observed in an 
SDS-PAGE gel, and a Western blot was required for the analysis. Samples of interest 
would be first run in an SDS-PAGE gel as described in the previous section, using a 
PageRuler™ Prestained Protein Ladder (Thermo Scientific) as a marker. The gel was 
later blotted using the iBlot® nitrocellulose mini Gel Transfer Stacks required for the 
iBlot® system (Thermo Scientific), following the manufacturer’s indications. Blots were 
blocked in blocking buffer (500 ml PBS with 25 g milk powder and 250 µl Tween®20 
(Sigma)) for 60 minutes. Afterwards, they were incubated in a blocking buffer solution 
containing 1:20000 V5 primary antibody (kindly provided by Prof. Richard Randall) for 
60 minutes and washed three times with fresh blocking buffer for 10 minutes each time. 
The blot was incubated then in a solution of fresh blocking buffer containing 1:10000 
IRDye 800CW Goat anti-Mouse IgG (H + L) (LI-COR) fluorescent secondary antibody 
for 60 minutes, protected from light, and washed again three times with PBS for 10 
minutes each time, always protected from light. All incubation and washing steps were 
performed at room temperature with mild rocking. Finally, blots were scanned using an 
Odyssey CLx instrument (LI-COR) with 778 nm excitation and 795 nm emission 
wavelengths. 
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2.3.2. Immunoprecipitation using a V5 antibody 
Immunoprecipitation (IP) experiments were performed to determine if the cloned His tag 
was sufficient to allow the whole TFIIH Core sub-complex to be pulled down. 50 µl 
Protein G magnetic beads (Invitrogen) and 200 µl PBS, 0.02% Tween® 20 containing 
10 µg V5 antibody were incubated in a rotator at room temperature for 10 minutes. The 
protein G beads/V5 antibody complex was crosslinked afterwards with 20 mM dimethyl 
pimelimidate (DMP), 0.2 M triethanolamine, pH 8.2 following the manufacturer’s 
indications. The supernatant containing the TFIIH Core subunits was added to the 
crosslinked complex, and the mixture was incubated in a rotator at room temperature for 
15 minutes. This supernatant was obtained by rupture of the Sf9 cells with a dounce 
homogenizer, following the same method described in section 2.3.1. TFIIH Core was 
excised from the beads/V5 antibody complex by cleaving with TEV, performed overnight 
both at room temperature and 4 °C, and the different fractions were analyzed by Western 
blotting. 
 
2.3.3. Immobilised metal ion affinity chromatography (IMAC) 
2.3.3.1. HisTrapTM Fast Flow (FF) column 
Cell pellet for the different TFIIH Core sub-complexes was harvested by centrifugation 
at 1000 rpm for 5 minutes at 4 °C (Allegra 21R centrifuge, Beckman Coulter) and 
resuspended in 5 ml lysis buffer per gram of pellet (PBS, 300 mM NaCl, 0.1% Triton, 
plus 10 units/ml DNAseI (Sigma) and a protease inhibitor cocktail (Roche), degassed 
with argon). Suspensions were then passed through a dounce homogeneizer (at least 
20 strokes, keeping suspension on ice at all times) and centrifuged at 40000 rpm for 45 
minutes at 4 °C (Optima L-90K ultracentrifuge, Beckman Coulter). The cleared 
supernatant was filtered (0.45 µm) afterwards and loaded into a 1 ml HisTrapTM FF 
column (GE Healthcare), and purification was performed using an Äkta system (GE 
Healthcare). After washing the column with buffer A (PBS pH 7.5, 300 mM NaCl, 30 mM 
imidazole, 10% glycerol), bound proteins were eluted in an imidazole gradient created 
by buffer B (PBS pH 7.5, 300 mM NaCl, 500 mM imidazole, 10% glycerol). Purified 
fractions containing the TFIIH core complex were pooled together and concentrated 
using an Amicon® concentrator with a 30K cutoff (Millipore).  
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2.3.3.2. XPD purification using detergent ANAPOE C12E8  
Pellet was harvested as previously described and resuspended in lysis buffer 50 mM 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.5, 300 mM potassium 
acetate, 2 mM 2-mercaptoethanol (BME), 5 mM ANAPOE C12E8, plus a protease 
inhibitor cocktail (Roche). The suspension was sonicated at 12 microns (10 seconds on 
and 20 seconds off, repeated 10 times) and centrifuged at 15000 rpm at 4 °C for 30 
minutes (centrifuge 5424, Eppendorf). The cleared supernatant was subsequently 
diluted to a final concentration of 1 mM ANAPOE C12E8 to facilitate binding to the 
HisTrapTM column, then filtered (0.45 µm) and loaded into a 1 ml HisTrapTM FF column 
(GE Healthcare). The following steps in the purification were as described in the previous 
section, with buffer A containing 50 mM HEPES pH 7.5, 300 mM potassium acetate, 2 
mM BME, 1 mM ANAPOE C12E8, 30 mM imidazole, and buffer B consisting of 50 mM 
HEPES pH 7.5, 300 mM potassium acetate, 2 mM BME, 1 mM ANAPOE C12E8, 500 mM 
imidazole. Fractions of interest were analyzed by SDS-PAGE and Western blotting. 
 
2.3.3.3. Talon® SuperflowTM resin 
In an attempt to increase the yield of subunit XPD the IMAC step was later modified, 
using a Talon® SuperflowTM resin (GE Healthcare) instead of a HisTrapTM FF column to 
maximize the contact between the helicase and the resin. The resin was prepared for 
purification following the manufacturer’s indications. Cleared supernatant obtained as 
previously described was added to 1-2 ml resin and incubated at 4 °C for 1 hour with 
rotation. Resin and supernatant were then transferred into an empty 10 ml gravity-flow 
column previously prepared as indicated by the manufacturer (Thermo Scientific). Resin 
was allowed to settle for 15-30 minutes, and after that time the supernatant was eluted. 
This step was repeated until all of the resin had been packed and all the supernatant had 
been eluted. Ten times resin bed volume of buffer A (PBS pH 7.5, 300 mM NaCl, 30 mM 
imidazole, 10% glycerol) were added to the column and incubated at room temperature 
for 10 minutes, then slowly eluted to wash the resin. The TFIIH Core sub-complex was 
eluted with five times resin bed volume of buffer B (PBS pH 7.5, 300 mM NaCl, 500 mM 
imidazole, 10% glycerol): first 1 ml buffer was eluted and collected. The rest of the 
volume was incubated with the resin at room temperature for 10 minutes, then eluted 
and collected in 1 ml fractions. The different fractions were analyzed by SDS-PAGE. 
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2.3.4. Size exclusion chromatography 
The concentrated sample obtained in the metal ion affinity chromatography previously 
described was loaded into a HiPrepTM 16/60 SephacrylTM S300 HR column (GE 
Healthcare) and eluted with 20 mM HEPES pH 7.0, 200 mM NaCl, 1 mM DTT, 10% 
glycerol. Fractions containing the complex were pooled together and concentrated as 
described in section 2.3.3.1. 
 
2.3.5. Cation exchange chromatography 
In a third purification step, the selected fractions from the size exclusion chromatography 
were loaded into a MonoSTM 4.6/100 PE column (GE Healthcare) after being 
concentrated. After a washing step with buffer A (20 mM HEPES pH 7.0, 50 mM NaCl, 
1 mM DTT, 10% glycerol), bound proteins were eluted in a gradient of salt created by a 
combination of buffer A and buffer B (20 mM HEPES pH 7.0, 500 mM NaCl, 1 mM DTT, 
10% glycerol). The sample was finally concentrated, aliquoted and stored at -80 °C. 
 
2.3.6. Affinity chromatography 
Sub-complex TFIIH Core carrying two 6xHis-V5-TEV tags at the N-terminal end of 
subunits p52 and p62 and a Twin-Strep-tag® at the C-terminal end of subunit XPD was 
purified through a Talon® resin first, then through a size exclusion column, and finally 
through a Strep-Tactin®XT resin (IBA GmbH). A Bio-Rad 1.5 x 20 cm gravity flow Econo-
column® packed with the Strep-Tactin®XT matrix was first equilibrated with two column 
volumes of wash buffer PBS pH 7.5, 300 mM NaCl. Fractions of interest collected after 
size exclusion were concentrated, added to the column and incubated with the resin for 
15 – 30 minutes at room temperature, and after that time the supernatant was eluted. 
The resin was then washed with one column volume of wash buffer. The TFIIH Core 
sub-complex was finally eluted with three column volumes of elution buffer (PBS pH 7.5, 
300 mM NaCl, 50 mM biotin). The different fractions were analyzed by SDS-PAGE, and 
the purified sub-complex was finally concentrated, aliquoted and stored at -80 °C. 
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2.4. Purification of XPC constructs 
2.4.1. XPC Extraction and BioSprint expression tests 
All XPC proteins (monomeric XPC, TCP-tagged XPC and heterodimer XPC- HR23B) 
were pelleted, extracted and tested for expression in a BioSprint station following the 
same protocol employed to obtain the different TFIIH constructs (section 2.3.1). 
 
2.4.2. Immobilised metal ion affinity chromatography  
2.4.2.1. HisTrapTM FF column 
Cell pellet for the different XPC proteins was harvested by centrifugation at 1000 rpm for 
5 minutes at 4 °C (Allegra 21R centrifuge, Beckman Coulter) and resuspended in 5 ml 
lysis buffer per gram of pellet (PBS, 300 mM NaCl, 0.1% Triton, plus 10 units/ml DNAseI 
(Sigma) and a protease inhibitor cocktail (Roche)). Suspensions were then passed 
through a dounce homogeneizer (at least 20 strokes, keeping suspension on ice at all 
times) and centrifuged at 40000 rpm for 45 minutes at 4 °C (Optima L-90K 
ultracentrifuge, Beckman Coulter). The cleared supernatant was filtered (0.45 µm) 
afterwards and loaded into a 5 ml HisTrapTM FF column (GE Healthcare). Purification 
was performed using an Äkta system (GE Healthcare). After washing the column with 
buffer A (PBS pH 7.5, 363 mM NaCl, 30 mM imidazole, 0.5 mM DTT, 10% glycerol), 
bound proteins were eluted in an imidazole gradient created by buffer B (PBS pH 7.5, 
363 mM NaCl, 300 mM imidazole, 0.5 mM DTT, 10% glycerol). Purified fractions 
containing the XPC construct were pooled together and concentrated using an Amicon® 
concentrator with a 30K cutoff (Millipore).  
 
2.4.2.2. Talon® SuperflowTM resin 
The HisTrapTM FF column was replaced by a Talon® SuperflowTM resin (GE Healthcare) 
in later purifications to maximize the contact between the protein and the resin, thus 
increasing protein recovery. Resin preparation, incubation with the cleared supernatant, 
and packing into a gravity-flow column was performed as previously described in section 
2.3.3.3. The resin was then washed with ten times resin bed volume of buffer A (PBS pH 
7.5, 363 mM NaCl, 30 mM imidazole, 0.5 mM DTT, 10% glycerol) and incubated at room 
temperature for 10 minutes, then slowly eluted to wash the resin. The XPC-HR23B 
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heterodimer was eluted with five times resin bed volume of buffer B (PBS pH 7.5, 363 
mM NaCl, 300 mM imidazole, 0.5 mM DTT, 10% glycerol). 1 ml Buffer was first eluted 
and collected; the remainder volume was incubated with the resin at room temperature 
for 10 minutes, then it was eluted and collected in 1 ml fractions that were finally analyzed 
by SDS-PAGE. 
 
2.4.3. Size exclusion chromatography 
The concentrated sample obtained from the metal ion affinity chromatography previously 
described was loaded into a HiPrepTM 16/60 SuperdexTM S200 prep grade column (GE 
Healthcare) and eluted with PBS pH 7.5, 63 mM NaCl, 0.5 mM DTT, 10% glycerol. 
Fractions containing the XPC construct were pooled together and concentrated as 
described in section 2.3.3.1. Purified heterodimer XPC-HR23B was concentrated, 
aliquoted and stored at -80 °C after this chromatographic step. 
 
2.4.4. Cation exchange chromatography 
Fractions containing the XPC protein eluted in the previous size exclusion 
chromatography were loaded into a MonoSTM 4.6/100 PE column (GE Healthcare) after 
being concentrated. The column-bound protein was then washed with buffer A (PBS pH 
7.5, 0.5 mM DTT, 10% glycerol), and finally eluted in a gradient of salt created by a 
combination of buffer A and buffer B (PBS pH 7.5, 863 mM NaCl, 0.5 mM DTT, 10% 
glycerol). TCP-tagged XPC was concentrated, aliquoted and stored at -80 °C after this 
step. 
 
2.4.5. Heparin chromatography 
The purification of monomeric XPC and TCP-tagged XPC required and additional 
chromatography step (in the case of TCP-XPC, this step replaces the size exclusion 
chromatography usually performed after IMAC). Fractions of interest collected after 
cation exchange (XPC) or IMAC (TCP-XPC) were concentrated and loaded into a 
HiTrapTM Heparin HP column (GE Healthcare). The column was washed with buffer A 
(PBS pH 7.5), before eluting bound proteins in a gradient of salt created by combining 
buffer A and buffer B (PBS pH 7.5, 1 M (total) NaCl) in different proportions. The purified 
protein was then concentrated, aliquoted and stored at -80 °C in the case of monomeric 
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XPC, while fractions containing TCP-XPC were pooled together, concentrated and 
loaded into a MonoSTM 4.6/100 PE column for a final cation exchange chromatographic 
step. 
 
2.5. Biochemical characterization of XPC and the TFIIH 
Core sub-complex 
2.5.1. ReAsH-EDT2 Labelling of TCP-tagged XPC and TFIIH Core 
Both TCP-tagged XPC and TFIIH Core (with subunit XPB carrying the TCP tag) were 
labelled with the resorufin-based biarsenical reagent ReAsH carrying two 1,2-
ethanedithiol (EDT) molecules (ReAsH-EDT2) (Adams et al., 2002) (Thermo Fisher 
Scientific) that becomes fluorescent when bound to the tetracysteine motif present in the 
TCP tag. Additionally, the rigid attachment of the ReAsH ligand to the tetracysteine motif 
offers a stronger signal compared to conventional fluorescent reagents that present more 
flexible bonds (Adams et al., 2002). 
 
A 100 µl reaction containing 1 mM tris(2-carboxyethyl)phosphine (TCEP), 1 mM BME, 
10 µM ReAsH-EDT2 and TCP-XPC or TCP-TFIIH Core to a final concentration of 2.2 µM 
and 0.57 µM, respectively, was incubated at 4 °C for 30 minutes (protocol adapted from 
(Park et al., 2004)). The TCEP and BME added to the reaction will break the disulphide 
bonds in the ReAsH-EDT2 reagent so it can bind to the tetracysteine motif present in the 
TCP tag cloned into N-terminal XPC and N-terminal XPB (within the TFIIH Core sub-
complex), becoming fluorescent as a result of the binding.  
 
After that time, ReAsH-labeled TCP-XPC and TCP-TFIIH Core were titrated in a Varian 
Cary Eclipse fluorescence spectrophotometer (Agilent) using the Scan application 
included in the software package provided with the instrument. The reagent was excited 
with a wavelength of 593 nm and the emitted fluorescence was collected at a wavelength 
of 608 nm. To perform the titration both reactions were diluted 100-fold, and 1 µl of the 
corresponding dilution was added to a cuvette containing 119 µl buffer 20 mM HEPES 
pH 7.0, 500 mM NaCl, 1 mM DTT in each titration step. A reaction in which buffer 20 mM 
HEPES pH 7.0, 500 mM NaCl, 1 mM DTT was added instead of TCP-XPC or TCP-TFIIH 
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was used as a control to measure the intensity of the non-bound ReAsH reagent. The 
obtained fluorescence emission intensity values were plotted against monomeric XPC / 
TFIIH Core concentration using the RStudio software (RStudio, Inc.). 
 
2.5.2. Crosslinking assays 
Crosslinking assays were performed in a 20 µl reaction containing buffer 20 mM HEPES 
pH 7.5, 50 mM NaCl, 1 mM DTT, 10% glycerol, 10 µg TFIIH Core sub-complex with 
subunits p52 and p62 tagged at their N-terminal end with 6xHis-V5-TEV, and different 
concentrations (0.25 µg/µl, 0.5 µg/µl, 0.75 µg/µl, and 1 µg/µl) of crosslinker 
bis(sulfosuccinimidyl)suberate (BS3) d0/d4 (Thermo Scientific). The different reactions 
were incubated at 25 °C with 350 rpm shaking for 1 hour, and then loaded into an SDS-
PAGE gel. Bands of interests were cut from the gel and analyzed by mass spectrometry 
(MS), and the resulting peptides were checked for crosslinks using the MassMatrix 
software. 
 
2.5.3. DNA substrate preparation 
Single strands of DNA were purchased from IDT (strands A to E) or Primetech ALC 
(strands F, G) and resuspended in 50 mM Tris pH 7.5 to a final concentration of 500 µM 
(see appendix D for sequences and substrate composition).  
 
Double stranded substrates employed in the experiments described in sections 2.5.4 
and 2.5.5 were obtained by annealing in a 50 µl reaction containing buffer 50 mM Tris 
pH 7.5, 100 mM NaCl and the appropriate single strands to a final concentration of 20 
µM. The mixture was heated in a water bath at 90 °C for 5 minutes and left to slowly cool 
down overnight. A final concentration of 3% Ficoll was added to the reaction now 
containing our double-stranded substrates and they were purified in a 10% 
polyacrylamide native gel, run in Tris – Borate – Ethylenediaminetetraacetic acid (EDTA) 
(TBE) buffer, 10 mM NaCl at 4 °C, 120 V for 3-4 hours, protected from light. Bands of 
interest were cut, placed in an Eppendorf tube and slightly crushed, then covered with 
buffer 50 mM Tris pH 7.5. The tubes were incubated at 4 °C overnight with rocking to 
promote diffusion of the substrates from the acrylamide towards the buffer. Afterwards, 
the buffer was separated from the acrylamide and the double-stranded substrates were 
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precipitated with 10% volume 3 M sodium acetate pH 5.2 and 250% volume chilled EtOH 
100% and incubated at -20 °C overnight. Finally, the reactions were centrifuged at 15000 
rpm at 4 °C for 30 minutes (centrifuge 5424, Eppendorf), the supernatant was 
immediately removed, and the pelleted DNA substrates were resuspended in an 
appropriate volume of 50 mM Tris pH 7.5 buffer. 
 
2.5.4. Electrophoretic mobility shift assays (EMSA) 
Band shifting assays were performed in a 10 µl reaction containing buffer 20 mM HEPES 
pH 7.5, 1 mM DTT, 50 mM NaCl, 1 mM EDTA, 4% glycerol, a 90 nM DNA substrate with 
a fluorescein label (figure 25, full sequence in appendix D) and either sub-complex TFIIH 
Core or heterodimer XPC-HR23B at several different concentrations. Reaction mixtures 
were incubated for 30 minutes at room temperature, protected from light. After that time, 
10 µl Ficoll 15% (Sigma) were added to each sample and they were loaded into a 5 - 
10% polyacrylamide native gel which was run at 4 °C and 180 V, protected from light, 
for 3 hours approximately; afterwards, the gel was scanned in a Typhoon FLA 7000 laser 
scanner (GE Healthcare). A control reaction that included the DNA substrate but not the 






Figure 25: DNA substrates employed in EMSA assays.  
Schematic representation of the different DNA substrates carrying a fluorescein label (yellow 
sphere) used in the band shifting assays performed with heterodimer XPC-HR23B and the TFIIH 
Core sub-complex. Substrates S7 and S8 also carry a Cy3 dye (pink sphere) at the left (S7) or 
right (S8) of the three-nucleotide bubble. 
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2.5.5. Fluorescence experiments 
2.5.5.1. Fluorescence anisotropy assays 
DNA binding of monomeric XPC, 10-subunit TFIIH and the TFIIH Core sub-complex was 
further analyzed by measuring fluorescence anisotropy (r). In these experiments, 
samples were excited with a polarized light, and emitted fluorescence was collected 
through a perpendicularly oriented polarizer with respect to the excitation light, allowing 
the calculation of the emission anisotropy ( r ) based on the equation  
 
                                          r = (I|| - GI^) / (I|| + 2GI^) 
 
where G is a geometric factor calculated to correct the polarization bias of the instrument. 
The fast rotation of our fluorescein-labelled substrates in the reaction solution leads to 
an efficient depolarization of the light (low r value), while binding to a large molecule such 
as XPC or the TFIIH sub-complex will cause a restriction in its movement and a less 
efficient depolarization (high r values). The emission anisotropy can now be plotted 
against protein concentration, and a KD value can finally be obtained.  
 
Reactions were carried out in a 150 µl solution containing 25 nM of a DNA substrate 
carrying a fluorescein label in buffer 20 mM 2-(N-morpholino)ethanesulfonic acid (MES) 
pH 6.5 (figure 26, full sequence in appendix D). Later experiments with construct TFIIH 
Core were performed in buffer 20 mM HEPES pH 7.0, 50 mM NaCl. The solution was 
loaded into a quartz cuvette and our protein / complex of interest was titrated using the 
Eclipse ADL application included in the software package provided with the Varian Cary 
Eclipse fluorescence spectrophotometer (Agilent Technologies), exciting the fluorescein 
molecule at 480 nm and collecting emitted fluorescence at 525 nm. Geometry factor G 
was calculated by the program at the beginning of every experiment, and each r value 
obtained was the resulting average of five measurements taken for every titration point. 
All experiments were carried out with automatic polarizers at 25 °C. The obtained r 
values were plotted against XPC-HR23B/ TFIIH Core concentration and the resulting 
data were fitted to a binding curve with the KaleidaGraph program (Synergy Software), 
using equation 
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A = Amin + [(D + E+ KD) – {(D + E + KD)2 – (4DE)}1/2] (Amax – Amin)/(2D) 
 
where A is anisotropy, Amin is anisotropy of free DNA, D is total DNA concentration, E is 
total protein concentration, KD is the disassociation constant and Amax is maximum 
anisotropy of the DNA-XPC-HR23B or DNA-TFIIH Core complex. The equation assumes 
a DNA:protein binding of 1:1 (Reid et al., 2001). 
 
                 
 
Figure 26: DNA substrates employed in fluorescence anisotropy assays.  
Schematic representation of the different DNA substrates tested for binding to monomeric XPC, 
10-subunit TFIIH or TFIIH Core by measuring their fluorescence anisotropy. Each substrate 
carries a fluorescein label (yellow sphere). Substrates S3 and S4 also present an 18-nucleotide 
bubble, and S5 and S6 carry a 3-nucleotide bubble. 
  
2.5.5.2. Bulk fluorescence resonance energy transfer (FRET) assays 
Binding of XPC-HR23B, TFIIH Core and XPC-HR23B-TFIIH Core was also analyzed by 
bulk FRET, a process based on the non-radiative transfer of energy from a donor 
molecule to an acceptor one, located in close distance. The XPC-HR23B heterodimer 
and TFIIH Core sub-complex were titrated in a quartz cuvette containing 150 µl of a 
solution of 20 mM HEPES pH 7.0, 50 mM NaCl and a 20 nM DNA substrate S7 or S8 
(figure 27, full sequence in appendix D). To analyze the binding of the complex XPC-
HR23B-TFIIH Core, the TFIIH Core sub-complex was titrated in a quartz cuvette 
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containing 150 µl of a solution of 20 mM HEPES pH 7.0, 50 mM NaCl, 0.5 mM DTT, a 
20 nM DNA substrate S7 or S8 and 100 nM XPC-HR23B heterodimer.   
 
All experiments were carried out at 25 °C in a Varian Cary Eclipse fluorescence 
spectrophotometer using the Scan application included in the Varian Eclipse software 
package. The fluorescein label (FRET donor) was excited at 490 nm, while the Cy3 
molecule (FRET acceptor) was excited at 542 nm. Ratio A values (defined as the 
calculated fluorescence signal of the acceptor, in this case Cy3, normalized by the 
acceptor fluorescence spectrum of the sample (Lorenz & Diekmann, 2006)) were 
calculated for each data point and plotted against the appropriate complex concentration. 
In the case of XPC-HR23B and XPC-HR23B-TFIIH Core the resulting data were fitted to 
a binding curve with the SigmaPlot program (Systat Software Inc.), using the Hill 
equation (Hill, 1910) 
 
                                        f = f0 + ((b(x)n) / ((KD)n + (x) n)) 
 
where f is FRET, f0 is minimum FRET, b is the amplitude of FRET, x is total protein 
concentration, KD is the disassociation constant and n is the Hill coefficient (a measure 
of the cooperativity of the binding process). 
 
Data corresponding to the binding of XPC-HR23B to substrate S7 was fit to a Hill 
equation comprising two components 
 
                         f = f0 + ((b(x)n1) / ((KD1)n1 + (x) n1)) + ((d(x)n2) / ((KD2)n2 + (x) n2)) 
 
In the case of TFIIH Core data were fitted to a binding curve, also with the SigmaPlot 
program, but using equation 
 
A = Amin + [(D + E+ KD) – {(D + E + KD)2 – (4DE)}1/2] (Amax – Amin)/(2D) 
 
which assumes a DNA:protein binding of 1:1 (Reid et al., 2001). In this equation A is 
FRET, Amin is minimum FRET, D is total DNA concentration, E is total protein 
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Figure 27: DNA substrates employed in bulk FRET assays.  
Cartoon representation of the different DNA substrates employed in bulk FRET experiments to 
study binding of XPC-HR23B, XPC-HR23B-TFIIH Core and TFIIH Core to double-stranded DNA. 
Both substrates carry a fluorescein label (yellow sphere) and a Cy3 dye (pink sphere) at the left 
(S7) or right (S8) of the 3-nucleotide bubble. 
 
2.5.5.3. Fluorescence-based helicase assays 
The unwinding activity of TFIIH Core was evaluated in a fluorescence helicase assay 
employing a series of substrates in which a quencher, placed to suppress a Cy3 dye, will 
be removed upon unwinding by the sub-complex, thus permitting the detection of the 
fluorescence emitted by Cy3. Initial helicase activity assays were carried out at 25 - 37 
°C in a 150 µl reaction containing buffer 20 mM HEPES pH 7.0, 50 mM NaCl, 0.1 mg/ml 
bovine serum albumin (BSA), 1 mM MgCl2, 25 - 50 nM DNA substrate containing a Cy3 
dye (figure 28) and 50 nM – 1 µM TFIIH Core sub-complex, with 0.5 – 1mM ATP added 
to the cuvette containing the full reaction or to the empty cuvette, to have the rest of the 
reaction loaded in a second step. Optimal conditions for the assay were finally 
established as 20 mM HEPES pH 7.0, 50 mM NaCl, 0.1 mg/ml BSA, 1 mM MgCl2, 25 
nM DNA substrate 50 nM TFIIH Core sub-complex, performed at 25 °C. The reaction 
mixture was then incubated at room temperature for 10 minutes before being added to 
a cuvette containing 1 mM ATP, previously incubated at room temperature for 10 
minutes, too. In the assays evaluating the effect of proteins XPA, RPA or both on TFIIH 
Core unwinding the reaction just described (containing the TFIIH Core sub-complex) was 
incubated at room temperature for 9 minutes approximately, then 50 nM XPA, RPA or 
both (as required) was added to the reaction and the final mixture was added to the 
quartz cuvette containing 1 mM ATP after a total incubation time of 10 minutes. Activity 
MATERIALS AND METHODS 
 
 60 
was measured for 15 minutes in a Varian Cary Eclipse fluorescence spectrophotometer 
using the Kinetics application included in the software package provided with the 
instrument. The Cy3 dye was excited at a wavelength of 547 nm, and emitted 
fluorescence was collected at a wavelength of 565 nm. The obtained fluorescence 
emission intensity values were plotted against TFIIH Core concentration and data were 
fitted to a bi-exponential model with the SigmaPlot program (Systat Software Inc.), using 
equation: 
 
                        F = F0 + A*exp(-k1*t) + B*exp(-k2*t) 
 
The equation describes a model with a burst phase (A*exp(-k1*t), with A being the 
amplitude and k1 the rate for the burst phase) and a slow phase (B*exp(-k2*t), with B 
being the amplitude and k2 the rate for the slow phase). 
 
 
                       
 
Figure 28: DNA substrates employed in helicase activity assays.  
Schematic representation of the different DNA substrates used in the helicase assays performed 
to study opening of a DNA duplex by the TFIIH Core sub-complex. All substrates carry a Cy3 dye 
(pink spheres) suppressed by a quencher (black spheres). 
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3. XPC: the protein that starts it all 
3.1. Introduction 
3.1.1. In vivo XPC is a heterotrimeric complex 
Human XPC is a 125 kDa protein, flexible and intrinsically unstable, that has an essential 
role in NER as a damage detector (Sugasawa et al., 1998). XPC also participates in the 
BER DNA repair pathway (previously described in chapter 1, section 1.1), and has an 
additional role in transcription regulation as a co-activator of pluripotency genes,  
supposedly acting as a bridge between transcription factors octamer-binding 
transcription factor 4 (OCT4) and sex- determining region Y (SRY)-box 2 (SOX2) and 
the transcription apparatus to increase the expression of said genes (Zhang et al., 2015).  
 
As it was already explained in chapter 1, section 1.2.2.1, the GGR reaction starts with 
protein XPC detecting a distortion in the double helix anywhere in the genome 
(Sugasawa et al., 1998). In vivo XPC is part of a heterotrimeric complex consisting of 
XPC itself and additional proteins HR23 (paralogs A or B) and CETN2 (Sugasawa et al., 
1996) (Nishi et al., 2005).  
 
HR23A and HR23B are the mammalian homologs of Saccharomyces cerevisiae protein 
RAD23, with a potentially redundant function in DNA repair (Ng et al., 2003). XPC has 
been reported to bind preferentially to HR23B, but this appears to be caused by a greater 
abundance in the cell of HR23B over HR23A, with HR23A binding more to XPC in the 
absence of HR23B  (Okuda et al., 2004). Only a small part of HR23A / HR23B is bound 
to XPC, which points to an additional function of these two proteins. In the context of 
NER, they appear to stabilise XPC by inhibiting its polyubiquitination, thus preventing the 
degradation of XPC by the 26S proteasome  (Ng et al., 2003). A further role has been 
proposed in which the XPC-HR23 complex is the real damage detector, with HR23 acting 
as a stabilising partner for XPC to help it  reach the site of the lesion properly folded, and 
then quickly dissociating from it (potentially induced by a conformational change in XPC 
or by influence of the subsequently recruited NER factors) as XPC is now stabilised by 
its binding to the damaged site (Bergink et al., 2012). 
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CETN2 is a small calcium-binding protein that augments XPC’s binding activity to 
damaged DNA (Nishi et al., 2005), although it is reportedly not required for the in vitro 
NER reaction (Araki et al., 2000). The N-terminal domain of CETN2 is thought to 
enhance the recruitment of XPA to the XPC-TFIIH complex already positioned at the 
lesion, while its C-terminal domain alone has been shown to increase the binding affinity 
of XPC to damaged DNA (Nishi et al., 2013). As with HR23B, the largest fraction of the 
protein is not bound to XPC, suggesting additional functions of CETN2 outside DNA 
repair (Nishi et al., 2005) 
 
3.1.2. XPC structure: what we know 
Our structural knowledge of human XPC is so far limited to a few domains (Okuda et al., 
2015), since a high-resolution structure of the protein has still not been obtained. XPC 
shares some conserved domains with its S. cerevisiae homologue Rad4, whose X-ray 
structure was published in 2007 (Min & Pavletich, 2007). Both XPC and Rad4 present 
an N-terminal a/b domain that contains the transglutaminase-homology domain (TGD), 
and three a/b domains next to it, named b-hairpin domain 1 (BHD1), 2 (BHD2) and 3 
(BHD3) because of the presence of a characteristic long b-hairpin in all three of them 
(figure 29).  
 
       
 
Figure 29: Cartoon view of XPC’s homologue Rad4.  
The representation includes conserved domains TGD (orange), BHD1 (pink), BHD2 (blue), and 
BHD3 (red) (Min & Pavletich, 2007). 
 
A structured region towards the otherwise disordered N-terminal domain of XPC was 
reported to interact with repair factor XPA, while the C-terminal domain interacts 
physically with both HR23B and CETN2 (Bunick et al., 2006).  
 
XPC recruits TFIIH through interactions with the p62 and, to a lesser extent, XPB 
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subunits within the complex (Yokoi et al., 2000) (Uchida et al., 2002) (Bernardes de 
Jesus et al., 2008). An unstructured region towards the N-terminus of XPC becomes an 
organized tertiary structure when bound to the pleckstrin homology (PH) domain in 
subunit p62, forming a string-like structure that broadly covers one side of said domain 
(figure 30). This binding is characterized by extensive electrostatic interactions with basic 
residues and insertion of a tryptophan and a valine residue in XPC into a binding pocket 
in p62. Mutation of these residues severely compromises damage removal from the DNA 




Figure 30: XPC interacts with TFIIH subunit p62.  
Representation of the backbone structure of XPC (pink) bound to the PH domain of TFIIH subunit 
p62 (orange) (A) and carton view (B) of the binding (Okuda et al., 2015) 
 
Furthermore, the C-terminal domain of XPC interacts with the N-terminal domain of XPB, 
and this interaction seems to reinforce the correct positioning of TFIIH at the damaged 
site, while also stimulating the ATPase activity of the helicase, launching the opening of 
the double helix at the bubble (Bernardes de Jesus et al., 2008). 
 
3.1.3. XPC detects mismatched bases in the DNA  
The binding of Rad4 to damaged DNA occurs in two places: the TGD and BHD1 domains 
bind to the undamaged portion of the DNA duplex 3’ to the lesion, while the BHD2 and 
BHD3 domains bind to the small segment containing the lesion so BHD3 can introduce 
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its b-hairpin through the duplex and make the two bases affected by the lesion flip out of 
the structure, resulting in a greater distortion of the double helix. BHD2 and BHD3 form 
a groove that now interacts with the two residues flipped out in the undamaged strand – 
therefore, there is no actual contact between Rad4 and the lesion (figure 31) (Min & 
Pavletich, 2007) (Sugasawa, 2016). This recognition of mismatched normal bases rather 
than identification of the actual damage (Maillard et al., 2007) explains the vast range of 
lesions detected and repaired by NER, but it also underlines the need for a mechanism 
to verify the presence of damage in the double helix before triggering the repair reaction. 
 
                              
 
Figure 31: XPC detects distortions in the DNA.  
Ribbon diagram showing Rad4 bound to a DNA substrate (depicted by the grey double helix) 
carrying a CPD lesion. The TGD domain is represented in orange, BHD1 in pink, BHD2 in blue 
and BHD3 in red (Min & Pavletich, 2007). 
 
Although the conservation between the overall sequences of XPC and Rad4 is not very 
high, the sequence identity between the BHD1, BHD2 and BHD3 domains and the 
similarity of their predicted structures suggest that binding of XPC might occur in a similar 
manner as that of Rad4. Their differences seem to be concentrated in areas associated 
with the role of XPC as a co-activator, consistent with Rad4 not being active in an in vitro 
transcriptional assay (Zhang et al., 2015).  
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Experiments carried out with a wide range of DNA substrates suggest that XPC acts as 
a general sensor for DNA instability, rather  than being a specific NER damage detector 
(Shell et al., 2013). The current model of damage detection proposes that XPC-HR23B 
scans the DNA in search of mismatches in the double helix by binding to it transiently 
(Hoogstraten et al., 2008), and upon finding one, a  b-hairpin is inserted between the two 
strands. Only the BHD1 and BHD2 domains and a b-turn structure actually participate in 
the rapid scanning of the DNA in search of mismatches, and only when one is found the 
BHD3 domain proceeds to insert its b-hairpin (figures 31 and 32), causing a considerable 
rearranging of the DNA structure. This two-step mechanism makes the damage-sensing 
process more energetically favorable (Camenisch et al., 2009).  It’s the formation of this 
more stable, longer-lived DNA-XPC complex that serves as a recruitment signal for 
downstream repair factors TFIIH, XPA and RPA. A further step to verify the lesion is now 
required before progressing with the repair reaction (Min & Pavletich, 2007)(Shell et al., 
2013). 
                     
 
Figure 32: Model showing the two-step detection of lesions in the DNA by XPC.  
The BHD1 and BHD2 domains, in conjunction with a b-turn structure, quickly scan the double 
helix in search of mismatches, and upon finding one the insertion of a b-hairpin between the two 
strands, carried out by domain BHD3, promotes the formation of a more stable DNA-XPC 
complex (Camenisch et al., 2009). 
 
As the first component to bind the damaged site in the double helix, thus initiating the 
repair bubble, we took an interest in how XPC binds to and alters the structure of the 
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DNA, specifically in the way DNA-bound XPC recruits and interacts with TFIIH at the 
repair bubble.  
 
In order to study this interaction, we cloned and produced XPC using Sf9 insect cells as 
an expression system. We have been able to obtain both XPC and its partner HR23B, 
allowing us to perform DNA binding assays demonstrating XPC’s binding to a variety of 
damaged substrates, pointing us in the right direction to continue with a more in-depth 
investigation regarding the interactions between XPC and TFIIH.  
 
3.2. Results 
3.2.1. Cloning, expression and purification of XPC 
3.2.1.1. Monomeric XPC 
3.2.1.1.1. Cloning and expression tests 
We cloned the XPC gene into a pACEBac2 plasmid containing the N-terminal tag 8xHis-
V5-spacer-TEV using enzymes NcoI and KpnI (Fermentas). The recombinant plasmid 
was transposed into the baculoviral genome, and the resultant bacmid was purified and 
later transfected into a monolayer of Sf9 cells. A 25 ml Sf9 suspension culture was 
infected with 3 ml of the recovered P0 viral stock and incubated at 27 °C for 60 hours. 
After that time the pellet was harvested and analyzed by small-scale affinity purification 
with magnetic Ni-NTA beads (BioSprint), as described in chapter 2, section 2.3.1. 
Analysis of the eluted fraction in an SDS-PAGE gel showed that expression levels for 
this 8xHis-V5-spacer-TEV-tagged XPC were high (figure 33). 
                    
 
 
Figure 33: Purification test of monomeric XPC.  
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Coomassie-stained gel showing a BioSprint purification test of monomeric XPC tagged at its N-
terminal end with 8xHis-V5-spacer-TEV (represented by a pink diamond in the cartoon view). 
Ladder sizes are indicated in kDa.  
 
3.2.1.1.2. Large-scale purification 
Scaling-up and optimization of the large-scale infections and purification of monomeric 
XPC was carried out by Mrs Biljana Petrovic-Stojanovska. We initially followed a protocol 
comprising the following steps: immobilised metal ion affinity (figure 34, blue box), 
followed by size exclusion (figure 34, grey box) and finally cation exchange 
chromatography (figure 34, yellow box), as described in chapter 2, sections 2.4.2.1, 2.4.3 
and 2.4.4. While this approach worked well enough, the need of an extra step to further 
purify XPC was evidenced by the presence of persistent contaminants after the cation 




Figure 34: Large-scale purification of monomeric XPC.  
The purification of monomeric XPC was carried out in four steps, shown in these Coomassie-
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stained gels. Ladder sizes are indicated in kDa. The blue box shows an SDS-PAGE gel containing 
eluted fractions from a HisTrapTM FF colum (IMAC); this step was followed by a size exclusion 
chromatography (HiPrepTM 16/60 SuperdexTM S200 prep grade column, grey box), a cation 
exchange chromatography (MonoSTM 4.6/100 PE column, yellow box) and finally a heparin 
chromatography (HiTrapTM Heparin HP column, green box). The two unspecific bands 
accompanying pure XPC in the SDS-PAGE gel showing fractions eluted from the heparin column 
were identified by MS as XPC degradation (approximately 110 kDa), and the insect cell 
homologue of HR23B (approximately 50 kDa). Data supplied by Mrs Biljana Petrovic-
Stojanovska. 
 
As XPC binds DNA, fractions of interest were pooled together and run through a 
HiTrapTM Heparin HP column (figure 34, green box) following the method described in 
chapter 2, section 2.4.5. Fractions containing XPC were analyzed in an SDS-PAGE gel 
that showed that two unspecific bands persisted even after this fourth chromatographic 
step. MS analysis of both bands showed that the upper band of about 110 kDa was a 
degraded form of XPC. Unexpectedly, a second band of about 50 kDa was identified as 
the Spodoptera frugiperda homologue of HR23B, the human partner of XPC (figure 34, 
green box).  
 
3.2.1.2. TCP-Tagged XPC 
3.2.1.2.1. Cloning and expression tests 
The cloning of a sequence encoding the 6-residue Cys-Cys-Pro-Gly-Cys-Cys tag into 
monomeric XPC and labelling of the tagged-protein with the red-emitting (608 nm) 
biarsenic ligand ReAsH-EDT2 will allow us to study XPC binding to a series of DNA 
substrates in a fluorescence anisotropy assay.  
 
The gene encoding monomeric protein XPC had previously been cloned into a 
pACEBac2 plasmid containing the N-terminal tag 8xHis-V5-spacer-TEV. A sequence 
encoding the CCPGCC tetracysteine tag was later cloned into this construct using 
restriction enzyme NcoI, and the presence of the tag was verified by sequencing. The 
recombinant plasmid was transposed into the baculoviral genome, and afterwards the 
purified bacmid was transfected into Sf9 cells. Later, a 25 ml Sf9 suspension culture was 
infected with 3 ml of a P0 viral stock, and after a 60-hour incubation the pellet was 
harvested, processed and analyzed in a BioSprint station as previously described. SDS-
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PAGE analysis of the eluted fraction showed that expression levels for the TCP-tagged 
XPC are considerably lower than previous results obtained with monomeric XPC when 
the Sf9 cells are infected with a P0 viral stock (figure 35).  
             
 
Figure 35: Purification test of TCP-tagged monomeric XPC.  
SDS-PAGE gel showing BioSprint tests for monomeric XPC and TCP-XPC, both of them tagged 
at N-terminal with 8xHis-V5-spacer-TEV (pink diamond in the cartoon representation). TCP-XPC 
also includes a tetracysteine CCGPCC tag (red sphere) at N-terminal, right after the TEV 
cleavage site. Ladder sizes are indicated in kDa. 
 
3.2.1.2.2. Large-scale purification   
Scaling-up and optimization of the large-scale infections and purification of TCP-tagged 
XPC was carried out by Mrs Biljana Petrovic-Stojanovska. This work was carried out in 
parallel with the cloning and expression of monomeric XPC, hence the absence of 
human HR23B in this construct. A very faint band matching the one corresponding to the 
Sf9 HR23B protein identified by MS in our monomeric XPC purification can also be seen 
here (figure 36, yellow box).  
 
The low expression levels of TCP-XPC shown in the SDS-PAGE gel containing fractions 
eluted from the IMAC step (figure 36, blue box) led us to reconsider the protocol 
employed in the purification of monomeric XPC, finally opting for removing the size 
exclusion chromatography and simplifying our protocol to three chromatographic steps 
in an attempt to reduce the loss of TCP-XPC (figure 36).  





Figure 36: Large-scale purification of TCP-tagged monomeric XPC.  
The purification protocol for TCP-tagged XPC was simplified to three chromatographic steps, 
depicted in these SDS-PAGE gels: the protein was first loaded into a HisTrapTM FF colum (IMAC, 
blue box), followed by a HiTrapTM Heparin HP column (heparin chromatography, green box), and 
finally a MonoSTM 4.6/100 PE column (cation exchange chromatography, yellow box). Ladder 
sizes are indicated in kDa. Data supplied by Mrs Biljana Petrovic-Stojanovska. 
 
A faint band for a degraded form of XPC can still be found in the gel accompanying our 
pure TCP-tagged XPC, and the Sf9 homologue of HR23B, although barely seen, is still 
present, too (figure 36, yellow box).  
 
3.2.1.2.3. ReAsH-EDT2 Labelling of TCP-tagged XPC 
The attachment of a label to a protein to determine its cellular localization or as an aide 
to perform a biochemical assay is a very useful and widely spread technique. The 
development of the small Cys-Cys-XXX-XXX-Cys-Cys tag meant an enormous 
advantage over other technologies involving huge inserts that can potentially affect the 
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folding or even the function of our protein of study. This short motif works in conjunction 
with a small, membrane-permeable biarsenical ligand whose binding affinity for the 
target sequence is in the nanomolar range, and which becomes fluorescent upon binding 
to the thiol groups of the four cysteine residues present in the TCP sequence  (Griffin et 
al., 1998) (figure 37). Optimization experiments reduced the length of the tag from the 
original 17 amino acids to the current  six-residue Cys-Cys-XXX-XXX-Cys-Cys 
sequence, with XXX being any amino acid other than cysteine, although a stronger 
binding has been observed when these two amino acids are proline and glycine (Adams 




Figure 37: ReAsH-EDT2 labelling of a TCP-tagged protein.  
Adapted from (Walker et al., 2016). 
 
The original tag was initially developed to be used in conjunction with the green-emitting 
FlAsH-EDT2 ligand (emission at 528 nm) (figure 38 (A)), obtained by introducing two 
arsenic (III) substituents in positions 4’ and 5’ into a fluorescein molecule, to which two 
molecules of EDT were also added to avoid binding of the ligand to endogenous cysteine 
residues (Griffin et al., 1998). The position of the two arsenic atoms permits binding to 
the four cysteine residues in the tag with significant specificity.  
 
The later developed, red-emitting (608 nm) phenoxazine analogue of FlAsH-EDT2, the 
resorufin-based ReAsH-EDT2 reagent (figure 38 (B)) additionally gives the advantage of 
a reduced cellular absorbance, scattering and autofluorescence compared to the original 
green-emitting molecule, due to its longer wavelength (Adams et al., 2002). 
         




Figure 38: Structure of biarsenic ligands FlAsH-EDT2 (A) and ReAsH-EDT2 (B)  
(adapted from (Walker et al., 2016)).  
 
This new technology not only permits the localization of tetracysteine-containing proteins 
by means of labelling, but the high affinity of the binding between the biarsenical ligands 
and the tetracysteine motif means that the immobilised ligand could potentially be 
employed in the affinity purification of proteins containing this tag, as the ligand-bound 
protein can easily be eluted with mM concentrations of a competing ligand such as 2,3-
dimercaptopropanesulfonate (DMPS). Our specific interest focuses on another useful 
application of this small tag: as opposed to other fluorescent ligands with more flexible 
bonds that offer a reduced signal, the rigid attachment of the biarsenical ligand to the 
tetracysteine motif now present in proteins XPC and XPB is perfect to perform anisotropy 
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ReAsH-EDT2 labelling of TCP-tagged XPC was carried out as described in chapter 2, 
section 2.5.1. 
 
             
Figure 39: ReAsH-EDT2 labelling of construct TCP-XPC.  
The ligand was excited at a wavelength of 593 nm and emitted fluorescence was collected 
at a wavelength of 608 nm. 
 
The first measured point shown in figure 39 corresponds to a control reaction in which 
no TCP-XPC was added, allowing us to determine the intensity corresponding to the free 
ReAsH-EDT2 reagent. As the intensity of fluorescence emission (collected at 608 nm) 
increases with the concentration of TCP-XPC, we conclude that this increment is due to 
the binding of the ReAsH-EDT2 ligand to the tetracysteine tag present in XPC, and so 
our protein can be successfully labelled.  
 
3.2.1.3. XPC-HR23B 
3.2.1.3.1. Cloning and expression tests 
The human HR23B gene was cloned by Mrs Biljana Petrovic-Stojanovska, who also 
tested the protein for expression in Sf9 insect cells. The HR23B gene was cloned into a 
pACEBac2 plasmid containing the N-terminal tag 8xHis-V5-spacer-TEV using the 
enzymes NcoI and KpnI, and it was later introduced into our pACEBac2 plasmid already 
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carrying the XPC gene using the multiplication module I-CeuI / BstXI present in both 
plasmids, following the method described in chapter 2, section 2.1.4. The bacmid 
resulting from the successful transposition of the plasmid containing both genes into the 
baculoviral genome was purified, transfected into a monolayer of Sf9 cells, and tested 
for expression in a 25 ml Sf9 infection, carried out with 3 ml of a P0 viral stock and 
incubated at 27 °C for 60 hours. Afterwards, the pellet was harvested and analysed as 
previously described. As already observed in the expression tests for monomeric XPC, 
expression levels were excellent, and proteins were produced in stoichiometric amounts 




Figure 40: Purification test of heterodimer XPC-HR23B.  
The SDS-PAGE gel shows the fraction eluted in a BioSprint purification test, containing both XPC 
and its partner HR23B, both carrying an 8xHis-V5-spacer-TEVtag at their N-terminal end (pink 
diamond in the cartoon view). Ladder sizes are indicated in kDa. Data supplied by Mrs Biljana 
Petrovic-Stojanovska. 
 
3.2.1.3.2. Large-scale purification 
The scaling-up of Sf9 suspension cultures infected with the XPC-HR23B heterodimer 
presented a new problem: although expression levels of both proteins were good when 
extracted from a 25 ml infection, they were considerably reduced when extracted from a 
larger infection (500 ml – 1 L infections).  
 
Optimization of our purification protocol lead us to employ a similar approach as to that 
used later in the optimization of the TFIIH Core sub-complex, using a cobalt Talon® 
SuperflowTM resin (IMAC (figure 41, blue box)) first, followed by a HiPrepTM S200 column 
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(size exclusion chromatography (figure 41, grey box)). This change in the protocol was 
forced by the amount of protein obtained after the IMAC step, compelling us to consider 
which of the columns previously tested for XPC would be more appropriate in this case. 
We finally opted for a single size exclusion step instead of our previous two-step heparin 
and cation exchange protocol to minimise protein loss.  
 
The chromatograph corresponding to the size exclusion column showed two peaks: a 
first peak containing the heterodimer (figure 41, grey box, peak 1) and second, smaller 






Figure 41: Large-scale purification of heterodimer XPC-HR23B.  
Coomassie-stained gels showing the different chromatographic steps followed in the purification 
of heterodimer XPC-HR23B, both carrying an 8xHis-V5-spacer-TEV tag at their N-terminal end. 
The purification protocol includes two steps: ion affinity (Talon® SuperflowTM resin, blue box), and 
size exclusion (HiPrepTM 16/60 SuperdexTM S200 prep grade column, grey box). Ladder sizes are 
indicated indicated in kDa.  
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3.2.2. Biochemical characterisation of XPC 
Once we obtained the purified XPC (monomer or HR23B-bound) we tested it for binding 
to a 44 bp DNA duplex substrate (S1, S2), a duplex presenting an 18-nucleotide bubble 
(S3, S4) or a duplex carrying a 3-nucleotide bubble (S5, S6, S7, S8) (figure 42).  
 
                    
 
Figure 42: Substrates used in the study of binding of monomeric XPC, heterodimer XPC-
HR23B and complex XPC-HR23B-TFIIH.  
Substrates include two 44 bp DNA duplexes, one carrying a fluoro-dT modification inside its 
sequence (S1) and another one carrying a 5’- fluorescein amino modified (FAM)-C6 modification 
(S2). 44 bp duplexes carrying bubbles include S3 (18-nucleotide mismatch with a fluoro-dT at the 
bubble), S4 (18-nucleotide bubble with a 5’-FAM-C6 modification), S5 (3-nucleotide mismatch 
with a fluoro-dT at the bubble) and S6 (3-nucleotide bubble with a 5’-FAM-C6 modification). 
Finally, substrates S7 and S8 are 44 bp duplexes with a 3-nucleotide bubble carrying a fluoro-dT 
nucleotide at the mismatch and a Cy3 dye left (S7) or right (S8) to the bubble. 
 
We tested monomeric XPC, heterodimeric XPC-HR23B and complex XPC-HR23B-
TFIIH binding using three different methods: fluorescence anisotropy, band shifting, and 
bulk FRET assays. The low amount of XPC we had available for these experiments 
(purification yields were always lower than 0.1 mg protein for 1 L culture) meant that 
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assays could not be carried out in triplicates, and so these results can only be considered 
as preliminary. 
 
3.2.2.1. Anisotropy assays 
We studied the binding of monomer XPC to several 44 bp DNA duplex species: one 
carrying a fluorescein-dT nucleotide at the centre of the sequence (S1); one with a 5’-
FAM-C6 modification on its 5’ end (S2); one with an 18-nucleotide mismatch and a fluoro-
dT nucleotide at the bubble (S3) and finally one with an 18-nucleotide bubble and a 5’-
FAM-C6 modification at the 5’ end of the substrate (S4). These were studied using a 
fluorescence anisotropy experiment (figure 43) as previously described in chapter 2, 
section 2.5.5.1. The titrations showed a progressive increase in the anisotropy values as 
we incremented the concentration of monomeric XPC. Anisotropy monitors variations in 
the rotational time of the biomolecule, which is a function of the mass of the complex. 
Therefore, an increase in anisotropy reflects a slower rotational time that is consistent 
with the formation of a higher mass complex induced by XPC binding. The initial and 
final anisotropy values vary between the different substrates investigated, although the 
relative change (Dr) is similar (approximately 0.2 units) across all of them. Different initial 
anisotropy values can arise from variations in the lifetime of the fluorescent probe due to 
the different locations (5-‘ end or internal) in the DNA and also due to the single or duplex 
configuration of the substrate (Nazarenko et al., 2002). The fluorescein probe used in 
our studies has a fluorescence lifetime of approximately 4 ns in solution. A decrease in 
this lifetime as a result of quenching by adjacent bases will result in an increase in the 
initial anisotropy value. The relative changes in anisotropy as a function of the 
concentration of monomeric XPC were fitted to a quadratic equation reflecting a 1:1 
binding model.  
  
The KD values obtained in these four experiments (table 4) were similar for S2, S3 and 
S4 (39 nM, 31 nM and 32 nM, respectively) but lower for S1 (5 nM), whose apparent 
binding affinity was 6-fold higher than the other substrates. This result was expected 
when comparing substrates S1 and S2, as the fluoro-dT would have introduced a point 
of weakness into our duplex substrate that would be interpreted by XPC as a mismatch, 
but it’s unclear why the same difference is not observed for substrates S3 and S4. It’s 
possible that the 18-nucleotide bubble introduced in these two substrates was just too 
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big to be interpreted as a mismatch. Lastly, the low yields obtained in every XPC 
purification hindered the biochemical characterization of the protein by limiting the 
number of data points taken in every measurement. This probably affected the fitting of 




Figure 43: Fluorescence anisotropy assay showing binding of monomeric XPC to 
substrates S1, S2, S3 and S4.  
S1 and S2 are 44-mer duplexes with a fluorescein molecule inside the duplex sequence, 
mimicking a lesion (S1), or at the 5’ end of the substrate (S2) and S3 and S4 are 44-mer duplexes 
with an 18-nucleotide bubble carrying the fluorescein molecule at the bubble (S3) or at the 5’ end 
of the substrate (S4). Final concentration for all substrates was 25 nM. KD’s obtained for all four 
isotherms were in the nM range.  
 
3.2.2.2. Electrophoretic mobility shift assay 
Heterodimeric XPC-HR23B was tested for binding to substrates S7 and S8 first (figure 
44) and then to substrates S2, S5 and S6 (figure 45) in two different band shifting assays 
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according to the method described in chapter 2, section 2.5.4. All substrates tested were 
44 bp long: S2 is a duplex, while S5, S6, S7 and S8 carry a 3-nucleotide mismatch. A 
fluoro-dT nucleotide also served as a bulky adduct in the DNA, placed at the centre of 
the bubble in substrates S5, S7 and S8. Substrates S7 and S8 are essentially a 
modification of substrate S5, but in addition to the fluoro-dT nucleotide they carry a Cy3 
dye at the left (S7) or right (S8) side of the 3-nucleotide bubble, making them suitable for 
their use in bulk FRET experiments.  
 
    
 
Figure 44: EMSA assay (10% polyacrylamide gel) showing binding of heterodimer XPC-
HR23B to substrates S7 and S8.  
S7 and S8 are 44-mer duplex substrates with a 3-nucleotide bubble carrying a fluoro-dT 
nucleotide mimicking a bulky adduct and a Cy3 dye left (S7) or right (S8) to the bubble, shown 
here in cartoon view. KD for the binding of the heterodimer seems to be between 0.48 µM (all of 
the substrate bound) and 0.16 µM (all of the substrate free) for both substrates.  
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The limitations of this EMSA assay meant that we could only estimate a range of KD 
values for this binding: 0.16 – 0.48 µM for both substrates (table 4). In order to determine 
a more accurate value for this KD we performed a second band shifting experiment with 
a finer grid of protein concentrations and substrates S2, S5 (equivalent to the already 




Figure 45: EMSA assay (6% polyacrylamide gel) showing binding of the XPC-HR23B 
complex to substrates S2, S5 and S6.  
S2 is a 44-mer duplex substrate with a fluorescein molecule at the 5’ end of the substrate and S5 
and S6 are 44-mer duplexes with a 3-nucleotide bubble carrying a fluorescein molecule at the 
mismatch, mimicking a bulky adduct (S5), or at the 5’ end of the substrate (S6). KD for these 
bindings seems to be between 0.42 µM (substrate mostly bound) and 0.21 µM (substrate mostly 
free) for S2, and between 0.21 µM and 0.11 µM for S5 and S6. The position of the fluorescent 
dye didn’t seem to affect XPC-HR23B binding to the substrate.  
 
Apparent KD values for this binding were narrowed down to 0.21 – 0.42 µM for S2, and 
0.11 – 0.21 µM for S5 and S6 (table 4). While the similar results obtained for substrates 
S5 and S6 were to be expected, a considerably higher KD for the duplex S2 had been 
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anticipated. Surprisingly, the gel shows two potentially different species binding to 
substrates S5 and S6 at a higher heterodimer concentration. 
 
Our EMSA assays confirmed that XPC-HR23B can effectively bind a dsDNA substrate, 
but the low resolution of our gels and the much wider range of the KD values obtained 
(values obtained in our anisotropy experiments were in the nM range) led us to consider 
a third approach to study XPC-HR23B binding.  
 
3.2.2.3. Bulk FRET assays 
We finally tested XPC-HR23B binding to substrates S7 and S8, both a 44 bp duplex 
carrying a 3-nucleotide bubble with a fluoro-dT nucleotide positioned at the mismatch 
and a Cy3 dye at the left (S7) or right (S8) side of the bubble, in a bulk FRET assay, 
following the method previously described in chapter 2, section 2.5.5.2. Fluorescence 
spectra were measured at an excitation wavelength of 490 nm (for the fluorescein dye) 
and 542 nm (for the Cy3 dye) for each protein concentration: the addition of XPC-HR23B 
induced a 2-fold increase in the fluorescein emitted fluorescence for both S7 and S8 
substrates, but the change in the case of Cy3 was only noticeable in the S8 substrate 
(figures 47 (A) and 48 (A)). We used the acceptor-sensitized method (RatioA method, 
figure 46) to study the effect of XPC-HR23B binding on the structure of our DNA 
substrates and their relative affinities.  
                            
Figure 46: Calculation of the RatioA.  
RatioA is the ratio between the Cy3 emitted fluorescence obtained via FRET (blue line) and the 
spectra of the sample excited at 542 nm (not represented). The Cy3 signal resulting from the 
excitation of the fluorescein dye is obtained by subtracting the spectra of our pure fluorescein 
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fluorophore (green line) to the spectra of the sample excited at 490nm (red line). 
 
The RatioA is the most widely used method to analyze data in FRET-based assays, as 
it removes potential artefacts resulting from variations in the intensity of the donor due 
to quenching or enhancement by the protein that are not related to changes in the donor-
acceptor distance. Similarly, because it is based on calculating the ratio of acceptor 
emission obtained by FRET (excitation at 490 nm) with respect to the emission obtained 
by exciting the acceptor directly, any potential variation in Cy3 emission due to processes 
other than FRET is removed. We observed a progressive increase in the RatioA as a 
function of the concentration of the proteins added in all of our experiments, and the 




Figure 47: FRET analysis of binding of XPC-HR23B to substrate S7.  
Addition of XPC-HR23B caused a 2-fold increase in the fluorescence emitted by the fluorescein 
dye, but barely affected Cy3 (initial intensity is indicated by a black line, and final intensity after 
addition of XPC-HR23B is indicated by a red line) (A). Representation of the RatioA as a function 
of the protein concentration showed two binding events with high cooperativity (B).  
 
RatioA calculations for the binding of the heterodimer to substrate S7 showed a KD1 of 
32 nM for the first binding event and a KD2 of 152 nM for the second event, with high 
cooperativity (n ~ 2), when fitting the data to a Hill model (figure 47 (B)). The FRET 
efficiencies are directly proportional to RatioA. These results (especially regarding the 
second binding step, due to the low change) are only preliminary, and experiments 
including a wider range of concentrations of XPC-HR23B are needed to confirm them. 
(A)
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KD1 = 32 ± 5 nM
KD2 = 152 ± 19 nM
n = 1.7 ± 0.4
R2 = 0.97
XPC-HR23B / nM
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Figure 48: FRET analysis of binding of XPC-HR23B to substrate S8.  
As seen for the S7 substrate, addition of XPC-HR23B caused a 2-fold increase in the fluorescence 
emitted by the fluorescein dye (initial intensity is indicated by a black line, and final intensity after 
addition of XPC-HR23B is indicated by a red line) (A). Representation of the RatioA as a function 
of the protein concentration showed a single binding event with high cooperativity (B).  
 
Representation of the RatioA values vs XPC-HR23B concentration showed a single 
binding step with an affinity of 22 nM and high cooperativity (n ~ 2) when the data 
obtained for the binding of the heterodimer to substrate S8 were fitted to a Hill model 
(figure 48 (B)). However, analysis of the Cy3 emitted fluorescence as a function of XPC-
HR23B concentration showed a biphasic binding isotherm (data not shown), similarly to 
our observations on XPC-HR23B binding to substrate S7, although the changes in the 
emitted fluorescence were much higher here than they were for the S7 substrate, 
suggesting that XPC-HR23B might be positioned closer to the Cy3 in S8 than in S7. 
 
In a second experiment we tried to see the effect of the TFIIH Core sub-complex on 
XPC-HR23B binding to these substrates (figures 49 and 50). In these assays we titrated 
the TFIIH Core by adding it to a quartz cuvette containing our binding buffer, DNA 
substrate and 100 nM of the XPC-HR23B heterodimer (see chapter 2, section 2.5.5.2), 
as XPC binds first to the damaged site at the DNA. Addition of TFIIH Core to our DNA-
bound XPC-HR23B caused an approximately 2-fold decrease of the fluorescence 
emitted by both the fluorescein and Cy3 dyes for both the S7 and S8 substrates (figures 
49 (A) and 50 (A)).  
 
The analysis of the RatioA values obtained for the binding of TFIIH Core to the S7-XPC-
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HR23B DNA-protein complex showed a KD of 12 nM, with a high cooperative ty (n ~ 3) 
(figure 49 (B)), possibly due to the experimental error in the first data points. 
 
 
Figure 49: FRET analysis of binding of TFIIH Core to the S7-XPC-HR23B complex.  
Addition of TFIIH Core causes a 2-fold decrease in the fluorescence emitted by both the 
fluorescein and Cy3 dyes (initial intensity is indicated by a black line, and final intensity after 
addition of XPC-HR23B is indicated by a red line) (A). A KD of 12 nM, with a high cooperativity 
(n= 2.6), was obtained in the analysis of the RatioA (B). 
 
The results obtained for the binding of TFIIH Core to the S8-XPC-HR23B complex were 
very similar to the ones obtained with the S7 substrate. Fitting of the data obtained in the 
analysis of the RatioA values offered a KD of 9 nM (figure 50 (B)), again with a high 




Figure 50: FRET analysis of binding of TFIIH Core to the S8-XPC-HR23B complex.  
Addition of TFIIH Core causes a 2-fold decrease in the fluorescence emitted by both the 
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fluorescein and the Cy3 dyes, as previously seen with the S7 substrate (initial intensity is indicated 
by a black line, and final intensity after addition of XPC-HR23B is indicated by a red line) (A). KD 
values obtained in the analysis of the RatioA (B) was 9 nM, with a high cooperativity (n ~ 3). 
 
The KD values obtained for the binding of TFIIH Core to the S7-XPC-HR23B and S8-
XPC-HR23B complexes were very similar to the ones obtained for the binding of XPC-
HR23B alone, indicating that the addition of the TFIIH Core sub-complex didn’t have an 
effect on the binding of XPC. Further experiments will be required to confirm these 
preliminary results. 
 
3.3. Discussion  
3.3.1. Heterologous expression of XPC constructs 
Damage-detector XPC is a heterotrimeric complex in vivo, composed of proteins XPC, 
HR23A/HR23B and CETN2 (Sugasawa et al., 1996) (Nishi et al., 2005), although the 
latter is not required for in vitro experiments (Okuda et al., 2015), and monomeric XPC 
has been proved enough to carry out the repair reaction in an in vitro system (Sugasawa 
et al., 1996) (Reardon et al., 1996). Monomeric XPC performs a quick scan of the DNA 
in search of mispaired bases (Maillard et al., 2007) (Hoogstraten et al., 2008), and upon 
locating a mismatch, it introduces a b-hairpin between the two strands, causing a further 
distortion in the double helix and stabilising XPC at the damaged site (Min & Pavletich, 
2007) (Camenisch et al., 2009). It’s this DNA-bound XPC structure that will act as a 
recruitment platform for the subsequent DNA repair factors involved in NER (Min & 
Pavletich, 2007) (Shell et al., 2013). 
 
3.3.1.1. Monomeric XPC 
As previous studies had reported that, despite being a heterotrimeric complex in vivo, 
the activity of XPC alone was sufficient to bind to the DNA and carry out successfully a 
repair reaction (Sugasawa et al., 1996) (Reardon et al., 1996), we initially aimed to clone 
the XPC gene and express the monomeric protein on its own.  
Expression tests performed in 25 ml infections offered robust expression levels (figure 
33), so we proceeded to scale-up our infections. We approached the purification of 
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monomeric XPC by following a three-step protocol consisting of IMAC, size exclusion 
and cation exchange chromatography. However, as the purification progressed, we 
encountered a problem: the sample presented persistent contamination even after three 
chromatographic steps.  
 
We attempted a further purification of the sample through heparin chromatography 
(figure 34), as the charge and structure of the polymer makes it an apt replacement for 
DNA, and so this method is ideal for the purification of DNA binding proteins. Analysis of 
the fractions eluted from the HiTrapTM Heparin HP column (figure 34, green box) showed 
a cleaner sample, but two bands of about 110 kDa and 50 kDa stubbornly remained in 
our purification. MS analysis showed that the higher molecular weight band was a 
degraded form of XPC. To our surprise, the 50 kDa band was identified as the 
Spodoptera frugiperda homologue of HR23B, the human partner of XPC.  
 
The fact that human XPC was able to pull down the untagged HR23B protein from the 
Sf9 cells we were using as an expression system pointed to the importance of their 
partnership, in agreement with more recent publications that suggested a stabilising role 
of HR23B upon its binding to XPC, helping the damage-sensor to reach the site of lesion 
properly folded (Bergink et al., 2012). In view of this result, and although our monomeric 
XPC was able to bind different DNA substrates in anisotropy experiments (figure 43), we 
decided to clone and express the heterodimeric XPC-HR23B complex for future 
experiments. The heterodimer would also allow us to compare the effect of HR23B on 
XPC’s activity. 
 
3.3.1.2. TCP-tagged XPC 
At the time we were cloning and expressing monomeric XPC, we were also working on 
a second monomeric construct, with XPC carrying a 6-residue Cys-Cys-Pro-Gly-Cys-
Cys tag this time. A BioSprint purification test carried out from a 25 ml suspension 
showed that expression levels of TCP-tagged XPC were significantly lower compared to 
the expression obtained with monomeric XPC when both 25 ml cultures were infected 
with a P0 viral stock (figure 35). This was probably due to a weaker P0 virus being 
responsible for a less efficient infection, but an interference of the TCP tag with the 
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expression of XPC or with the pull-down of the protein by the magnetic Ni-NTA beads 
used in the BioSprint station (as we also observed with the TFIIH Core sub-complex) 
has also to be considered.  
 
The lower expression levels obtained for this construct led us to simplify our purification 
protocol in order to minimize protein loss: based on previous results obtained in the 
purification of monomeric XPC, we decided that the best strategy for this sample was to 
remove the size exclusion chromatography in favour of a heparin column, effectively 
removing a chromatographic step from our protocol (figure 36). As we had already seen 
in the purification of monomeric XPC, a 110 kDa band corresponding to a degraded form 
of XPC and a faint 50 kDa band corresponding to the Sf9 homolog of HR23B can still be 
found accompanying our TCP-tagged XPC construct (figure 36, yellow box). Although it 
didn’t yield a completely pure protein, this simplified purification process represented an 
improvement over our previous results, as it was much more efficient than our four-step 
protocol in removing unspecific contaminants from our sample, regardless of the extra 
chromatographic step. 
 
Our TCP-tagged XPC protein can be successfully labelled with a ReAsH-EDT2 biarsenic 
ligand, as shown in figure 39. A control reaction with no added protein established the 
intensity corresponding to the free ReAsH-EDT2 reagent when excited at 593 nm, 
observing afterwards a consistent increase in the intensity of its emitted fluorescence 
(608 nm) as the concentration of TCP-XPC present in the reactions grows.  
 
Time restrictions have stopped us from performing any experiments with this TCP-
tagged protein yet, but future work includes confirmation of our preliminary data 
regarding DNA binding of XPC to damaged and undamaged substrates in fluorescence 
anisotropy and FRET assays. Cloning of the HR23B partner of XPC will also be 
considered as a means to stabilise XPC and potentially improve the protein yield once a 
successful, standardized protocol for the expression and purification of the heterodimer 
not carrying the TCP tag is established.  
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3.3.1.3. Heterodimer XPC-HR23B 
Expression levels were good for both partners when extracted from a small-scale 
infection (figure 40), but they dropped dramatically when the heterodimer was extracted 
from larger infections.  
 
The scaling-up of infections is a delicate, frequently tricky process in which many factors 
have to be taken into account, with the viability and growth rate of the suspension culture 
and titre of the viral stock probably being two of the most important ones. Viability and 
growth rate of a suspension of Sf9 cells can be easily measured, using that information 
to decide the suitability of a culture to be infected. In our experience the titre of the virus 
is more difficult to determine, as plaque assays are very time-consuming and can be 
difficult to interpret, and we have often observed encouraging results with a P0 viral 
stock, only to obtain a poor or very poor yield from an infection performed with the next 
generation of that same virus (P1).  
 
The expression levels observed for the scaled-up infections were quite low, seriously 
limiting the amount of pure heterodimer we obtained. This forced us to explore a series 
of combinations of chromatographic steps based on the quality of our samples (IMAC – 
heparin or IMAC – size exclusion), finally determining that a two-step Talon® 
SuperflowTM resin followed by purification through a HiPrepTM 16/60 SuperdexTM S200 
prep grade column was the best option for the majority of our infections with the 
heterodimer.  The chromatograph obtained during the purification through the S200 
column (figure 41) showed two peaks, but only the first one contained the heterodimer 
XPC-HR23B. Analysis of the fractions eluted in both peaks in a SDS-PAGE gel showed 
that the second peak contained very small amounts of XPC, but no HR23B, pointing to 
a lower expression of the stabilising protein. 
 
Future work with this construct involves the expression of the heterodimer in High Five™ 
insect cells (Thermo Fisher Scientific), as they reportedly express 5 to 10 times more 
heterologous protein than our current expression system. This will require the prior 
establishment of a standardized work routine and new infection protocol adapted to 
these High Five™ cells. Optimization of the purification protocol for this construct is also 
a work in progress. 
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3.3.2. XPC binds to a range of double-stranded DNA substrates 
with similar affinity 
Early studies characterising the biochemical properties of the damage-detection protein 
reported that monomeric XPC alone was able to bind a duplex DNA substrate with similar 
affinity as the heterodimer XPC-HR23B, and was able to even correct a repair defect, 
albeit less efficiently than the heterodimer (Reardon et al., 1996) (Sugasawa et al., 1996).  
 
Table 4: Dissociation constants for binding of monomeric XPC, heterodimer XPC-HR23B 
and complex XPC-HR23B-TFIIH to a range of substrates in a fluorescence anisotropy, 
EMSA or bulk FRET assay.  
The limitations of the EMSA experiment meant that KD could only be determined as an apparent 
KD within a range of values. Data from anisotropy experiments were fitted to a binding model that 
assumes 1:1 DNA:protein (see chapter 2, section 2.5.5.1). Data from bulk FRET experiments 
were fitted to a Hill model (see chapter 2, section 2.5.5.3). 
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More recently, an exhaustive study of XPC-HR23B binding to a wide range of DNA 
substrates was carried out by the Chazin group (Shell et al., 2013). Using a high-
throughput fluorescence anisotropy assay, they tested XPC-HR23B binding to DNA 
substrates of different lengths, with and without mismatches, and presenting a variety of 
lesions repaired by the NER and BER systems. Their findings showed that length of the 
substrate did not affect XPC-HR23B binding, as the KD values obtained were similar for 
all tested lengths. The presence of a 2-nucleotide or a 6-nucleotide bubble increased 
binding affinity 9-fold compared to the same-length duplex substrate, but it only 
increased 2-4-fold when binding to substrates carrying a lesion. Interestingly, XPC-
HR23B bound both BER and NER substrates with the same affinity, supporting the 
current model that considers XPC a sensor of distortion in the double-helix rather than a 
specific damage detection factor (Hoogstraten et al., 2008) (Min & Pavletich, 2007) (Shell 
et al., 2013).  
 
Unfortunately, the low and frequently unreliable expression levels of XPC in our 
infections severely limited our experiments. We opted for testing binding using 
fluorescence anisotropy, band shifting, and bulk FRET assays to try to determine the 
best method to observe binding for this protein. Apparent KD obtained for each construct 
and each experiment are summarised in table 4.  
 
3.3.2.1. Anisotropy experiments 
We obtained similar KD values when testing binding of monomeric XPC to duplex 
substrate S2 (39 nM), and to duplex substrates carrying an 18-nucleotide bubble S3 and 
S4 (31 nM and 32 nM, respectively) (table 4). In the case of duplex substrate S1 the 
binding affinity was 6-fold higher than that observed for the other substrates. As XPC 
shows a reportedly higher affinity for substrates carrying a mismatch (Shell et al., 2013), 
we expected to see this difference in binding affinity when comparing substrates S1 and 
S2, as the fluoro-dT nucleotide in the middle of the sequence of the S1 substrate 
introduces a mismatch that would be interpreted by XPC as a lesion, but unexpectedly 
we don’t see the same difference for substrates S3 and S4, both carrying an 18-
nucleotide mismatch (S3 additionally carries a fluoro-dT nucleotide at the centre of the 
bubble, similarly to substrate S1).  
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It’s possible that the length of the bubble introduced in substrates S3 and S4 might be 
affecting our experiment: Shell et al. 2013 reported that in a 60 bp substrate with a 6-
nucleotide mismatch the binding equilibrium DNA:XPC changed from 1:1 to 1:2, but it 
stayed 1:1 when the substrate contained a 2-nucleotide bubble. As our bubble is 3-times 
bigger, it’s entirely possible that the binding we see is not following the same model as 
binding to substrates S1 and S2.   
 
It can neither be ignored that at this point in our project we hadn’t obtained the XPC 
partner HR23B yet – figure 34 shows that a small amount of the Sf9 HR23B homologue 
is pulled down together with XPC in our sample, but it’s unclear if it is functional, and in 
any case the purified amount is small enough that only a minimum of our sample would 
be the heterodimer XPC-HR23B instead of monomeric XPC, and so the effect of HR23B 
in binding (if any) could probably not be appreciated. 
 
Our current efforts are focused on the expression and biochemical characterization of 
heterodimer XPC-HR23B, so future experiments featuring monomeric XPC are unlikely.  
 
3.3.2.2. Electrophoretic mobility shift assay  
The results obtained in our purification shown in figure 41, coupled with the results for 
the anisotropy assays summarized in table 4 led us to adopt a different approach in our 
experiments attempting to characterize XPC binding to DNA: we next studied the binding 
of heterodimer XPC-HR23B instead of monomeric XPC to mismatched substrates now 
carrying a 3-nucleotide bubble instead of an 18-nucleotide one.  
 
Apparent KD values for binding to substrates S7 and S8 (44 bp long, carrying a 3-
nucleotide bubble and a fluoro-dT nucleotide at the centre of the bubble as a lesion) were 
in the range of 0.16 – 0.48 µM for both substrates (figure 44). We tried to determine a 
more accurate KD value in our next experiment, performed with a finer grid of protein 
concentrations and substrates S2, S5 (equivalent to the already tested S7 and S8 
substrates) and S6. Apparent KD values were narrowed down to 0.21 – 0.42 µM for S2 
(44 bp duplex), and 0.11 – 0.21 µM for S5 and S6 (44 bp long, carrying a 3-nucleotide 
bubble – S5 additionally carries a fluoro-dT nucleotide at the centre of the bubble 
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mimicking a bulky adduct). Figure 45 shows two potentially different species binding to 
substrates S5 and S6. This could point to two XPC molecules binding to the mismatched 
substrate at higher concentrations of the heterodimer, as reported by Shell et al. 2013 
and Hilton and co-workers (Hilton et al., 2016). 
 
The fact that substrates S7 and S8, and S5 and S6 have a similar KD (table 4) is 
consistent with XPC detecting a distortion in the double helix rather than an actual lesion 
in the DNA (Maillard et al., 2007) (Shell et al., 2013). However, we expected a 
considerably higher KD for the duplex S2 (a 9-fold difference was reported by Shell et al 
2013 for the binding of XPC-HR23B to a 42 bp duplex substrate, both unmodified and 
with a 6-nucleotide mismatch).  
 
While our EMSA assays demonstrated that heterodimer XPC-HR23B can effectively 
bind a double-stranded DNA substrate (both unmodified and presenting a mismatch), 
the low resolution of our gels and the KD values obtained (in the µM range, as opposed 
to KD values reported by Shell et al in their 2013 paper and our own results obtained in 
our anisotropy experiments, both in the nM range) made us reconsider the suitability of 
EMSAs to study the binding of XPC-HR23B to DNA. With this results in mind, we next 
tried to observe binding in bulk FRET assays.  
 
3.3.2.3. Bulk FRET assays 
Bulk FRET analysis of binding of the heterodimer XPC-HR23B to substrates S7 and S8 
(44 bp duplex carrying a 3-nucleotide bubble with a fluoro-dT nucleotide positioned at 
the mismatch and a Cy3 dye at the left (S7) or right (S8) side of the bubble) helped us 
to narrow down the KD values for a substrate with a mismatch from the µM range seen 
in our EMSA assays to a nM range (table 4). Surprisingly, these values are similar to the 
KD obtained for the binding of monomer XPC to S3 (31 nM), the S7 and S8 equivalent 
with an 18-nucleotide bubble. This seems to indicate that the size of the mismatch is not 
relevant to the binding of XPC, as opposed to the report of Shell et al. 2013, and it also 
points to HR23B not having an effect on XPC binding to DNA, confirming the findings of 
Reardon et al. 1996 and Sugasawa et al. 1996.  
 
Fitting of our FRET data to a Hill model showed two binding events with high 
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cooperativity (the binding of the first XPC molecule helps incorporation of a second XPC 
to the bubble) for both the S7 and S8 substrates, as previously reported in the literature 
((Shell et al., 2013), (Hilton et al., 2016)) and our own observations for the S5 and S6 
substrates (also carrying a 3-nucleotide bubble) in previous EMSA assays. The binding 
of a second XPC to such a small bubble might be possible due to a further disruption of 
the double helix, caused by the binding of the first XPC. Changes in the Cy3 emitted 
fluorescence are much more pronounced in the S8 substrate than the S7 substrate, 
suggesting that XPC might be positioned closer to Cy3 in S8 than in S7. This change 
might be related to the relative orientation of XPC in our bubble, as recently observed by 
the Penedo group in experiments using FRET to look at distances between a Cy3-Cy5 
donor-acceptor pair positioned at the stems of the substrate. Our RatioA data have not 
been transformed into FRET efficiencies; however, both are directly proportional, so that 
an increase in RatioA would represent an increase in FRET efficiency, and therefore, a 
decrease in inter-dye distance. Addition of the TFIIH Core sub-complex to the S7-XPC-
HR23B or S8-XPC-HR23B complexes did not alter the binding of XPC, although further 
experiments will be required to confirm these initial results. The KD values obtained for 
these binding experiments were very similar to the ones obtained for binding of XPC-
HR23B alone, and similar again to the value obtained for binding of monomeric XPC to 
substrate S3 (table 4).  
 
Our data suggest that XPC-HR23B and XPC-HR23B-TFIIH distort the structure of the 
DNA substrate so that the fluorescein and Cy3 dyes are positioned at a closer distance 
in the protein-substrate complex compared to the DNA alone. We have not characterized 
in detail the exact structural change induced by XPC or XPC-TFIIH binding, but given 
the positioning of the FRET pair, we hypothesise that this could arise from a combination 
of bubble melting and bending. XPC-induced bending of the DNA substrate has been 
previously reported by Janićijević and co-workers (Janićijević et al., 2003). 
 
3.4. Conclusions 
We have analyzed the binding affinity of monomeric XPC, heterodimer XPC-HR23B and 
complex XPC-HR23B-TFIIH Core to a variety of DNA duplexes, both unmodified and 
carrying an 18-nucleotide or a 3-nucleotide mismatch, by three different methods: 
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fluorescence anisotropy, EMSA, and bulk FRET. 
 
Anisotropy experiments performed with monomeric XPC showed a higher affinity for 
substrate S1 (duplex with a simulated bulky adduct at the center of the sequence), and 
we expected the same high affinity for substrates S3 and S4 (both carrying an 18-
nucleotide bubble, with S3 also carrying the simulated bulky adduct at the center of the 
mismatch), but the KD values obtained were actually similar to the binding affinity 
observed for substrate S2, a DNA duplex with no internal modifications.  
 
EMSA experiments performed with XPC-HR23B showed a higher affinity of the 
heterodimer for substrates S5 and S6 (both carrying a 3-nucleotide bubble, with S5 also 
carrying the simulated bulky adduct at the center of the mismatch) compared to substrate 
S2, but the presence of a lesion in S5 did not increase XPC’s binding affinity. Our EMSA 
gels also suggest that two XPC molecules might be binding the mismatched substrates 
(but not a duplex) at higher concentrations of the heterodimer. 
Bulk FRET experiments performed with XPC-HR23B helped narrow down the KD values 
obtained in our EMSA assays from the µM to the nM range. Surprisingly, the results 
obtained were similar to the values observed for the binding of monomeric XPC to 
substrates S3 and S4. They also suggest that two molecules of XPC bind to both our S7 
and S8 substrates with high cooperativity at higher concentrations of the heterodimer, 
and that binding of the protein altered the structure of our bubble. The addition of the 
TFIIH Core sub-complex didn’t seem to have an effect on the binding of XPC once the 
protein is positioned at the repair bubble. 
 
Taken together, our results seem to indicate that XPC preferentially binds to substrates 
carrying a mismatch, although the size of that mismatch doesn’t seem to be relevant to 
binding. The presence of a simulated lesion at the mismatch, the addition of partner 
HR23B to our sample or the addition of the TFIIH Core sub-complex didn’t affect XPC’s 
binding affinity either.  However, our experiments were severely limited by the amount 
of available protein, and EMSA experiments in particular offered a low resolution, hence 
our decision to continue our study performing bulk FRET experiments. For these 
reasons, these results can only be considered as preliminary, and further experiments 
are needed to confirm them. 
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Future work includes: 
 
• Optimization of the XPC-HR23B yield (using High Five® cells as an expression 
system) and its purification protocol. 
• Anisotropy experiments with unmodified and mismatched duplex substrates and 
a substrate carrying a cisplatin lesion, using our TCP-tagged XPC construct, 
potentially having included partner HR23B. 
• Analysis of TFIIH recruitment by XPC by means of single molecule (Total internal 
reflection fluorescence (TIRF) and Fluorescence correlation spectroscopy (FCS) 
assays). 
• Analysis of the nature of the alterations caused in the structure of our substrates 
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4. Cloning, expression and purification of the 
TFIIH complex  
4.1. Introduction 
TFIIH is a 10-subunit complex of about 500 kDa that plays important roles in two very 
different, yet equally essential processes: transcription and DNA repair (Compe & Egly, 
2012). TFIIH was first described in 1992, although only its role in transcription was 
reported then (Flores et al., 1992), with its role as a DNA repair factor in the NER pathway 
being described the following year (Feaver et al., 1993). 
 
The first published structure of TFIIH, reported by the Egly group in 2000, revealed two 
distinctive regions within the complex: a ring surrounding a central cavity that interacts 
with DNA, corresponding to the Core sub-complex (subunits XPB, p62, p52, p44 and 
p34), and a structure protruding from the ring, corresponding to the CAK sub-complex 
(subunits cdk7, MAT1 and cyclin H), with subunit XPD bringing the two of them together 
(Schultz et al., 2000). The structure reported by Schultz et al. only included nine of the 
ten TFIIH subunits, as subunit p8 was lost in the first obtained samples due to its small 
size, and it was not until 2004 that it was finally described when a TTD phenotype was 
observed that did not correspond to any mutations in the XPB or XPD subunits (Giglia-
Mari et al., 2004). Last year a more detailed cryoEM structure of the TFIIH Core sub-
complex plus CAK subunit MAT1 was published, finally allowing the positioning of the 
different subunits unambiguously, and offering more information about the interactions 
between them. In the reported structure, helicases XPB and XPD occupy the ends of a 
horseshoe-like structure, with subunits p44, p62, p34, p52 and p8 forming an arch that 
connects them (Greber et al., 2017) (figure 51). 
 
Purification of eukaryotic multi-protein complexes has remained a challenge until 
recently due to the limitations of the available cloning and expression tools. The first 
reported purification of TFIIH included three different fractionation procedures, four 
columns and four dialysis steps (Flores et al., 1992), making it a very difficult and 
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laborious process that unfortunately remained that way for many years. The 
development of baculovirus expression systems (BEVs) in the last decades opened new 
and exciting possibilities that have offered ground-breaking results (Bieniossek et al., 
2012). One of the most recent reports regarding the extraction of TFIIH involved the 
cloning and expression in insect cells of each protein as pair-units, making it a better 
alternative than the traditional methods, but still a long and arduous process (Sugasawa 
et al., 2009).  
 
 
Figure 51: Structure of the 10-subunit complex TFIIH.  
The first structure of the human TFIIH complex was reported in 2000, showing two different 
regions within the complex (A) (adapted from (Schultz et al., 2000)), but it was not until 2017 that 
a more detailed cryoEM structure was obtained and the position of the different subunits could be 
assigned unambiguously (B) (adapted from (Greber et al., 2017)). TFIIH presents two different 
areas, corresponding to its two different sub-complexes: the Core sub-complex shows a ring-like 
structure surrounding a pore that interacts with DNA, while the CAK sub-complex protrudes from 
the ring. Subunit XPD acts as a bridge between the two structures (C).  
 
A particularly interesting BEV is the MultiBacTM system, a cloning and expression tool 
specifically designed for the production of complexes containing several subunits 
(Berger et al., 2004). All five MultiBacTM plasmids contain a multiplication module that 
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allows the introduction of multiple genes into a single plasmid without requiring unique 
restriction sites for every new cloning reaction (Bieniossek et al., 2013). The multi-gene 
construct will be later transposed into a baculoviral genome engineered for improved 
protein expression (Bieniossek et al., 2012) (Berger et al., 2004), the bacmid will be 
purified and transfected into a monolayer of insect  cells and the recombinant viral stock 
obtained will be finally used to infect a suspension culture for overexpression of the 




Figure 52: Overview of the cloning and expression of the TFIIH complex.  
Summary of all the steps required for the cloning and expression of the TFIIH complex using the 
MultiBacTM system. 
 
The combined use of the MultiBacTM expression system, together with simple, multi-
function purification tags designed by our group and 2A-like auto-cleavable peptides that 
permit the fusion of two genes into a single unit (Luke et al., 2009) have allowed us to 
considerably simplify both the cloning and expression processes. Still, designing and 
CLONING, EXPRESSION AND PURIFICATION OF THE TFIIH COMPLEX 
 
 100 
optimising a protocol for the cloning, expression and purification of a complex as large 
as TFIIH has been a challenging process that involved many different constructs, 
summarised in figure 53 for future reference. 
 
 
Figure 53: TFIIH constructs cloned and expressed in this PhD project.  
Cartoon view of the different TFIIH Core and CAK constructs cloned for this PhD project. 6-
residue His tags are indicated with a yellow diamond; 8-residue His tags are represented with a 
pink diamond; 10-residue His tags are depicted with a blue diamond, and finally a Strep tag is 




4.2.1. TFIIH Core sub-complex  
4.2.1.1. TFIIH Core cloning and expression: first attempts 
The 10-subunit TFIIH complex is composed of sub-complexes TFIIH Core and CAK, and 
while the whole complex participates in transcription (Hanawalt & Spivak, 2008), only the 
Core sub-complex is required for the NER reaction (Compe & Egly, 2012). As our main 
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interest regarding the TFIIH complex focuses on its role as a DNA repair factor, we first 
aimed to clone and express the TFIIH Core sub-complex on its own. 
 
The first consideration we took into account was the number and position of the 
purification tags. Observing the position of each TFIIH Core subunit within the complex, 
we decided that the best approach would be to place a 6-residue His tag at the N-terminal 
end of subunit p52, due to its strategic position at the base of the ring, and another 6-
residue His tag at the N-terminal end of the XPD helicase which, as the bridge between 
the Core and CAK sub-complexes (Schultz et al., 2000) (Greber et al., 2017), is the most 
flexible subunit within TFIIH. All seven sequences encoding the different TFIIH Core 
subunits were first cloned into individual pACEBac2 plasmids, then sequentially cloned 
into multi-gene constructs using the I-CeuI/BstXI multiplication module as described in 




Figure 54: Steps in the cloning of TFIIH Core with 6xHis-V5-TEV-tagged p52 and XPD. 
Workflow showing the different reactions performed for the cloning of construct TFIIH Core, with 
subunits p52 and XPD tagged with 6xHis-V5-TEV (indicated in red) at their N-terminal end. 
 
The integrity of each intermediate construct was checked by restriction with 
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combinations of several different enzymes, comparing the band pattern predicted in 
silico by the NEBcutter® tool (New England Biolabs) with the one we obtained after 
running our restricted plasmids in a 1% agarose gel. The final seven-gene construct was 
further analysed by PCR and lastly, by sequencing (GATC Biotech) of the seven genes 
using the primers listed in table C1, appendix C. Figures 55 and 56 show the restriction 
gels and PCR results that confirmed that the TFIIH Core construct with subunits p52 and 




Figure 55: Cloning of TFIIH Core with 6xHis-V5-TEV-tagged p52 and XPD (I).  
(A) Cartoon view of construct TFIIH Core, with subunits p52 and XPD tagged with 6xHis-V5-TEV 
(yellow diamonds) at their N-terminal end. (B) NcoI/KpnI restriction of construct p44-p34/p52-p8. 
The red arrow indicates the only clone showing the expected band pattern for plasmid pACEBac2 
containing genes p44-p34 and p52-p8 (bands 2826 bp, 2164 bp, 1702 bp and 486 bp). (C) KpnI 
and NdeI restrictions of construct p44-p34/p52-p8/p62. Expected band pattern for clones 
containing all five genes are 4471 bp, 2650 bp and 2188 bp bands for restriction with KpnI and 
7320 bp and 1989 bp bands for restriction with NdeI (D) KpnI and NcoI restrictions of construct 
XPB/XPD. The red arrows point to successful clones containing both the XPB and XPD genes. 
Expected patterns are 5107 bp and 2833 bp bands for restriction with KpnI and 5173 bp and 2767 
bp bands for restriction with NcoI. All ladder sizes are indicated in base pairs. 
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Figure 56: Cloning of TFIIH Core with 6xHis-V5-TEV-tagged p52 and XPD (II).  
NcoI, KpnI, NdeI and XhoI restrictions (A) and PCR (B) of construct p44-p34/p52-
p8/p62/XPB/XPD. Ladder sizes are indicated in base pairs. The red arrows indicate successful 
clones showing the band pattern expected for plasmid pACEBac2 containing all seven TFIIH 
Core genes (bands 5081 bp, 2767 bp, 2742 bp, 2223 bp and 2188 bp for NcoI; bands 4379 bp, 
2859 bp, 2833 bp, 2650 bp and 2280 bp for KpnI; bands 8082 bp, 4930 bp and 1989 bp for NdeI; 
and bands 5509 bp, 5081 bp and 4411 bp for XhoI). A set of primers for each gene (see appendix 
C for sequences) was designed to perform a PCR, targeting the middle of the gene sequence 
rather than the 3’ and 5’ ends to avoid overlapping with the repeated pACEBac2 fragments on 
both ends of every gene. As a result, we expected to obtain fragments of 2197 bp (XPD), 1910 
bp (XPB), 1637 bp (p62), 1317 bp (p52-p8) and 1038 bp (p44-p34), as seen in the gel.  
 
The recombinant plasmid containing all seven TFIIH Core genes was next transposed 
into the baculoviral genome as described in chapter 2, section 2.1.5. The transposition 
protocol had to be adapted as new genes were introduced into our recombinant plasmid, 
increasing both the incubation and recovery times. Using freshly-made chemically 
competent cells also helped to improve the transposition efficiency, although the number 
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of white colonies obtained per reaction was frequently still lower than five.  
 
The successfully transposed recombinant plasmid, called bacmid, was purified and 
transfected into a monolayer of Sf9 cells. The P0 virus recovered from this transfection 
was used to infect a 25 ml suspension culture, which was harvested and tested for TFIIH 
Core expression after 60 hours of incubation. To verify the Core sub-complex expression 
levels, we ran a BioSprint purification test as described in chapter 2, section 2.3.1, which 
easily and quickly allowed us to see that this particular construct was not highly 




                           
 
Figure 57: Purification test of TFIIH Core with 6xHis-V5-TEV-tagged p52 and XPD.  
Coomasie gel (left) and Western blot (right) showing a BioSprint purification test for an infection 
with a P0 recombinant virus containing construct TFIIH Core with subunits p52 and XPD tagged 
at their N-terminal end with 6xHis-V5-TEV. Ladder sizes are indicated in kDa.  
 
A Western blot performed with an anti-V5 primary antibody and IRDye 800CW Goat anti-
Mouse IgG (H + L) as a secondary antibody showed a strong signal for p52, but not for 
XPD, suggesting lower expression levels for the helicase than for the rest of the Core 
subunits, or a loss of the protein during the purification process. Quantification of the blot 
bands also showed that although cleaving of the 2A-like sequence joining subunits p52 
and p8 was very efficient (87%), a small percentage (13%) remained uncleaved. 
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4.2.1.2. A redistribution of the purification tags is required 
After optimisation of the transfection and infection protocols failed to improve the 
expression levels of construct TFIIH Core with subunits p52 and XPD carrying an N-
terminal 6xHis-V5-TEV tag, we reconsidered our strategy regarding the position of the 
purification tags. The Western blot on figure 57 shows that the tag placed on N-terminal 
p52 worked better than the one placed on XPD, so we pondered if placing a second tag 
in subunit p62 could help to keep the sub-complex together during the purification 
process, given the more central position of the subunit within the ring-like structure of the 




Figure 58: Steps in the cloning of TFIIH Core with 6xHis-V5-TEV-tagged p62 and p52. 
Workflow showing the different steps performed for the cloning of construct TFIIH Core sub-
complex, with subunits p52 and p62 tagged with 6xHis-V5-TEV (indicated in red) at their N-
terminal end. Only the cloning steps highlighted in yellow had to be carried out to obtain the full 
seven-gene plasmid, as intermediates (white boxes) had already been obtained in the cloning of 
a previous construct. 
 
Many of the intermediate constructs required for the cloning of this new TFIIH Core sub-
complex with subunits p52 and p62 carrying a 6xHis-V5-TEV tag at their N-terminal end 
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had already been obtained during the cloning process of our previous construct. The 
characteristics of the MultiBacTM system allow the use of these intermediate multi-gene 
plasmids (Bieniossek et al., 2012), which meant that the new construct was obtained in 
only three cloning steps. This advantage considerably reduced the time scale necessary 
to obtain a new full TFIIH Core sub-complex construct, as can be appreciated in figure 
58. 
 
As with the previous construct, the integrity of the final seven-gene TFIIH Core sub-
complex was verified by restriction with enzymes KpnI, BamHI / HindIII and SalI / XhoI 




Figure 59: Cloning of TFIIH Core with 6xHis-V5-TEV-tagged p62 and p52.  
(A) Cartoon view of construct TFIIH Core with subunits p52 and p62 tagged with 6xHis-V5-TEV 
(yellow diamonds) at their N-terminal end. Restriction reactions (B) and a PCR (C) were 
performed to analyse the integrity of this construct. The red arrows indicate the clones showing 
the expected band pattern for plasmid pACEBac2 containing all seven TFIIH Core genes (bands 
5000 bp, 4471 bp, 2650 bp, 2280 bp and 748 bp for KpnI; bands 6767 bp, 6030 bp, and 2352 bp 
for BamHI/HindIII; and bands 9584 bp, 2916 bp and 2649 bp for SalI/XhoI). A PCR performed 
with primers targeting the middle of the gene sequence further confirmed the successful cloning 
of genes XPD, XPB, p62, p52-p8 and p44-p34. Ladder sizes are indicated in base pairs. 
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The recombinant plasmid containing all seven TFIIH Core genes was transposed into 
the baculoviral genome and successfully transposed bacmids, selected as described in 
chapter 2, section 2.1.5, were transfected into a monolayer of Sf9 cells. The P0 virus 
recovered was used to infect a 25 ml Sf9 suspension culture from which the new TFIIH 
Core construct was extracted and analysed for expression levels in a BioSprint 
purification test as previously described (figure 60 (A)). 
 
 
            
 
Figure 60: Purification test of TFIIH Core with 6xHis-V5-TEV-tagged p62 and p52.  
Coomasie-stained gel showing a BioSprint expression test (A) and a BioSprint test in anaerobic 
conditions (B) of an infection with a P0 recombinant virus containing construct TFIIH Core with 
subunits p52 and p62 carrying a 6-residue His tag at their N-terminal end. Ladder sizes are 
indicated in kDa. XPD is missing in both gels.  
 
This result was an enormous improvement over our first attempt to purify the Core sub-
complex, as subunits XPB, p62, p52, p44, p34 and p8 all clearly appear in the gel in 
stoichiometric quantities and were confirmed by MS analysis (data not shown), but the 
achievement was somewhat dampened by the fact that subunit XPD was missing from 
the gel.  
 
With this in mind, we performed a BioSprint purification test under anaerobic conditions 
that would prevent the iron-sulfur (4FeS) cluster present in XPD from being oxidized, 
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hopefully avoiding loss of the helicase during the purification of the Core sub-complex. 
However, a SDS-PAGE gel with the samples extracted in anaerobiosis showed a similar 
result to that obtained with the aerobic BioSprint (figure 60 (B)). 
 
 
Figure 61: Purification of TFIIH Core with 6xHis-V5-TEV-tagged p62 and p52.  
Coomassie-stained gels showing peak fractions for the different chromatographic steps followed 
in the purification of the TFIIH Core sub-complex with subunits p52 and p62 tagged at their N-
terminal end with 6xHis-V5-TEV: ion affinity (HisTrapTM FF column, blue box), size exclusion 
(HiPrepTM 16/60 SephacrylTM S300 HR column, grey box) and cation exchange (MonoSTM 4.6/100 
PE column, yellow box). Ladder sizes are indicated in kDa.  
 
Since the purification of the sub-complex in anaerobic conditions didn’t represent any 
improvement regarding helicase XPD or any of the other Core subunits, our efforts 
focused on scaling up our infections to improve the yield for the sub-complex and 
troubleshoot our aerobic purification protocol to solve the issues affecting XPD.  This 
involved testing and optimising different buffers and conditions until a 3-step procedure 
was finally established. In this 3-step protocol, the Core sub-complex was first run 
through a Nickel column (immobilized metal ion affinity chromatography (IMAC)), as 
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described in chapter 2, section 2.3.3.1, followed by a size-exclusion chromatography 
step (section 2.3.4) and finally a cation exchange chromatography (section 2.3.5). Peak 
fractions were checked in a SDS-PAGE gel after every purification step, showing that 
our protocol allows the extraction of a highly pure complex containing subunits XPB, p62, 
p52, p44, p34 and p8, but no XPD (figure 61).  
 
Scaling up and optimisation of the expression and purification procedures increased 
yield to 1 mg of pure sub-complex for every 2 L culture. Subunits XPB, p62, p52, p44, 
p34 and p8 can be efficiently purified with this protocol, but subunit XPD is lost along the 
process.  
 
To investigate why XPD was not being purified we took samples from every different 
step along our purification protocol and performed a Western blot that would allow us to 
confirm if XPD was indeed being expressed, and if so, where exactly it was that the 




Figure 62: Subunit XPD is lost in the purification of TFIIH Core.  
Western blot showing XPD after every purification stage included in our protocol. 31% of the 
helicase was lost due to poor binding (flow-through, washing step), and only 0.3% of the loaded 
protein was recovered after IMAC, to finally retrieve only 0.1% of the initial XPD available in our 
sample after three purification steps. Ladder sizes are indicated in kDa.  
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The Western blot showed that although the helicase is clearly present in the extract, 
significant losses occur at every step, even before binding to the first chromatography 
column, to finally end with as little as 0.1% XPD at the end of the process. Only 0.3% of 
the initial XPD is recovered after its purification through a HisTrapTM FF column, 
suggesting that most of the helicase present in the extract probably precipitates and/or 
aggregates as it passes through the column. Taken together, these results pointed to 
XPD being more susceptible to dissociation from the sub-complex after extraction and 
binding not being as strong as it was for the rest of the subunits in the Core sub-complex.  
 
Our three-step IMAC – size exclusion – cation exchange protocol was further improved 
by substituting the nickel column for a Talon® SuperflowTM resin and adapting our 
method as described in chapter 2, section 2.3.3.3. Purification with a loose resin instead 
of the pre-packed matrix present in the HisTrapTM FF column we had been using so far 
allowed us to increase the binding time, resulting in a higher recovery of the sub-
complex. Loss of the sub-complex was also further reduced by eliminating the cation 
exchange chromatographic step: after IMAC with the Talon® resin and size exclusion in 
a HiPrepTM 16/60 SephacrylTM S300 HR column, the recovered sample had 
approximately the same quality standards as the sample obtained after our previous 
three-step protocol, but recovery of the sub-complex was slightly higher, and the 
purification process was now shorter and simpler. Fractions of interest were analyzed in 
a SDS-PAGE gel after every purification step, showing again a pure complex containing 
stoichiometric amounts of subunits XPB, p62, p52, p44, p34 and p8, but no XPD could 
be detected by the Coomassie-staining of the gel (figure 63).  
 
MS analysis confirmed that this sample contained a considerably reduced amount of 
XPD compared to the other six TFIIH Core subunits (data not shown), thus making it not 
suitable for the biochemical characterization of the sub-complex, but this didn’t affect a 
crosslinking assay, which further confirmed the presence of XPD in our purified sample, 
and also offered additional information regarding the interactions between the different 
Core subunits. 
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Figure 63: Optimised purification of TFIIH Core with 6xHis-V5-TEV-tagged p62 and p52. 
Coomassie-stained gels showing a simplified purification protocol for construct TFIIH Core with 
subunits p52 and p62 tagged at their N-terminal end with 6xHis-V5-TEV. The procedure was 
reduced to two steps: ion affinity (Talon® SuperflowTM resin, blue box), and size exclusion 
(HiPrepTM 16/60 SephacrylTM S300 HR column, grey box). Ladder sizes are indicated in kDa.  
 
The TFIIH Core sub-complex was crosslinked with a BS3 amine-reactive crosslinker, 
able to link lysine residues both within a single subunit (intralinks) or between two 
different subunits (interlinks) situated as far as 30 Å apart. Crosslinked samples were 
loaded into a SDS-PAGE gel (figure 64) and bands showing potential crosslinks were 
analyzed as explained in chapter 2, section 2.5.2, obtaining a total of 25 interlinks and 
10 intralinks (table 5). Nine of the 25 interlinks had not been previously reported (Luo et 
al., 2015), and two of those were obtained more than once (a p52-p62 interlink (positions 
440:453 and 544:548), obtained three times, and a XPB-p34 interlink (positions 326:334 
and 150:158), obtained twice).  
 




                                         
 
Figure 64: TFIIH complex and sub-complexes obtained by crosslinking.  
Coomassie-stained gel showing the different complexes and sub-complexes obtained by 
crosslinking of TFIIH Core with subunits p52 and p62 carrying an N-terminal 6-residue His tag. 
Ladder sizes are indicated in kDa. Bands 1, 2 and 3 were analysed by MS and the resulted data 
was further evaluated with the MassMatrix software. 
 
Table 5: Crosslinks connecting TFIIH Core subunits.  
Summary of all the intralinks (top) and interlinks (bottom table) obtained in our experiments. Novel 
crosslinks not reported in previous works are highlighted in yellow. Crosslinked lysine residues 































INTRALINKS POSITION SUBUNIT REGION REPEATED
201:222












  370:378 Arch
199:218 N-terminal 





NSEGEATELITETFTSK($217)SAISK  K($326)MFGNGR XPB DRD x1
FGTMSSMSGADDTVYMEYHSSRSK($767)APSK  FLVDQGYSFK($688)VITK XPB C-terminal x1
NDSVNPDINIDLKPTAVLRPYQEK($322)SLR  K($326)MFGNGR XPB DRD x1
NDSVNPDINIDLK($311)PTAVLRPYQEK  SLRK($326)MFGNGR XPB DRD x1
LVLK($171)HNR  MGK($3)RDR XPB N-terminal x1
SWEAERVMEWLK($431)TQEWGLMILDEVHTIPAK  EYVAIKTK($528)K XPB x1
GK($671)TDYGLMVFADKR  K($370)PLRFCAER XPD x1
TYPAVKMK($206)YAENVPHNMTEK  VVK($492)MKSNLER p62 x1
LMVVTPAGHSDVK($452)R  K($77)EFSK p52 x1
LMVVTPAGHSDVK($452)R  FWK($456)R p52 C-terminal x1
         CLONING, EXPRESSION AND PURIFICATION OF THE TFIIH COMPLEX 
 
   113 
 
 
The representation of our crosslinks over a model of the TFIIH Core sub-complex 
showed a compact, tightly bound structure with multiple interactions (figure 65). These 
findings were obtained at the same time the Ranish group published an exhaustive and 
excellent paper on this same line of research (Luo et al., 2015), showing good agreement 
with our own observations and overlapping with most of the interlinks and intralinks 
obtained in our experiments, with the exception of nine novel interlinks exclusively seen 
in our studies. 
 
Although a Western blot confirmed that XPD was indeed expressed (figure 62), and our 
crosslink assays (table 5 and figure 65) even proved that some XPD was present in our 
purified sample, we still hadn’t managed to purify XPD in the same quantity as the other 
Core subunits. Since the Western blot seemed to suggest that the most pressing issue 
was the binding of the helicase to the HisTrapTM FF column, we next focused on 
improving the extraction and binding of XPD during the IMAC step.  











120:140 p52 N-terminal 
142:157 XPB N-terminal 
147:158 p34 VWA
53:62 XPB N-terminal 
36:61 XPD N-terminal 
326:332 XPB DRD





291:301 p34 Zn finger
142:157 XPB N-terminal 
153:165 p34 VWA
143:165 XPB N-terminal 
378:381 p62 C-terminal








78:94 p52 N-terminal 
07:12 XPB N-terminal 
TRAHPVMLK($378)QTPVLPPTITDQIR  SK($112)R x3
VGELMDQNAFSLTQK($71)  TK($528)K x3
LMVVTPAGHSDVK($452)R  LMKK($547)T x3
K($326)MFGNGRAR  EVK($152)DNQEMK x2
DAVK($93)DLLQQLLPK  IADLVSK($223)ELARK x1
IALLGGGK($127)AWSDDTSQLGPDK  KLSK($145)TGVPDGIMQFIK x1
MNK($149)EVKDNQEMK  VDEYGAK($59)DYR x1
GHGVLEMPSGTGK($48)TVSLLALIMAYQR  K($326)MFGNGR x1
SIK($296)ENSNAAIIKR  TMEDQDLK($77)PNR x1
K($113)NLCIHPEVTPLRFGK  K($378)SDR x1
EVPLPAGIYNLDDLK($181)ALGRR  ISLPPVLKAK($300)K x1
K($142)LSKTGVPDGIMQFIK  DNQEMK($158)SRILVIK x1
LSKTGVPDGIMQFIK($157)LCTVSYGK  K($378)SDR x1
SAISK($222)TAESSGGPSTSR  MATSSEEVLLIVK($13)K x1
EFSK($81)AQEESTGLLSGLR  ADRDK($11)K x1
K($648)GMVAEEYNAFFYSLVSQDTQEMAYSTK  GK($603)VSEGIDFVHHYGR x1
YNLTSDIIESIFRTYPAVK($204)MK  EVK($152)DNQEMK x1
MATSSEEVLLIVK($13)K  TDYGLMVFADK($682)R x1




Figure 65: Map of the crosslinks obtained in our assays.  
Intralinks are shown as blue lines, previously reported interlinks are represented with black lines, 
and brand-new interlinks reported in this thesis are shown as green lines.  
 
4.2.1.3. A different purification tag might be the answer 
Since the versatility of the MultiBacTM system allowed us to obtain different Core 
constructs in a relatively short time, we also tried different approaches to obtain the TFIIH 
Core sub-complex while optimising the purification protocol for the Core construct with 
subunits p52 and p62 carrying a 6xHis-V5-TEV N-terminal tag. 
  
The 6xHis-V5-TEV tag had been designed with several functions in mind: (1) purification 
of our proteins in an IMAC by means of the 6-residue His tag, (2) Western blot detection 
and immunoprecipitation (IP) of the complex through the V5 epitope, and (3) removal of 
the tag from the purified protein if necessary thorough cleaving at the TEV site. However, 
our attempts to purify the Core sub-complex by IP (data not shown) exposed a problem 
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with this design: when release of the protein with the appropriate elution buffer failed, we 
tried to achieve this by cleaving with TEV protease, but the sub-complex still remained 
bound to the beads. This was probably due to the closeness between the V5 epitope 
and the TEV cleavage site in our tag, which meant that a bound V5 antibody would block 
access to the TEV site. To solve this problem, we introduced a 9-residue spacer between 
the V5 and TEV sequences (see chapter 2, section 2.1.2), and we cloned the new tag 
into three different constructs: TFIIH Core with subunits p52 and XPD tagged at their N-
terminal end with 8xHis-V5-spacer-TEV, and a 6-subunit (XPB, p62, p52, p44, p34 and 
p8) Core construct with p52 carrying the N-terminal 8xHis-V5-spacer-TEV tag, with XPD 
(also tagged with 8xHis-V5-spacer-TEV at its N-terminal end) cloned into a separate 




Figure 66: TFIIH constructs carrying an 8xHis-V5-spacer-TEV tag.  
Cartoon view of constructs (A) 6-subunit (XPB, p62, p52, p44, p34 and p8) TFIIH Core, (B) XPD 
and (C) 7-subunit (XPD, XPB, p62, p52, p44, p34 and p8) TFIIH Core. Subunits p52 and XPD 
carry the N-terminal 8xHis-V5-spacer-TEV tag (represented here by a pink diamond) in all three 
constructs. 
 
We first cloned and expressed the sub-complex containing all seven Core subunits 
following the same method explained for previous constructs. Our first BioSprint test 
showed very poor expression levels (figure 67, (A)), so we tried a second infection and 
BioSprint test. This second attempt (figure 67, (B)) only offered slightly better results, 
and subunit XPD still could not be seen in the gel. A Western blot confirmed that XPD is 
present in our extract, although approximately 5 times less abundant than p52, and it 
mostly remains in the unbound fraction of our purification. As for subunit p52, we only 
recover 4% of the total protein present in our extract, but it’s still 9-fold the amount of the 
recovered XPD. The Western blot also confirms that a lot of the sub-complex present in 
our original sample (78% XPD and 72% p52) is lost, probably due to precipitation or 
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Figure 67: Purification test of TFIIH Core with 8xHis-V5-spacer-TEV-tagged XPD and p52.  
Coomasie-stained gel showing our first BioSprint expression test (A) and a second BioSprint test 
for a new infection (B) for construct TFIIH Core with subunits p52 and XPD carrying an 8-residue 
His tag at their N-terminal end. A Western blot was also performed for this second infection (C), 
showing that only 2% of the total XPD available is recovered after purification, with 20% of it lost 
due to poor binding. In the case of p52 the recovered percentage increases to 4%, with 24% of 
the protein lost in the process of binding the beads (unbound and wash fractions). However, as 
the initial amount of p52 available in the sample is considerably higher than that of XPD, the final 
amount of purified p52 is still 9 times higher than purified XPD. Ladder sizes are indicated in kDa.  
 
Scaling up our infections and purifying the construct following our IMAC - size exclusion 
- cation exchange chromatography protocol offered much better results with regards to 
the yield of subunits XPB, p62, p52, p44, p34 and p8, but the SDS-PAGE gels showed 
no noticeable improvement regarding XPD (figure 68); moreover, the sub-complex with 













































































100% 10% 14% 4%
Sample volume (ml)       5        2.5         5       0.25
Loaded volume (µl) 10 20        20 20
(C)
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Figure 68: Purification of TFIIH Core with 8xHis-V5-spacer-TEV-tagged XPD and p52. 
Construct TFIIH Core with subunits p52 and XPD tagged at their N-terminal end with 8xHis-V5-
spacer-TEV was purified following the same protocol developed for the sub-complex with subunits 
p52 and p62 tagged with 6xHis-V5-TEV. The Coomassie-stained gels included here show the 
sub-complex at the different stages: ion affinity (HisTrapTM FF column, blue box), size exclusion 
(HiPrepTM 16/60 SephacrylTM S300 HR column, grey box) and cation exchange (MonoSTM 4.6/100 
PE column, yellow box). Ladder sizes are indicated in kDa.  
 
As the 7-subunit, 8xHis-V5-spacer-TEV-tagged Core sub-complex had not offered any 
improvement over our previous results, we moved onto the expression of the 6-subunit 
sub-complex, with XPD produced separately. This new approach, with helicase XPD 
cloned and expressed on its own, offered us two options: we could either co-infect our 
cultures with two different viruses (one containing XPD and the other containing the 6-
subunit Core sub-complex) or we could infect cultures with each virus separately, 
expressing and purifying the constructs on their own and combining our purified samples 
at the end. Unfortunately, the BioSprint expression test for the 6-subunit Core sub-
complex showed that the subunits were not expressed equally in this particular construct 
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(figure 69), with subunits XPB and p52 clearly more abundant than p62, p44, p34 and 
p8. A scaled-up infection and purification following the previously described three-step 
protocol confirmed this result (figure 70). 
 
Figure 69: Purification test of 6-subunit TFIIH Core with 8xHis-V5-spacer-TEV-tagged p52. 
Coomassie-stained gel showing a BioSprint expression test for construct 6-subunit TFIIH Core 




Figure 70: Purification of 6-subunit TFIIH Core with 8xHis-V5-spacer-TEV-tagged p52. 
Coomassie-stained gels showing the different chromatographic steps followed to purify construct 
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6-subunit TFIIH Core sub-complex with subunit p52 tagged at its N-terminal end with 8xHis-V5-
spacer-TEV. The protocol included the same steps followed in the purification of previous TFIIH 
Core constructs: ion affinity (HisTrapTM FF column, blue box), size exclusion (HiPrepTM 16/60 
SephacrylTM S300 HR column, grey box) and cation exchange (MonoSTM 4.6/100 PE column, 
yellow box). Ladder sizes are indicated in kDa. 
 
Expressing XPD as an independent subunit didn’t offer the results we hoped to obtain 
either. When our traditional approach (cloning, expression test in Sf9 cells followed by a 
BioSprint purification test) once more failed to yield pure XPD (figure 71 (A)), we tried to 
extract and purify the helicase in an anaerobic atmosphere to prevent the oxidation of 
the 4FeS cluster, using both Ni-NTA beads (figure 71 (B)) and Protein G beads (figure 
71 (C)), following a method adapted from our regular BioSprint test (see chapter 2, 




Figure 71: Purification test and anaerobic purification of the 8xHis-V5-spacer-TEV-tagged 
XPD helicase.  
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(A) Coomassie-stained gel showing a BioSprint expression test for subunit XPD carrying an 
8xHis-V5-spacer-TEV tag at its N-terminal end. Purification of the helicase in anaerobic conditions 
using Ni-NTA beads (B) and protein G beads (C). All three methods failed to produce any pure 
XPD. Ladder sizes are indicated in kDa. 
 
While the Western blot performed after the anaerobic purification of XPD using Ni-NTA 
beads (figure 71, (B), right panel) demonstrated that the enzyme could only be found in 
the unbound fraction, the Western blot for the protein G beads (figure 71, (C), right panel) 
showed that while a small part of XPD could bind to the beads, most of it could not be 
cleaved by TEV, and the majority of the helicase remained in the unbound fraction as 






Figure 72: IMAC and IP purification of 8xHis-V5-spacer-TEV -tagged XPD helicase.  
(A) Western blot showing the IMAC purification of construct XPD tagged with 8xHis-V5-spacer-
TEV at its terminal end. The extraction buffer contained 5 mM ANAPOE C12E8 detergent, which 
was diluted to 1 mM in the subsequent buffers employed in the purification process. (B) 
Purification of XPD by means of IP also failed to produce pure XPD as the helicase was unable 
to bind the protein G beads, as shown in the Western blot. 
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We tried to improve the amount of XPD obtained by extracting the protein with a buffer 
containing 5 mM ANAPOE C12E8 detergent, as reported in (Pullara et al., 2013), following 
the procedure described in chapter 2, section 2.3.3.2. After extraction the sample was 
loaded into a 1 ml HisTrapTM FF column, and fractions of interest were analysed by SDS-
PAGE and Western blotting. The expression levels were good, and extraction had 
indeed improved compared to previous experiments, but binding to the column remained 
very weak (figure 72 (A)). Finally, an attempt to obtain the helicase by IP completely 
failed to pull down any protein at all because of poor binding to the protein G beads 
(figure 72 (B)).  
 
4.2.1.4. Tagging the C-terminal end of XPD 
The poor results obtained for the many different methods used to try to purify helicase 
XPD forced us to once again reconsider our approach to obtain this subunit. Since none 
of the different tags attached to the N-terminal end of the helicase had made a difference 
regarding its recovery, we pondered if using a C-terminal tag instead of an N-terminal 
one might improve our results.  To test this, the XPD gene was first cloned into plasmid 
pACEBac2 using enzymes NcoI and KpnI, then a sequence encoding the TEV-10xHis-
V5 C-terminal tag was cloned into the recombinant plasmid using enzymes ScaI and 
KpnI. The P0 viral stock obtained from the transfection of the recombinant bacmid was 
used to infect a 25 ml Sf9 suspension culture, and the pellet harvested was analysed in 
a BioSprint station as previously described (figure 73 (A)). 
 
 
We tried to improve the extraction step, which seemed to be even more inefficient than 
that observed in previous experiments, by performing a BioSprint using different lysis 
buffers with different detergents as suggested in the 2013 Levine paper (Pullara et al., 
2013) (figure 73 (B)). A Western blot performed with samples from the extract and eluted 
fractions showed a worrying degradation of XPD that we had not seen before.  
CLONING, EXPRESSION AND PURIFICATION OF THE TFIIH COMPLEX 
 
 122 




Figure 73: Purification tests of 8xHis-V5-spacer-TEV-tagged XPD helicase using different 
detergents.  
(A) Western blot showing a BioSprint purification test for helicase XPD tagged with TEV-10xHis-
V5 at its C-terminal end. The new tag fails to bind to the magnetic Ni-NTA beads, as evidenced 
by the fact that roughly the same amount of protein is found both in the extract and the unbound 
fractions. (B) Western blot showing BioSprint tests performed after extraction of XPD using three 
different cell lysis buffers: PBS, 300 mM NaCl, 0.1% Triton (B1), PBS, 300 mM NaCl, 1% Triton 
(B2), and 50 mM HEPES pH 7.5, 300 mM potassium acetate, 2 mM BME, 5 mM ANAPOE C12E8 
(B3), all of them containing DNAseI and a protease inhibitor cocktail. All three of them show the 
same degradation of XPD, and extraction seems to be less efficient rather than improving with 
the new lysis buffers. The poor signal obtained for the ANAPOE extracted fraction can probably 
be attributed to the fact that although extraction is performed with 5 mM ANAPOE, the sample 
must be diluted to 1 mM to allow binding to the Ni-NTA beads. Ladder sizes are indicated in kDa. 
 
 
4.2.1.5. Twin-Strep tag®: the solution to our problem  
The use of a Strep-Tactin®XT Superflow® resin to purify proteins carrying a matching 
Twin-Strep-tag® is currently very extensive due to a reported affinity in the pM range. As 
one of our most pressing problems was the low binding of the XPD subunit to any of the 
means we employed in the purification of the TFIIH Core sub-complex, the cloning of a 
Twin-Strep-tag® into XPD seemed like a very promising, potential solution to our 
difficulties in purifying the helicase. The new tag was cloned at the C-terminal end of 
XPD using enzymes ScaI and KpnI, then the Strep-tagged XPD was cloned into a 
pACEBac2 plasmid already containing subunits XPB, p62, p52, p44, p34 and p8 as 
previously described. This new construct was cloned, expressed and purified by Mrs. 
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Biljana Petrovic-Stojanovska, following the method previously described. 
 
The combined use of the Twin-Strep-tag® cloned into XPD and the Strep-Tactin®XT 
Superflow® resin as a third recovery step (figure 74, orange box) in our purification 
protocol finally allowed us to obtain helicase XPD in similar amounts as TFIIH Core 
subunits XPB, p62, p52, p44, p34 and p8 (confirmed by MS), and with a yield very similar 
to that obtained previously with our simplified two-step procedure, despite the addition 




Figure 74: Purification of TFIIH Core with 6xHis-V5-TEV-tagged p62 and p52 and helicase 
XPD carrying a Twin-Strep-tag® at its C-terminal end. 
Cartoon view of construct TFIIH Core with subunits p52 and p62 carrying an N-terminal 6xHis-
V5-TEV tag (yellow diamond) and helicase XPD carrying a C-terminal Twin-Strep-tag® (green 
diamond) (A) and Coomassie-stained gels showing the purification process for construct TFIIH 
Core with subunits p52 and p62 tagged at their N-terminal end with 6xHis-V5-TEV and subunit 
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ion affinity (Talon® SuperflowTM resin, blue box), size exclusion (HiPrepTM 16/60 SuperdexTM 
S200 prep grade column, grey box) and Streptavidin affinity (Strep-Tactin®XT Superflow® resin, 
orange box). Ladder sizes are indicated in kDa. Subunit XPD is clearly visible in a Coomassie-
stained gel together with the other six TFIIH Core subunits. 
           
 
4.2.2. 10-Subunit TFIIH complex  
4.2.2.1. Obtaining the CAK sub-complex  
Cloning of the genes encoding the three subunits integrating the CAK sub-complex into 
our TFIIH Core construct was approached as a way to stabilise XPD and facilitate its 
purification at a time when we had yet to attempt the cloning of the Twin-Strep-tag® into 
the helicase.  
 
       
 
Figure 75: Purification test of the CAK sub-complex with 8xHis-V5-spacer-TEV-tagged 
MAT1, cdk7.  
Cartoon view and SDS-PAGE gels showing BioSprint expression tests for two different CAK 
constructs: one with subunit MAT1 tagged at N-terminal with 8xHis-V5-spacer-TEV (A) and 
another one with the same tag attached to the N-terminal end of subunit cdk7 (B). Both gels show 
that the tag is only able to pull down the subunit it is attached to. Ladder sizes are indicated in 
kDa. 
 
Synthetic genes encoding the three CAK subunits MAT1, cdk7 and cyclin H were 
ordered, with these last two designed as a single unit, joined by a 2A-like auto-cleavable 
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sequence as previously described for subunits p52-F2A-p8 and p44-T2A-p34. Two 
different CAK constructs (one with subunit MAT1 carrying an 8xHis-V5-spacer-TEV tag 
at its N-terminal end (figure 75 (A)) and another one with subunit cdk7 carrying the same 
tag at its N-terminal end (figure 75 (B))) were cloned as previously described for the 
TFIIH Core constructs. The two different three-gene plasmids were transposed into the 
baculoviral genome, which was subsequently purified and transfected into Sf9 cells and 
the P0 virus obtained from this transfection was used to infect a 25 ml Sf9 suspension 
that was later processed and tested in a BioSprint station as previously described. The 
eluted fractions were analysed by SDS-PAGE, showing in both cases that one tag is 
insufficient to pull down the untagged subunits present in the sub-complex. This result 
hints to a weak interaction between the three CAK subunits.  
 
To solve this problem we cloned, following the same method, a third CAK construct in 
which both the MAT1 and cdk7 subunits were tagged at their N-terminal end with 8xHis-
V5-spacer-TEV. The construct was transposed, transfected, and finally a 25 ml Sf9 
suspension infected with this P0 virus was tested for expression as explained before. 
This time all three subunits were pulled down, and expression was robust for all of them 
(figure 76). 
             
 
Figure 76: Purification test of the CAK sub-complex with 8xHis-V5-spacer-TEV-tagged 
MAT1 (A) and 8xHis-V5-spacer-TEV-tagged cdk7 (B).  
Cartoon view and SDS-PAGE gel showing a BioSprint expression test for a third CAK construct 
in which both the MAT1 and cdk7 subunits were tagged at their N-terminal end with 8xHis-V5-
spacer-TEV. All three subunits were successfully pulled down this time. Ladder sizes are 
indicated in KDa. 
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4.2.2.2. Co-infecting to obtain the 10-subunit TFIIH complex 
Cloning of the CAK sub-complex-encoding sequences into our plasmid already carrying 
the seven Core genes was attempted, but when we didn’t get immediate positive results 
we opted for the more straight-forward alternative of co-infecting a Sf9 suspension 
culture using two different viral stocks: one carrying the TFIIH Core sub-complex and 






Figure 77: Purification test of the 10-subunit TFIIH complex. 
A Sf9 cell suspension culture co-infected with two different viral stocks (one obtained after 
infection with the TFIIH Core construct (A) and another obtained with the CAK construct (B), both 
shown here in cartoon view) was tested in a BioSprint station for 10-subunit TFIIH complex 
expression. Fractions of interest were analysed in a SDS-PAGE gel (C) which showed clear 
bands for subunits XPB, p62, p52 and p8, and mixed bands for subunits cdk7/p44, p34/MAT1, 
and cyclin H, as these subunits are very close in size (41/44 kDa, 34/32 kDa and 38 kDa, 
respectively). A MS analysis of a liquid sample further confirmed the presence of all 10 TFIIH 
subunits (D). Ladder sizes are indicated in kDa. 
 
A 25 ml Sf9 suspension was co-infected as described in chapter 2, section 2.2.4, with 
constructs TFIIH Core with subunits p52 and XPD tagged at their N-terminal end with 
8xHis-V5-spacer-TEV (figure 77 (A)) and CAK with subunits MAT1 and cdk7 carrying 
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the same tag at their N-terminal end (figure 77 (B)). After the appropriate incubation time, 
the pellet was harvested and processed as previously described for our TFIIH Core 
constructs, and the cleared supernatant was tested for complex expression in a BioSprint 
station. The eluted fraction was subsequently analysed in a SDS-PAGE gel (figure 77 
(C)). Subunits XPB, p62 and p52 were obvious in the gel, and a second band could be 
seen right under XPB, presumably corresponding to XPD. The bands for subunits p44, 
p34, MAT1, cdk7 and cyclin H were difficult to see individually, as all five subunits have 
similar sizes, all in a narrow range (34 to 44 kDa). A sample of the eluted fraction was 
analysed by MS, confirming the presence of all ten subunits (figure 77 (D)).  
 
4.2.2.3. Purification of 10-subunit TFIIH  
After the encouraging results obtained for the expression test, we scaled-up our 
infections and tried to pull-down the 10-subunit TFIIH complex following our updated 
IMAC – size exclusion – cation exchange chromatography purification protocol, in this 
case using a Talon® SuperflowTM resin for the IMAC step (figure 78, blue box). Fractions 
containing the 10-subunit TFIIH complex were concentrated and diluted to a 1:3 ratio 
with buffer 20 mM HEPES pH 7, 1 mM DTT, 10% glycerol before being loaded into a 
MonoSTM 4.6/100 PE column (figure 78, yellow box), removing the size exclusion 
chromatography step due to the lower expression of the complex obtained in this 
infection. 
 
The chromatogram obtained for this purification showed six different peaks, which hinted 
to a probable break down of the complex into smaller sub-complexes as the purification 
progresses. This was confirmed by the SDS-PAGE analysis of selected fractions taken 
from all six peaks, with peak 5 containing the 7-subunit TFIIH Core complex we initially 
aimed to purify. All fractions of interest from peak 5 were subsequently concentrated and 
a sample was analysed by SDS-PAGE again, revealing a band directly under the one 
corresponding to the XPB subunit which was identified as a mixture of both XPB and 
XPD by MS analysis. This represented a significant improvement over our previous 
attempts to purify XPD, and definitely was our best result in terms of extraction of the 
helicase up to that date. Despite this improvement, very little XPD was actually 
recovered, and the pattern of peaks obtained could not be reproduced in subsequent 
purifications, so we focused our efforts in other alternatives to finally obtain all seven 
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Figure 78: Purification of the 10-subunit TFIIH complex.  
Coomassie-stained gels showing the different chromatographic steps followed to purify our 10-
subunit TFIIH complex. The protocol was simplified to two steps: ion affinity (Talon® SuperflowTM 
resin, blue box), and cation exchange (MonoSTM 4.6/100 PE column, yellow box). Ladder sizes 
are indicated in kDa. The six peaks obtained during cation exchange were analysed in a SDS-
PAGE gel, confirming that the 10-subunit complex breaks down into several different sub-
complexes along its purification. Fractions included in peak 5 were concentrated and further 
analysed in a gel that showed the 7-subunit TFIIH Core sub-complex, with the band immediately 
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4.2.3. Cloning and expression of other TFIIH constructs 
4.2.3.1. TCP-Tagged TFIIH Core 
4.2.3.1.1. Cloning and expression tests 
A CCGPCC tetracysteine tag encoding sequence was cloned into TFIIH Core subunit 
XPB, as we had previously done with damage-detector protein XPC to aid in our 
fluorescence anisotropy and bulk FRET assays. To build up the seven-gene TFIIH Core 
construct, the sequence encoding the TCP-tagged XPB was cloned into a pACEBac2 
plasmid already containing the XPD gene as previously described. The TCP-tagged 
XPB/XPD cassette was subsequently cloned into another pACEBac2 plasmid containing 
the genes encoding subunits p62, p52, p44, p34 and p8, following the same protocol. 
Subunits p62 and p52 had previously been tagged at N-terminal with 6xHis-V5-TEV. The 
TCP tag had previously been confirmed by sequencing, and the seven-gene construct 
was verified by restriction with enzymes KpnI, BamHI/HindIII and SalI/XhoI. 
 
                           
 
Figure 79: Purification test of the TCP-tagged TFIIH Core sub-complex.  
SDS-PAGE gel showing a BioSprint expression test for construct TFIIH Core with subunits p52 
and p62 tagged at their N-terminal end with 6xHis-V5-TEV (yellow diamond) and subunit XPB 
tagged with a CCGPCC tretracysteine motif at its N-terminal end, too (red sphere). The presence 
of the TCP tag had previously been confirmed by sequencing. Ladder sizes are indicated in kDa. 
 
The TCP-tagged, seven-gene plasmid was transposed into the baculoviral genome, and 
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afterwards the purified bacmid was transfected into a monolayer of Sf9 cells. An 
expression test was carried out in a 25 ml Sf9 suspension culture infected with 3 ml of a 
P0 viral stock and expression levels were analyzed in a BioSprint purification test as 
previously described. The eluted fraction was analysed in a SDS-PAGE gel, and as with 
other TFIIH constructs, the gel showed a good expression for subunits XPB, p62, p52, 
p44, p34 and p8, with helicase XPD expressed in a much lower concentration, hence 
not showing in the gel (figure 79).  
 
4.2.3.1.2. Purification  
The next step involved the scaling-up of the infected Sf9 suspension cultures and 
purification of the TCP-tagged TFIIH Core sub-complex in two steps: IMAC utilising a 
Talon® SuperflowTM resin (figure 80, blue box) and a cation exchange chromatography 
through a MonoSTM 4.6/100 PE column (figure 80, yellow box). Fractions eluted after 
IMAC were diluted 1:3 with buffer 20 mM HEPES pH 7, 1 mM DTT, 10% glycerol before 




Figure 80: Purification of the TCP-tagged TFIIH Core sub-complex.  
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Coomassie-stained gels showing the two chromatographic steps followed to purify our TCP-
tagged TFIIH Core sub-complex: IMAC (Talon® SuperflowTM resin, blue box), and cation 
exchange (MonoSTM 4.6/100 PE column, yellow box). Ladder sizes indicated in kDa. Fractions 
eluted in peak 3 contained similar amounts of XPB, p62, p52, p44, p34 and p8, and residual 
amounts of XPD (not seen in the gel). Surprisingly, fractions eluted in peak 2 also contained the 
Core sub-complex, but TCP-tagged subunit XPB was barely present here.  
 
4.2.3.1.3. ReAsH-EDT2 Labelling of TCP-tagged TFIIH Core 
The fractions collected in peak 3 were pooled together and concentrated, and TCP-
tagged TFIIH Core was labelled with the biarsenic ligand ReAsH-EDT2 as described in 
chapter 2, section 2.5.1.   
 
           
 
Figure 81: ReAsH labelling of construct TFIIH Core.  
Subunit XPB carries the tetracysteine motif at its N-terminal end. The ligand was excited at a 
wavelength of 593 nm and emitted fluorescence was collected at a wavelength of 608 nm. 
 
No TCP-TFIIH Core sub-complex was added to the reaction corresponding to the first 
measured point shown in the graph, acting as a control to determine the intensity 
corresponding to the free ReAsH-EDT2 reagent. An increment in the intensity of the 
emitted fluorescence, collected at 608 nm, was observed as the concentration of TCP-
TFIIH Core increases (figure 81). This increment was expected as a result of the binding 
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of the ReAsH-EDT2 ligand to the tetracysteine tag cloned into subunit XPB, confirming 
that our Core sub-complex can be labelled successfully. 
 
4.3. Discussion 
4.3.1. Cloning and expressing the TFIIH Core sub-complex 
The TFIIH complex not only carries out different functions in transcription and in DNA 
repair: its structure itself is different in the two processes. All ten subunits (holo-TFIIH) 
participate in the role of the complex in transcription, but only the Core sub-complex is 
required for NER (Svejstrup et al., 1995). The CAK sub-complex has even been reported 
to inhibit the NER process by down-regulating the helicase activity of XPD (Sandrock & 
Egly, 2001), and so it is removed after the holo-complex binds to the damaged site in a 
reaction reportedly promoted by XPA (Coin et al., 2008). Taking this into account, and 
as our interest regarding the TFIIH complex focuses on its role as a DNA repair factor, 
we initially attempted the cloning of the TFIIH Core sub-complex on its own, with subunits 
XPD and p52 carrying a 6xHis-V5-TEV tag at their N-terminal end.  
 
We obtained a seven-gene construct containing the sequences encoding subunits XPD, 
XPB, p62, p52, p44, p34 and p8 by cloning every gene, one at a time, into a single 
plasmid using the multiplication module present in the vectors comprising the MultiBacTM 
system (Bieniossek et al., 2013), a BEV for the cloning and expression of multi-protein 
complexes (Berger et al., 2004). To facilitate the cloning of the sub-complex the genes 
for subunits p52 and p8, and p44 and p34, were designed as a single unit, with each pair 
of genes separated by a 2A-like auto-cleavable peptide (Luke et al., 2009), meaning that 
only five cloning reactions were needed to obtain the seven-gene construct. 
Unfortunately, expression levels in Sf9 cells for this construct were quite disappointing 
(figure 57), and after optimisation of the transfection and infection processes failed to 
improve our results a change of strategy concerning the position of the purification tags 
was approached to try to solve this problem. The Western blot on figure 57 also shows 
a remarkable cleaving efficiency for the 2A-like peptides, with almost 90% of the p52-
F2A-p8 gene actively translated into independent subunits p52 and p8. 
 
As several multi-gene intermediates had already been obtained in the cloning of the 
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previous TFIIH construct, the characteristics of the MultiBacTM plasmids (Bieniossek et 
al., 2012) allowed the construction of a new seven-gene TFIIH Core sub-complex with 
subunits p52 and p62 carrying a 6xHis-V5-TEV tag in only three cloning steps. Analysis 
of the fractions eluted in an expression test for the new construct in a SDS-PAGE gel 
clearly showed subunits XPB, p62, p52, p44, p34 and p8 in stoichiometric amounts, but 
no XPD (figure 60 (A)). Furthermore, an expression test performed in anaerobic 
conditions also failed to improve the extraction and purification of XPD (figure 60 (B)). 
 
Although disappointing, this result was not very surprising, as it was already hinted in 
our previous purifications of the sub-complex that we might be losing XPD during the 
process. Our observations were reinforced by the knowledge that XPD is not only the 
most flexible subunit within the TFIIH Core sub-complex, being able to bind to both the 
Core and CAK sub-complexes (Greber et al., 2017), but the presence of an 4FeS cluster 
in its structure (Rudolf et al., 2006) also affects the purification of the sub-complex 
enormously.  
 
Scaling-up and optimisation of the protocol for the purification of the TFIIH Core sub-
complex in aerobic conditions finally resulted in an easily reproducible procedure that 
included an IMAC step, followed by size-exclusion chromatography and finally a cation 
exchange chromatography (figure 61). This protocol yielded up to 1 mg of pure sub-
complex (containing subunits XPB, p62, p52, p44, p34 and p8, with most of subunit XPD 
lost along the process as confirmed by the Western blot in figure 62) for every 2 L culture. 
TFIIH Core yield was further improved by substituting the HisTrapTM FF column in the 
IMAC step for a Talon® SuperflowTM resin that allowed longer binding times, and the 
removal of the cation exchange chromatography, which translated into a significantly 
reduced loss of the complex (figure 63). 
 
The presence of a reduced amount of XPD in our purified sample was further confirmed 
by crosslinking assays. A total of 25 interlinks (nine of which had not been previously 
reported) and 10 intralinks (table 5) were obtained, depicting a compact structure 
profusely connected. The publication of an extensive structural study based on 
crossliking (Luo et al., 2015) around the time we were carrying out these assays led us 
to pursue a different line of research, focusing on a biochemical approach rather than a 
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structural study of the sub-complex. However, after the recent publication of the cryoEM 
structure of the Core sub-complex plus CAK subunit MAT1 (Greber et al., 2017) we 
revisited our data to check how our unreported crosslinks fit within the structure. 
Unfortunately, all of our crosslinks seem to fall on unstructured, poorly defined zones in 
the published structure, so no information could be extracted from this comparison other 
than a further confirmation of TFIIH’s flexibility. Although the publication of the cryoEM 
structure obtained by the Nogales group meant a considerable advance in our 
knowledge of TFIIH, our observations emphasise the need for improved structural 
information on the complex. 
 
4.3.2. The elusive XPD helicase 
IP experiments revealed a weakness in the design of our 6xHis-V5-TEV tag: when 
antibody V5 was bound to its epitope in the tag, the TEV site was not accessible for 
cleaving with the protease. To solve this problem, a new tag with a 9-residue spacer 
between the V5 and TEV sites (8xHis-V5-spacer-TEV) was designed and cloned into 
three different TFIIH constructs: a 7-subunit Core with subunits p52 and XPD tagged at 
their N-terminal end, a 6-subunit (XPB, p62, p52, p44, p34 and p8) Core with only subunit 
p52 carrying the tag, and a tagged XPD subunit cloned on its own. By cloning these 
three constructs we hoped to solve our ongoing problem of not recovering enough XPD 
in our purification, either by introducing a stronger tag that would be able to pull down all 
seven subunits in the Core sub-complex, or by expressing problematic XPD on its own 
and later adding it to a purified sample containing the other six Core subunits.  
 
Expression and purification of the new 8xHis-V5-spacer-TEV-tagged 7-subunit Core 
construct revealed no noticeable improvement regarding XPD (figures 67 and 68), and 
its yield for the remaining six subunits was never as good as levels offered by its 6xHis-
V5-TEV-tagged counterpart. Expression and purification of the 6-subunit sub-complex 
showed that the Core subunits were not expressed stoichiometrically for this construct 
(figure 69), with only subunits XPB and p52 remaining in our purified sample after the 
cation exchange chromatography. This could point to subunits XPB and p52, and 
possibly p8 (as seen in the SDS-PAGE gel corresponding to the size exclusion 
chromatography in figure 70, grey box) forming a smaller sub-complex within TFIIH Core, 
supported by the tight relationship between the three subunits, as p52 and p8 act as 
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regulators of the helicase (Coin et al., 2006) (Coin et al., 2007) (Luo et al., 2015).  
 
Different approaches to try to obtain helicase XPD as an independent subunit didn’t 
offered the expected results either. We initially tried our previous approach of expression 
in Sf9 cells followed by an aerobic BioSprint purification test (figure 71 (A)). When this 
didn’t work, an anaerobic purification using both Ni-NTA beads (figure 71 (B)) and protein 
G beads (figure 71 (C)) was attempted, but while the helicase failed to bind to the Ni-
NTA beads, most the fraction bound to the protein G beads could not be cleaved by TEV, 
suggesting that the spacer introduced in the tag was insufficient to make the cleaving 
site available to the protease.  
 
A final attempt to try to improve the amount of XPD obtained was made by adding 5 mM 
ANAPOE C12E8 detergent to the extraction buffer, and 1 mM detergent to our purification 
buffers A and B, as reported in (Pullara et al., 2013). Although the addition of the 
detergent somewhat improved the amount of extracted XPD compared to previous 
experiments, it did not enhance the weak binding of the helicase to the column (figure 
72 (A)). Trying to obtain the helicase by IP didn’t work either, as the protein completely 
failed to bind to the protein G beads (figure 72 (B)). This might be due to the presence 
of 1 mM ANAPOE C12E8 detergent in our buffers, as a previous IP also performed with 
protein G beads showed that XPD did bind to the beads, and it was actually unable to 
be cleaved from them (figure 71 (C)). 
 
As none of the different methods approached to obtain XPD offered an improvement on 
the recovery of the helicase, we pondered if the N-terminal position of the two different 
tags used in our constructs might be the cause behind these poor results. To test this 
hypothesis, a sequence encoding a new TEV-10xHis-V5 C-terminal tag was cloned into 
the helicase, and purification of XPD in a BioSprint test was attempted, adding a variety 
of detergents to our lysis buffer as a means to improve the extraction of the protein 
(Pullara et al., 2013). Surprisingly, the results obtained with the C-terminal tag were even 
worse than those seen for the N-terminal tags. A Western blot performed with fractions 
obtained after purification of the protein with three different buffers showed that most of 
XPD was cleaved in two, with one of the fragments showing roughly the size expected 
for C-terminal XPD, independently of the buffer used for cell lysis (figure 73 (B)). 
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The optimised purification process we had developed so far meant that we were able to 
obtain pure TFIIH Core sub-complex in a higher yield than any purification reported until 
the publication of the Yang paper in 2015 (Li et al., 2015), but the loss of the majority of 
the XPD helicase present in our sample meant that our sub-complex was not suitable for 
a biochemical characterization of its unwinding activity. The presence of two His tags in 
subunits p52 and p62 was sufficient to pull down all six Core subunits (XPB, p62, p52, 
p44, p34 and p8), but the recovery of XPD remained a challenge for us. Finally, and 
although previous results seemed to discourage the use of a C-terminal tag on XPD, we 
were able to obtain the elusive protein by cloning a Twin-Strep-tag® precisely at the C-
terminal end of the helicase.  
 
The use of the Strep-Tactin®XT Superflow® resin, which reportedly has an affinity in the 
pM range for the matching Twin-Strep-tag®-encoding sequence cloned into XPD, proved 
to be the solution to the low binding affinity the helicase had shown in all of our previous 
purification attempts. With construct TFIIH Core with subunits p52 and p62 carrying a 
6xHis-V5-TEV N-terminal tag and subunit XPD carrying a C-terminal Twin-Strep-tag® 
we were finally able to obtain all seven Core subunits in stoichiometric amounts (figure 
74). Moreover, the introduction of a third chromatographic step only had a minimal impact 
in our complex yield compared to our previous two-step protocol. The seven-subunit 
TFIIH Core sub-complex obtained in this manner has been tested for DNA binding and 
helicase activity and has been proved to be active in a variety of assays described in 
chapter 5.  
 
4.3.3. Cloning and expressing the 10-subunit TFIIH complex 
Obtaining helicase XPD in a similar amount as the other Core subunits when purifying 
the sub-complex was for a long time the hardest challenge of this PhD project. As XPD 
binds to both the Core and the CAK sub-complexes (Schultz et al., 2000) (Greber et al., 
2017), one of the approaches we pursued (before we introduced the Twin-Strep-tag® 
into our construct) was cloning the three genes encoding the CAK sub-complex into our 
7-subunit construct in an effort to stabilise XPD, hopefully improving its purification this 
way. A BioSprint purification test showed that a single 8xHis-V5-spacer-TEV tag was not 
enough to pull down all three CAK subunits (figure 75), hinting to a weak interaction 
between subunits cdk7, cyclin H and MAT1. This problem was solved by cloning a new 
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CAK construct in which subunits MAT1 and cdk7 were tagged at their N-terminal end 
with 8xHis-V5-spacer-TEV, which showed excellent expression levels in a BioSprint 
purification test (figure 76).  
 
Analysis in a SDS-PAGE gel of a purification test for a co-infection experiment with two 
different recombinant viruses, one carrying the TFIIH Core sub-complex and another one 
carrying the CAK sub-complex, showed clear bands for subunits XPB, p62 and p52, with 
a fainter band right under XPB that was tentatively identified as XPD. The bands for 
subunits p44, p34, MAT1, cdk7 and cyclin H were more difficult to differentiate, as sizes 
for these subunits are very close (34 to 44 kDa), but the presence of all ten TFIIH 
subunits was confirmed by MS analysis of a sample of the eluted fraction (figure 77). 
The hit list obtained for this analysis showed that expression levels for XPD were much 
closer to those of the other TFIIH Core subunits than anything obtained in purification 
attempts carried out up to that date. However, a scaled-up purification showed that the 
complex broke down into different sub-complexes as the purification progressed (figure 
78), with one of these sub-complexes being the 7-subunit Core we aimed to purify 
initially. A concentrated sample of the fractions containing the Core sub-complex was 
further analyzed in a SDS-PAGE gel, showing a band that MS identified as a mixture of 
both XPB and XPD (with the sample containing a slightly higher amount of XPD), thus 
making this the first time we were able to see XPD in a Coomassie-stained gel (figure 
78). Unfortunately, very little XPD was actually recovered, and more importantly this 
purification was extremely difficult to reproduce, which convinced us to go back to our 
original plan of cloning the TFIIH Core construct on its own, eventually achieving our 
goal with the introduction of a Twin-Strep-tag® at the C-terminal end of the helicase. 
 
4.3.4. Cloning and expression TCP-tagged TFIIH Core 
A TFIIH Core construct in which subunit XPB carried a 6-residue Cys-Cys-Pro-Gly-Cys-
Cys motif was cloned to help us study binding of the sub-complex to a DNA substrate in 
anisotropy and bulk FRET experiments. Previous purifications of the TFIIH Core sub-
complex we used to introduce the TCP tag (TFIIH Core with subunits p52 and p62 tagged 
at the N-terminal end with 6xHis-V5-TEV and XPD carrying no tag) had showed good 
expression levels and stoichiometric amounts for the Core subunits, with the exception 
of XPD, which was obtained in a much lower amount. Since the tetracysteine motif is 
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only six amino acids long and unlikely to interfere with the folding or the purification of 
XPB, we expected the same result for our TCP-tagged construct. However, in the course 
of this purification we obtained not one, but two peaks containing the TFIIH Core sub-
complex (figure 80), and while peak 3 contains all seven subunits as we expected, TCP-
tagged XPB is noticeably missing in peak 2, suggesting that the tag might be affecting 
XPB expression. 
 
The concentrated sample obtained from peak 3 was successfully labelled with a ReAsH-
EDT2 biarsenic ligand (figure 81), as a progressive increase in the intensity of 
fluorescence emitted at 608 nm was observed as the concentration of TCP-TFIIH Core 
construct grows. Intensity corresponding to the free ReAsH-EDT2 reagent when excited 
with wavelength 593 nm had previously been established. 
 
This construct was cloned in parallel with another TCP-tagged XPC construct, and as 
with the damage detector, no experiments have actually been performed with it yet due 
to time restrictions. The introduction of a Twin-Strep-tag® at the C-terminal end of XPD 
to increase the yield of the helicase in our TCP-tagged sample is a priority in our future 
plans for this construct. The presence of the TCP tag in our construct will potentially 
improve our anisotropy and FRET assays and will offer confirmation of our preliminary 
data regarding TFIIH Core binding to DNA and to a DNA-XPC complex. 
 
4.4. Conclusions 
We have cloned and expressed the ~ 500 kDa, 10-subunit TFIIH complex using the 
MultiBacTM system, a BEV specifically designed for the production of eukaryotic multi-
protein complexes that allows the expression of every subunit in equimolar amounts 
(Berger et al., 2004), as opposed to infection with several different viral stocks. 
Purification of the sub-complex was achieved after establishing a simple and efficient 3-
step protocol that allows the extraction of up to 1 mg of pure sub-complex from a 2 L 
culture.  
 
The cloning of the genes encoding the Core sub-complex was simplified by the 
introduction of 2A-like sequences (Luke et al., 2009), designing the synthetic genes for 
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subunits p52 and p8, p44 and p34 and cdk7 and cyclin H as a single unit, with each pair 
of genes separated by these autocleavable peptides – hence reducing the number of 
cloning steps necessary to obtain the multi-gene construct. Cleaving efficiency was 
shown to be close to 90%.  
 
The purification process was optimised until a 3-step IMAC – size exclusion – 
streptavidin affinity chromatography was established as a standardized protocol, aided 
by the introduction of a Twin-Strep-tag® at the C-terminal end of helicase XPD and a 
6xHis-V5-TEV tag at the N-terminal end of subunits p52 and p62. This small, versatile 
tag designed by our lab has a triple purpose: purification of the desired peptide through 
its His tail, Western blot detection by means of its V5 epitope and removal of the tag by 
cleaving at its TEV site.  
 
We are currently working on the cloning and expression of the TFIIH Core sub-complex 
carrying helicase mutants XPD K46R (Coin et al., 1998) and XPB K346R (Tirode et al., 
1999) (both affecting the Walker A domain) and XPD Y192A and XPD K196R (Mathieu 
et al., 2013) (affecting the DNA binding pocket on the enzyme). We intend to study the 
binding (or lack thereof) of these mutants to damaged and undamaged DNA substrates 
in fluorescence anisotropy and bulk FRET assays, and their unwinding capacity in 
fluorescence-based helicase assays.  These studies will further reinforce and 
complement our current observations of the binding of the wild type TFIIH Core sub-
complex.  
 
Future work regarding the extraction of the TFIIH Core sub-complex will focus on the 
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5. Studying TFIIH interactions with DNA 
5.1. Introduction 
5.1.1. TFIIH: Early structural knowledge  
The publication of several crystal structures of archaeal homologues of the helicases 
XPB (Fan et al., 2006) and XPD (Liu et al., 2008) (Wolski et al., 2008) (Fan et al., 2008) 
and cryoEM structures of TFIIH itself (Schultz et al., 2000) (Greber et al., 2017) (He et 
al., 2016) (Schilbach et al., 2017) have helped us understand the roles the complex plays 
in transcription and NER and the mechanisms it employs to carry out both functions (both 
extensively discussed in chapter 1, sections 1.2.2.2 and 1.3.2).  
 
The structure of the XPB helicase from the archaeon Archaeoglobus fulgidus was 
published by Fan and co-workers in 2006 (figures 82 and 84). A comparison between 
AfXPB and HsXPB showed that both of them included the two RecA like helicase 
domains HD1 (containing helicase motifs I, Ia, II and III) and HD2 (containing helicase 
motifs IV, V and VI) present in all helicases from the SF1 and SF2 families (Fan et al., 
2006). Motifs I, II, III and VI are known to participate in ATP-binding, while motifs Ia, IV 
and V participate in DNA-binding (Fairman-Williams et al., 2010). They also share a 
series of structural elements: an area for interaction with damaged DNA (the Damage 
Recognition Domain (DRD), situated at N-terminal) and the R210-E211-D212 (RED) 
motif in HD1, suggested by Fan and co-workers to be involved in DNA unwinding in a 
similar manner as the b-hairpin of the UvrB helicase in bacterial NER (Theis et al., 2000). 
At its C-terminal end, the protein presents a Thumb (ThM) domain, a flexible insertion 
into HD2 of approximately 60 residues that participates in binding to the DNA (Fan et al., 
2006). HsXPB presents extended C-terminal and N-terminal domains compared to 
AfXPB that are thought to carry out accessory functions for the human protein (i.e. 
interaction with other repair factors), as viable mutations have only described for these 
regions (Weeda et al., 1997) (Coin et al., 2004), hinting that the core presented in the 
AfXPB is essential for XPB function and so mutations in this area are lethal (Fan et al., 
2006).  






Figure 82: Structure of the XPB homologue from A. fulgidus.  
Structure of the N-terminal domain (A), C-terminal domain (B) and full-length (C) AfXPB, showing 
different orientations of the canonical helicase domains 1 and 2 and XPB’s specific domains DRD, 
Thm and the RED motif. Adapted from (Fan et al., 2006) 
 
Three different crystal structures of the archaeal XPD were published in 2008: an XPD 
homologue from Sulfolobus tokodaii (Liu et al., 2008), one from Sulfolobus 
acidocaldarius (Fan et al., 2008) and a last one from Thermoplasma acidophilum (Wolski 
et al., 2008) (figures 83 and 84). As with XPB, all of them showed the seven canonical 
helicase motifs distributed in two different helicase domains (I, Ia, II and III in HD1; IV, V 
and VI in HD2), with the two domains separated by an interface for ATP hydrolysis (Liu 
et al., 2008). Liu and co-workers additionally identified motifs Ib, Va and VII, thought to 
interact with ssDNA (Liu et al., 2008). The XPD structure also presents two specific 
domains as inserts in HD1: an Arch domain and an FeS domain. The Arch domain 
presents a novel fold and is located between HD1 motifs II and III (Fan et al., 2008). Liu 
et al. proposed a role for this domain as a platform to anchor the CAK sub-complex to 
TFIIH Core, later confirmed by the work of the Egly and Poterszman groups 
(Abdulrahman et al., 2013). XPD also presents a 4FeS cluster situated between HD1 
motifs Ia and II (Fan et al., 2008) and coordinated by four cysteine residues, three of 
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which are highly conserved. This 4FeS cluster has been proposed to have an essential 
role in the function of XPD either as a stabiliser of the overall structure of the helicase 
(Fan et al., 2008), a structural aid to open the DNA (Rudolf et al., 2006) (Liu et al., 2008) 
or a damage-sensor component (Wolski et al., 2008). The three groups coincide in 
proposing that these three elements (HD1, Arch and 4FeS cluster) form a channel for 
the translocation of DNA during unwinding.  
 
 
Figure 83: Crystal structure of different archaeal homologues of helicase XPD.  
The structures of the XPD homologues from S. acidocaldarius (A), T. acidophilum (B) and S. 
tokodaii (C) all show the two canonical helicase domains 1 and 2, and the novel Arch domain. (A) 
and (B) also show the 4FeS domain, delimited in (C) by the green spheres as it was not visible in 
the electron density map. Figure (A) adapted from (Fan et al., 2008), (B) from (Wolski et al., 2008) 
and (C) from (Liu et al., 2008). 
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The little information available regarding the structure of the remaining TFIIH subunits 
was limited to a few domains. The publication of the structure of the N-terminal domain 
of subunit p62 revealed a pleckstrin homology (PH)-like fold (figure 84), the first 
described in a transcription factor, and it was shown to be involved in the recruitment of 
NER factor XPG (Gervais et al., 2004). Since then several publications have proved the 
essential role of the PH domain of p62 in establishing interactions between the TFIIH 
complex and a wide range of different proteins like damage-recognition factor XPC 
(Okuda et al., 2015), transcription factor TFIIE (Okuda et al., 2008) or the Epstein-Barr 
virus protein EBNA2 (Chabot et al., 2014).  
 
The crystal structure of the interaction between Tfb5 and Tfb2 (the yeast orthologues of 
subunits p8 and p52, respectively) revealed that almost the whole of Tfb5 binds to C-
terminal Tfb2, with the two regions sharing a similar fold (figure 84) (Kainov et al., 2008). 
Deletion of the Tfb5-interacting domain in Tfb2 didn’t affect the architecture of the TFIIH 
complex, but it led to impaired NER (Kainov et al., 2008). As it is known that the absence 
of p8 drastically reduces the cellular levels of TFIIH (Giglia-Mari et al., 2004), Kainov and 
co-workers proposed that Tfb5 protects TFIIH from degradation through binding to Tfb2.  
 
The crystal structure of the N-terminal domain of protein Ssl1 (the Saccharomyces 
cerevisiae homologue of subunit p44) showed a von Willebrand factor A (VWA) fold 
(figure 84) with a loop essential for stimulation of Rad3, the yeast homologue of helicase 
XPD, as proved by the fact that a double mutant in the b4-a5 loop showed both 
significantly reduced binding to XPD and helicase activity (Kim et al., 2015). A second 
study produced the structure of the C-terminal domain of p44, proposed to be involved 
in binding to subunit p34 (Kellenberger et al., 2005). This structure shows a C4C4 RING 
domain with two zinc atoms coordinated by eight cysteine residues and the overall fold 
stabilised by hydrophobic residues conserved across all RING folds (Kellenberger et al., 
2005). The research of Schmitt and co-workers also showed a VWA-like fold (figure 84) 
in the structure of the N-terminal domain of the p34 protein from Chaetomium 
thermophilum, corresponding to an area that binds tightly to subunit p44, potentially 
forming a regulatory dimer for the activity of XPD (Schmitt et al., 2014). 
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Figure 84: Architecture of the different TFIIH Core subunits.  
Representation of the structural characteristics of all TFIIH Core subunits, with specific domains 
of known structure indicated by coloured bars. Unlabeled green bars represent predicted a-
helices, while unlabeled blue bars represent predicted b-sheets. Adapted from (Greber et al., 
2017). 
 
5.1.2. TFIIH’s redefined mechanism of action 
The work carried out by the Ranish group provided additional information about the 
interaction of the TFIIH subunits within the complex. Based on extensive crosslinking 
experiments with both the human and the yeast TFIIH, they proposed a novel model in 
which subunit p62 interacts with subunits p44 and p34, located at the base of the 
complex, and with XPD, thus anchoring the helicase to the TFIIH Core (Luo et al., 2015). 
Similarly, the interaction between p52 and p8 not only regulates the ATPase activity of 
XPB, but also ties the ATPase to the sub-complex (Luo et al., 2015). Luo et al also 
proposed that the binding of the CAK sub-complex to the Core occurs through 
interactions not only with XPD, but also with Core subunits XPB and p44.  
 
The Ranish model was later validated with the publication of the cryoEM structure of the 
human TFIIH Core sub-complex plus CAK-subunit MAT1 (Greber et al., 2017) and the 
structure of the S. cerevisiae homologue of TFIIH as part of the PIC (Schilbach et al., 
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2017). Greber and co-workers show a horseshoe-shaped complex with helicases XPB 
and XPD positioned at the open ends. Importantly, p62 could not be unequivocally 
placed in their cryoEM map, although observation of the unassigned density in the 
structure led Greber et al. to agree with Luo’s previous assessment regarding the 
importance of p62 as the subunit that holds the TFIIH Core together. The extended 
contacts and positioning of p62 within TFIIH were confirmed in the structure of PIC-




Figure 85: TFIIH opens DNA through the combined action of XPB and XPD.  
Proposed mechanisms for the initial opening of DNA by XPB (A) and posterior unwinding and 
extension of the repair bubble by XPD (B). Figure (A) adapted from (Schilbach et al., 2017) and 
(B) from (Constantinescu-Aruxandei et al., 2016). 
 
Although an initial model in which XPB experienced a huge ATP-dependent 
conformational change to anchor TFIIH to the damaged site and open the DNA was first 
proposed (Fan et al., 2006) (Oksenych et al., 2009), recent works regarding TFIIH’s role 
in transcription support a model in which XPB opens the duplex not by unwinding it as 
XPD does, but by translocating along the DNA (Fishburn et al., 2015) (He et al., 2016) 
(Schilbach et al., 2017) from its position downstream the transcription starting site, 
threading DNA into the RNApol (figure 85 (A)) (Schilbach et al., 2017). Hypothetically, 
                                                     STUDYING TFIIH INTERACTIONS WITH DNA 
 
   147 
this would happen without the need for substantial conformational changes, as the 
remaining TFIIH subunits might already provide enough support for XPB to carry out its 
function without a drastic reorganization (Greber et al., 2017). On the contrary, the new 
model regarding how XPD unwinds DNA proposes that HD2 engages ssDNA before the 
transient opening of the interface between the Arch and 4FeS domains, which will allow 
ssDNA to pass through the channel formed by Arch, 4FeS and HD1 to finally engage 
with HD1 (figure 85 (B)) (Constantinescu-Aruxandei et al., 2016).  
 
5.2. Results  
5.2.1. Observing TFIIH binding to damaged DNA  
We tested the binding of three different TFIIH complexes (10-subunit TFIIH complex, 
TFIIH Core sub-complex with suboptimal amounts of XPD (referred to as TFIIH Core) 
and TFIIH Core sub-complex with all seven subunits in stoichiometric amounts (referred 
to as XPD-enriched TFIIH Core) to a series of 44 bp DNA duplex substrates (S1, S2), 
substrates presenting an 18-nucleotide bubble (S3, S4) or a 3-nucleotide bubble (S5, 
S6, S7, S8) (chapter 3, section 3.2.2, figure 42). As we previously did with XPC, TFIIH 
binding was tested by three different methods: band shifting, fluorescence anisotropy 
and bulk FRET assays.  
 
5.2.1.1. Electrophoretic mobility shift assay (EMSA) 
The TFIIH Core sub-complex was tested for binding to substrate S8 in a band shifting 
assay according to the method described in chapter 2, section 2.5.4. S8 is a 44 bp-long 
duplex carrying a 3-nucleotide mismatch, with a fluoro-dT nucleotide placed at the centre 
of the bubble serving as a bulky adduct. Substrates S7 and S8 only differ in the position 
of the Cy3 dye they carry additionally to the fluoro-dT nucleotide (Cy3 located at the left 
(S7) or right (S8) side of the 3-nucleotide bubble). Both substrates had been previously 
tested for binding of damage-detector XPC in an EMSA assay, proving that the position 
of the Cy3 dye did not affect the binding of the protein in this type of assay. For this 
reason, only substrate S8 was tested for binding of the sub-complex (figure 86).   
  
The assay showed an apparent KD of approximately 0.4 µM (table 6). While this 
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experiment confirmed that TFIIH Core can bind a dsDNA substrate without XPC being 
present at the bubble, making it a promising starting point in our research, the lack of 
precision of the assay as shown in our previous results obtained for the binding of XPC 
to substrate S8 led us to approach the study of TFIIH Core binding to DNA in 
fluorescence anisotropy assays rather than further exploring additional band shifting 
assays.  
                          
 
Figure 86: EMSA assay (10% polyacrylamide gel) showing binding of the TFIIH Core to 
substrate S8.  
The TFIIH Core sub-complex binds to substrate S8 (44-mer duplex with a 3-nucleotide bubble 
carrying a fluorescein molecule mimicking a bulky adduct and a Cy3 dye right to the bubble) with 
an apparent KD of approximately 0.4 µM (50% substrate bound). 
 
5.2.1.2. Anisotropy assays 
5.2.1.2.1. 10-subunit TFIIH complex 
We first analysed the binding of the complete 10-subunit TFIIH complex to a 44-mer 
dsDNA substrate carrying a fluoro-dT modification at the centre of its sequence (S1) 
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(figure 87) in a fluorescence anisotropy assay following the method described in chapter 
2, section 2.5.5.1. 
 
                                  
 
 
Figure 87: Fluorescence anisotropy assay showing binding of the 10-subunit TFIIH 
complex to substrate S1.  
KD obtained for the binding isotherm corresponding to substrate S1 (44-mer duplex with a 
fluorescein molecule mimicking a lesion inside the sequence, final concentration 25 nM) was in 
the nM range. 
 
Data obtained in this experiment were fitted to a quadratic equation assuming a 1:1 
binding model, offering a KD of 16 nM, considerably lower than the 0.4 µM value obtained 
in our EMSA assay performed with TFIIH Core and the mismatched duplex S8. 
Unfortunately, the difficulties experienced in reproducing the purification of the 10-
subunit TFIIH complex meant that the sample available for the biochemical 
characterization of the full complex was extremely limited, so we focused on the study 
of the binding of the TFIIH Core sub-complex instead.  
 
5.2.1.2.2. TFIIH Core sub-complex 
Initial fluorescence anisotropy experiments to characterize the binding of the TFIIH Core 
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sub-complex to DNA were performed using substrates S1, S2, S3 and S4 (44-mer 
duplexes carrying a fluoro-dT nucleotide (S1 and S3 – the latter additionally carrying an 
18-nucleotide bubble) or a 5’FAM-C6 modification (S2 and S4 – as S3, S4 additionally 
carries an 18-nucleotide mismatch) (figure 88). All four experiments were performed in 
buffer 20 mM MES pH 6.5, as we had previously done in the XPC and 10-subunit TFIIH 




Figure 88: Fluorescence anisotropy assay showing binding of the TFIIH Core sub-complex 
to substrates S1, S2, S3 and S4 in buffer MES.  
Substrates S1 and S2 are 44-mer duplexes carrying a fluorescein molecule at the centre of the 
sequence (S1, panel A) or at the 5’ end of the substrate (S2, panel B). Substrates S3 (panel C) 
and S4 (panel D) are equivalent to S1 and S2, respectively, but presenting an 18-nucleotide 
mismatch besides the fluorescein molecule (which also mimics a bulky adduct in the case of 
substrates S1 and S3). Final concentration for all substrates was 25 nM. KD’s obtained for all four 
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As we previously saw in our anisotropy assays with protein XPC, initial and final 
anisotropy values change for the different substrates tested due to variations in the 
lifetime of our fluorescein probe as a result of its 5‘ end or internal location in the substrate 
(Nazarenko et al., 2002). The relative change is approximately 0.2 units for all four 
substrates. Data were fitted to a quadratic equation reflecting a 1:1 binding model.  
 
KD values obtained were 40 nM for substrate S1, 28 nM for S2, 29 nM for S3 and 8 nM 
for S4 (table 6). All four values are quite similar, suggesting that the presence of a 
mismatch does not increase TFIIH’s affinity for the DNA. The binding affinities observed 
here are about 10 times lower than the value obtained in the EMSA assay for substrate 
S8 (similar to S3 but with a 3-nucleotide bubble instead of an 18-nucleotide one), 
validating our decision to employ fluorescence anisotropy assays in our research as they 
offer much more accurate information.  
 
We observed that the addition of the Core sub-complex to our substrates caused a 
considerable enhancement of the emitted fluorescence (figure 89) when the reaction was 
performed in MES buffer.  As we purify the TFIIH Core in HEPES buffer, we decided to 
perform the binding reactions in 20 mM HEPES pH 7.0, 50 mM NaCl, as an attempt to 
eliminate this enhancement and minimize the changes in the sub-complex. The 
fluorescein molecule behaved more stably in these conditions, probably due to the effect 
of the salt component in the HEPES buffer on the two negative charges present in the 
dye, so our binding reactions were subsequently carried out in this buffer in our remaining 
experiments.  
 





Figure 89: Influence of the reaction buffer in our anisotropy experiments.  
Addition of TFIIH Core to substrates S1, S2, S3 and S4 caused a considerable enhancement of 
the emitted fluorescence (yellow lines) compared to free substrate (dark blue lines) when the 
reaction is performed in MES buffer. The same reaction performed in HEPES buffer with 50 nM 
NaCl showed a less pronounced influence of protein binding in the fluorescent response of the 
dye. Final concentration for all substrates was 25 nM. 
 
To verify that the change of buffer did not alter the binding affinity of the complex we next 
analyzed the binding of TFIIH Core to substrates S3 and S4 in a reaction carried out in 
buffer 20 mM HEPES pH 7.0, 50 mM NaCl (figure 90). KD values obtained were 13 nM 
for S3 and 42 nM for S4, very close to the values obtained in our previous experiment 
performed in MES buffer (table 6). The binding affinity for substrate S3 was 
MES Buffer HEPES Buffer
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approximately 3 times higher than affinity for substrate S4, hinting a possible preference 
for a damaged substrate over an undamaged one, although the difference between the 




Figure 90: Fluorescence anisotropy assay showing binding of the TFIIH Core sub-complex 
to substrates S3 and S4 in buffer 20 mM HEPES, 50 mM NaCl.  
KD’s obtained for substrates S3 (A) and S4 (B) were still in the nM range and very close to the 
values obtained when the reaction was performed in MES buffer. Final concentration for all 
substrates was 25 nM. 
 
Previous experiments carried out with damage-detector XPC suggested that an 18-
nucleotide bubble was too big to be recognised by the protein as a mismatch, and so 
binding to a similar substrate, carrying a 3-nucleotide bubble (substrates S5 and S6) 
instead of an 18-nucleotide one (substrates S3 and S4), was further studied. With this 
result in mind, TFIIH Core was tested for binding to substrates S5 and S6 to determine 
if the size of the bubble also had an effect on the binding of the sub-complex (figure 91).  
 





Figure 91: Fluorescence anisotropy assay showing binding of the TFIIH Core sub-complex 
to substrates S5 and S6.  
Substrates S5 and S6 are very similar to S3 and S4, carrying a 3-nucleotide bubble instead of an 
18-nucleotide one. A fluorescein molecule is positioned at the centre of the bubble, mimicking a 
bulky lesion (S5, A), or at the 5’ end (S6, B). Final concentration for all substrates was 25 nM. KD 
obtained were in the nM range and similar to the values obtained for binding of the sub-complex 
to the substrates carrying an 18-nucleotide bubble. 
 
KD obtained for binding to substrate S5 was 15 nM, while KD for binding to substrate S6 
was 29 nM. These values are similar to the ones obtained for the substrates carrying the 
18-nucleotide bubble, and the KD obtained for substrate S5 (equivalent to S3) is 
approximately two times lower than the KD obtained for S6 (equivalent to S4). Although 
this supports our previous observation that the presence of damage at the mismatch 
might increase the binding affinity of the Core sub-complex, the difference between the 
two KD values is again too small to draw a final conclusion. A further investigation will be 
required to confirm this point.  
 
Once we solved the ongoing issues reducing the amount of helicase XPD available in 
our samples we tested our new XPD-enriched TFIIH Core sample for binding to 
substrates S5 and S6 to see if the presence of the helicase in similar amounts as the 
other six Core subunits had an effect on the binding of the sub-complex (figure 92).  
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Figure 92: Fluorescence anisotropy assay showing binding of the XPD-enriched TFIIH 
Core sub-complex to substrates S5 and S6.  
Substrates S5 and S6 are 44-mer duplexes with a 3-nucleotide mismatch carrying a fluorescein 
molecule at the bubble, mimicking a lesion (S5, A), or at the 5’ end of the substrate (S6, B). Final 
concentration for the two substrates was 25 nM. The higher presence of XPD in this sample (now 
stoichiometrically similar to the other six TFIIH Core subunits) didn’t increase the binding affinity 
of the sub-complex. 
 
KD values obtained for substrates S5 and S6 were 8 nM and 15 nM, respectively, which 
is approximately two-fold lower than the values of 15 nM and 29 nM previously obtained 
with our sample containing suboptimal amounts of XPD (table 6). Although the binding 
affinity of the sub-complex had been slightly increased by the presence of XPD, this 
enhancement is not enough to determine if XPD contributes to binding of the TFIIH sub-
complex to DNA.  
 
5.2.1.3. Bulk FRET assays 
The preliminary results obtained in our fluorescence anisotropy experiments suggested 
that the TFIIH Core sub-complex can tightly bind a duplex substrate, and a substrate 
presenting either an 18-nucleotide or a 3-nucleotide mismatch, and the binding affinity is 
approximately two times higher when a bulky adduct is present at the site of the 
mismatch. 
 
We further tested the binding capacity of the TFIIH sub-complex in a bulk FRET assay 
using substrates S7 and S8 (44 bp long duplexes carrying a 3-nucleotide mismatch and 
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a fluoro-dT nucleotide at the centre of the bubble, plus a Cy3 dye at the left (S7) or the 
right (S8) side of the mismatch) (figure 93), following the method described in chapter 2, 




Figure 93: Bulk FRET assay showing binding of TFIIH Core to substrates S7 and S8. 
Substrates S7 and S8 are 44-mer duplexes with a 3-nucleotide bubble carrying a fluorescein 
molecule mimicking a bulky adduct and a Cy3 dye left (S7, A) or right (S8, B) to the bubble. KD 
obtained for the two of them were in the nM range. Initial intensity for both the fluorescein and the 
Cy3 dyes are indicated by a black line, while final intensity after addition of the TFIIH sub-complex 
is indicated by a red line. 
 
KD values obtained were 16 nM for substrate S7 and 32 nM for substrate S8. These 
values are similar to those obtained for substrates S3, S4, S5 and S6 in our anisotropy 
assays (table 6), further supporting our previous observation that TFIIH Core is able to 
bind a DNA duplex carrying a mismatch without the presence of damage-detector XPC.  
The emitted fluorescence of both the fluorescein and Cy3 dyes was collected after every 
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approximate quenching of 80% for both dyes when directly excited, although no change 
of the ratio A was observed (data not shown). 
 
5.2.2. Characterization of TFIIH’s unwinding activity  
The helicase activity of the XPD-enriched Core sub-complex was tested in a 
fluorescence-based unwinding assay with several different substrates, as discussed in 
chapter 2, section 2.5.5.3: an undamaged splayed duplex (SD), a damaged splayed 
duplex with a fluorescein molecule mimicking a bulky adduct located in either the non-
translocating strand (SD13) or the translocating strand (SD24), an asymmetric duplex 
with a 5’ overhang and a translocating strand mainly composed of purine bases  (XPD12) 
or pyrimidine bases (XPD34) and an asymmetric duplex with a 3’ overhang and a 
translocating strand mainly composed of purine bases (REV12) or pyrimidine bases 




Figure 94: DNA substrates employed to characterize TFIIH’s unwinding activity.  
Schematic representation of the different DNA substrates used in the helicase assays performed 
to study the unwinding activity of the TFIIH Core sub-complex. All substrates carry a Cy3 dye 
(pink spheres) suppressed by a quencher (black spheres). 
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All these substrates include a Cy3 dye, whose fluorescence is supressed by a quencher 
in the duplex. Upon binding of the TFIIH Core sub-complex, the XPD helicase will unwind 
the substrate in an ATP-dependent reaction, effectively removing the quencher and 
allowing the detection of the fluorescence emitted by the Cy3 dye (figure 95). 
 
 
Figure 95: Mechanism of action of our fluorescence-based helicase assay.  
The ATP-dependent unwinding activity of XPD will open the splayed duplex substrate, thus 
removing a quencher that was suppressing the emission of the Cy3 dye, observing now an 
increment of its emitted fluorescence in time. 
 
5.2.2.1. Determining the polarity of the TFIIH Core unwinding 
The TFIIH Core sub-complex possesses two helicases of opposite polarities: XPB (3’ to 
5’) and XPD (5’ to 3’). However, XPB has recently been defined as a translocase rather 
than a helicase in the canonical sense (Fishburn et al., 2015) (He et al., 2016) (Schilbach 
et al., 2017). To verify the lack of helicase activity of XPB and the polarity of the 
unwinding by XPD we performed an initial fluorescence helicase experiment with an 
undamaged splayed duplex (SD) and an asymmetrical duplex with a 3’ overhang end 
(REV34) (figure 96). 
 
The assay showed that unwinding only happened when a 5’ overhang end was available, 
as only the SD substrate was opened by the sub-complex while the REV34 substrate 
was not unwound at all, thus confirming the 5’ to 3’ polarity of the unwinding activity 
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Figure 96: TFIIH Core unwinds a substrate with a 5’ overhang.  
The helicase activity of the TFIIH Core sub-complex was tested in a fluorescence helicase assay 
with two different substrates: a splayed duplex (SD) and an asymmetric duplex with a 3’ overhang 
(REV34), both at a final concentration of 50 nM. A control reaction without ATP showed no 
unwinding (blue line). TFIIH Core was able to efficiently unwind the SD substrate (pink line), but 
not the REV34 substrate (yellow line).  
 
To further study this result we tested the unwinding capacity of the TFIIH Core sub-
complex with four asymmetric duplexes, two with a 5’ overhang (XPD12 and XPD34) 
and another two with a 3’ overhang (REV12 and REV34), with each pair differing in the 




















Figure 97: TFIIH Core opens a splayed duplex substrate preferentially.  
Fluorescence helicase assay showing unwinding of substrates SD (yellow), XPD12 (pink), XPD34 
(purple), REV12 (blue) and REV34 (orange), all at a final concentration of 25 nM.  The REV 
substrates were not opened, as expected, due to their 3’ to 5’ polarity. The asymmetric duplexes 
XPD12 and XPD34 can be unwound by XPD, but the sub-complex shows a marked preference 
for a splayed duplex conformation. 
 
The REV12 and REV34 substrates could not be unwound, reaffirming the lack of 
apparent 3’ to 5’ helicase activity of TFIIH Core. Although the sub-complex showed a 
marked preference for the SD substrate, both the XPD12 and XPD34 substrates were 
unwound too, and a possible preference for the XPD12 substrate (with a majority of 
purine bases making up the translocating strand) over the XPD34 substrate (with a 
majority of pyrimidine bases making up the translocating strand) was hinted at. This was 
further confirmed by our experiments in a separate assay using substrates XPD12 and 
XPD34 alone, with XPD12 showing approximately 50% more unwound product than 
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Figure 98: XPD discriminates substrate composition.  
Fluorescence helicase assay showing the unwinding of two asymmetric duplexes with a 5’ 
overhang end, one with a majority of purine bases (XPD12) and the other with a majority of 
pyrimidine bases (XPD34) composing the translocating strand. Unwinding of the XPD12 substrate 
(blue line) is approximately 2-times higher than unwinding of the XPD34 substrate (yellow line), 
suggesting that XPD can differentiate and open preferentially a substrate based on its nucleotide 
composition. Final concentration for both substrates was 25 nM. 
 
5.2.2.2. Stablishing the optimal conditions for the assay 
Next, we investigated the effect of TFIIH Core concentration on the unwinding of 
substrate SD (figure 99). Increasing concentrations of the sub-complex (25, 50, 100 and 
200 nM) were added to our unwinding assay, showing a progressive increment of about 
50% of the unwound product as concentration of the sub-complex increases, which 
confirms that unwinding is dependent on TFIIH Core concentration. As this assay 
requires a considerable amount of sub-complex to be performed and there is only a 30% 
difference in the amplitude of the unwinding between 50 nM, 100 nM and 200 nM TFIIH 











Figure 99: Unwinding of the SD substrate increases with TFIIH Core concentration. 
Fluorescence helicase assay showing unwinding of substrate SD (25 nM) by increasing 
concentrations of the TFIIH Core sub-complex: 25 nM (purple), 50 nM (pink), 100 nM (orange), 
and 200 nM (yellow). The blue line represents a control reaction in which no ATP was added. The 
graph shows that unwinding is dependent on TFIIH Core concentration, as duplex opening at a 
sub-complex concentration of 200 nM is about 50% higher than unwinding at 25 nM. 
 
We then further tested the optimal conditions for our assay by trying different ATP 
concentrations (figure 100 (A)) and different temperatures (figure 100 (B)). To determine 
the best ATP concentration the reaction was performed at 25 °C, showing approximately 
30% more unwound substrate when the reaction was performed with 1 mM ATP 
compared to a reaction performed with 0.5 mM ATP. We took 1 mM as the standard ATP 
concentration for our assays, and verified the best temperature for our experiment by 
comparing unwinding at 25 °C and 37 °C. As the assay showed that there was only a 
difference of about 15% between the amount of unwound product obtained at 25 °C and 
that obtained at 37 °C, we continued to perform our assays at 25 °C, establishing this 
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Figure 100: Establishing the ideal ATP concentration and temperature for our assay. 
Fluorescence helicase assay showing unwinding of substrate SD (25 nM) by the TFIIH Core sub-
complex at different ATP concentrations (A). 1 mM ATP (yellow line) was confirmed as the optimal 
ATP concentration for the assay after comparing this result with the one obtained in a reaction 
containing 0.5 mM ATP (dark blue line). Different temperatures were also analyzed (B) by running 




5.2.2.3. Effect of RPA and XPA on TFIIH Core unwinding 
The XPA and RPA proteins are the next factors to join the repair bubble after TFIIH is 
recruited by XPC. Our previous experiments had confirmed that TFIIH can bind to and 
unwind a dsDNA substrate in vitro without the presence of XPC, so we subsequently 
studied the effect of the addition of RPA, XPA or both on TFIIH Core unwinding of a 
splayed duplex substrate in an assay performed as described in chapter 2, section 
2.5.5.3. 
 
RPA is a heterotrimeric complex essential in multiple cellular processes. As part of the 
NER machinery, RPA binds to the undamaged, single-stranded portion of the repair 
bubble and protects it from degradation (Krasikova et al., 2010) until the damaged 
fragment is removed and the gap left is filled by a polymerase  (Riedl et al., 2003). RPA 
is recruited together with XPA (Krasikova et al., 2010), a modular protein with no 
enzymatic activity that acts as a fundamental scaffold for interaction with multiple repair 
factors and other proteins (Sugitani et al., 2016). In NER, XPA is responsible for the 
STUDYING TFIIH INTERACTIONS WITH DNA 
 
 164 
removal of the CAK sub-complex from TFIIH (Svejstrup et al., 1995) (Coin et al., 2008) 
and the recruitment of endonucleases XPG and XPF/ERCC1 (Krasikova et al., 2010). 
The RPA and XPA proteins, expressed in E. coli, were produced and purified in our lab 
by Mrs. Biljana Petrovic-Stojanovska. 
 
Addition of RPA to a reaction already containing the TFIIH Core sub-complex increased 
the amplitude of the unwinding by approximately 47%. By contrast, addition of XPA 
alone, or XPA and RPA together to the TFIIH Core-containing reaction did not alter 





Figure 101: Effect of XPA and RPA on TFIIH Core unwinding of substrate SD.  
Fluorescence-based helicase assays showing how the addition of proteins RPA (dark blue line), 
XPA (purple line) or both (pink line) affect the unwinding of substrate SD (25 nM) by the TFIIH 
Core sub-complex. The yellow line represents a control in which only the TFIIH Core sub-complex 
was added to the reaction. Unwinding amplitude was considerably increased by the addition of 
RPA. Addition of XPA alone or XPA and RPA together didn’t alter unwinding by TFIIH Core. 
 
5.2.2.4. Unwinding of damaged DNA substrates 
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substrates carrying a fluoro-dT nucleotide mimicking a bulky adduct in the double-
stranded portion of the substrate, with substrate SD13 carrying the lesion in the non-
translocating strand, while the damage is located in the translocating strand in substrate 
SD24 (figure 102). The assay showed that the amplitude of unwinding of the damaged 
substrates was considerably lower than unwinding of the undamaged SD substrate (58% 





Figure 102: TFIIH Core is stalled by damage in the translocating and the non-translocating 
strands.  
Fluorescence-based helicase assay showing unwinding of an undamaged SD substrate (dark 
blue line) and two splayed duplexes with a fluorescein molecule mimicking a bulky adduct located 
in the translocating strand (SD24, yellow line) and the non-translocating strand (SD13, pink line). 
The presence of a bulky adduct reduces unwinding by 58% approximately when the damage is 
located in the non-translocating strand, and by 73% when located in the translocating strand. 
Final concentration for all three substrates was 25 nM. 
 
Analysis of the kinetics for the unwinding of these substrates showed that all of them 
fitted a bi-exponential model with a burst phase followed by a slow phase, which is in all 
cases the major component of the reaction (figure 103). Other models including a linear 
phase representing non-specific binding were also tested, but they did not significantly 
improve the results compared to the bi-exponential model. The fast component is quite 
similar in the unwinding of the two damaged substrates (12% for SD13 and 9% for 
SD24); interestingly, this component is higher for the SD substrate (30%). 
 





Figure 103: Kinetics of the TFIIH Core unwinding of substrates SD, SD13 and SD24.  
TFIIH Core unwinding of undamaged substrate SD and damaged substrates SD13 and SD24 
was fitted to a bi-exponential model, with a minor fast component (dotted lines) and a major slow 
component (dashed lines) in all three cases. The fast component is higher in the unwinding of 
substrate SD, compared to substrates SD13 and SD24, which showed lower and similar values.  
 
 
5.3. Discussion  
5.3.1. TFIIH binds dsDNA without the presence of XPC 
During NER the TFIIH complex is recruited to the damaged site to open and extend the 
mismatch detected by XPC, in order to allow the subsequent repair factors to access the 
lesion and repair it. A study by the Yang group reported that the TFIIH Core sub-complex 
binds a 45-nucleotide ssDNA substrate with a much higher affinity (2.5 nM) than a 45-
base pair dsDNA substrate (binding barely detectable in an EMSA assay), and this 
affinity was not altered by the presence of a lesion in the DNA (Li et al., 2015). Our group 
studied the binding of the Core sub-complex to a range of 44-mer dsDNA substrates in 
three different assays: EMSA experiments, fluorescence anisotropy assays and bulk 
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Table 6: Dissociation constants for binding of different TFIIH constructs to a range of 
substrates in EMSA, fluorescence anisotropy or bulk FRET assays.  
The limitations of the EMSA experiment meant that KD could only be determined as an apparent 
(approximated) KD. Data from anisotropy and bulk FRET experiments were fitted to a binding 
model that assumes 1:1 DNA:protein (see chapter 2, sections 2.5.5.1 and 2.5.5.2).   
 
 
The EMSA assays we performed with damage-detector XPC didn’t offer accurate KD 
values for the binding, but they revealed an interesting result: the possible binding of two 
molecules of the protein to the substrate. We followed the same approach in our study 
of the binding of the TFIIH Core sub-complex: first we performed an EMSA assay that 
would offer an overview on the binding, before moving on to more precise techniques, 
such as fluorescence anisotropy and bulk FRET. Also based on the results obtained in 
our XPC experiments, we decided to test the binding of the sub-complex to substrate S8 
only, a 44-mer dsDNA substrate with a 3-nucleotide bubble with a bulky lesion at the 
centre of the mismatch. The assay showed that TFIIH Core binds the S8 substrate with 
an apparent KD of approximately 0.4 µM (table 6) (figure 86). The gel didn’t offer any 
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other insights regarding the binding mode of the sub-complex, so next we tried to confirm 
the KD value obtained here in a fluorescence anisotropy assay. 
 
The 10-subunit TFIIH complex was first construct tested in an anisotropy assay. The full 
complex includes both the TFIIH Core sub-complex (subunits XPD, XPB, p62, p52, p44, 
p34 and p8), thoroughly described in previous sections,  and the CAK sub-complex 
(subunits MAT1, cyclin H and cdk7), which inhibits the helicase activity of XPD (Sandrock 
& Egly, 2001) (Abdulrahman et al., 2013) and is removed from the Core sub-complex 
after binding to the damaged site in order to complete the repair reaction (Svejstrup et 
al., 1995) (Coin et al., 2008). The assay showed that the TFIIH complex could bind 
substrate S1 (a 44-mer dsDNA substrate carrying a bulky adduct at the centre of its 
sequence) with a KD of 16 nM (table 6) (figure 87). Although the differences between this 
assay and the EMSA assay previously performed are too many to allow a real 
comparison of the two results (different composition of the constructs, substrate S1 
carries a lesion but not a mismatch as opposed to substrate S8, higher accuracy of the 
anisotropy assay compared to EMSA), the great disparity between the two KD values 
encouraged us to continue this binding study by means of fluorescence anisotropy 
assays. This value is also three times higher than the KD obtained for the binding of XPC 
to the same substrate, consistent with XPC’s role as the mismatch detector (Sugasawa 
et al., 2001).  
 
The difficulties in obtaining more 10-subunit TFIIH sample led us to focus on the study 
of the binding to dsDNA of the TFIIH Core sub-complex next. Binding to substrates S1, 
S2, S3 and S4 (44-bp duplexes carrying a fluorescein molecule at the mismatch, 
mimicking a bulky adduct (S1, S3), or at its 5’ end (S2, S4); S3 and S4 also present an 
18-nucleotide mismatch) in a reaction carried out in 20 mM MES pH 6.5 buffer offered 
KDs of 40 nM, 28 nM, 29 nM and 8 nM, respectively (table 6) (figure 88). The similarity 
shown by these four values supports a previous report that stated that TFIIH showed no 
preference for damaged substrates over undamaged ones (Nocentini et al., 1997).  
 
Substituting our 20 mM MES pH 6.5 reaction buffer for 20 mM HEPES pH 7.0, 50 mM 
NaCl minimized protein-induced effects on the fluorescent emission of the dye present 
in our substrates (figure 89), and a repetition of the assay using this new reaction buffer 
                                                     STUDYING TFIIH INTERACTIONS WITH DNA 
 
   169 
and substrates S3 and S4 (as a mismatched dsDNA is the natural substrate for the TFIIH 
complex) offered KD values of 13 nM for S3 and 42 nM for S4 (table 6) (figure 90). 
According to this result, the Core sub-complex shows 3-fold higher affinity for a substrate 
with a lesion accompanying the mismatch than for an undamaged substrate.  
 
TFIIH Core binding experiments to substrates S5 and S6 (44-bp duplexes carrying a 3-
nucleotide bubble with a fluorescein molecule at the mismatch, mimicking a lesion (S5), 
or at its 5’ end (S6)) offered a KD value of 15 nM for S5 and 29 nM for S6 (table 6) (figure 
91). The affinity of the sub-complex for the damaged substrate S5 is only 2-fold higher 
than its affinity for the undamaged substrate S6, similar to our observations for substrates 
S3 and S4. This reinforces our previous result and allows us to conclude that the binding 
affinities for both damaged and undamaged substrates are too similar to permit us to 
unambiguously affirm that TFIIH Core binds preferentially to a damaged substrate (S3, 
S5) over an undamaged one (S4, S6). Interestingly, the similarity between the KD values 
obtained for substrates S3-S4 (carrying an 18-nucleotide bubble) and substrates S5-S6 
(carrying a 3-nucleotide bubble) suggests that the size of the mismatch does not play a 
role in the binding of the sub-complex to the substrate. 
 
A final XPD-enriched, TFIIH Core sub-complex was tested for binding to substrates S5 
and S6, showing a KD of 8 nM and 15 nM, respectively (table 6) (figure 92). This sub-
complex shows an affinity for the mismatched substrates 2-times higher than that of the 
TFIIH Core previously employed in our assays, in which only a residual amount of XPD 
remained attached to the sub-complex after purification. This result further supports our 
conclusion that the preference of the Core sub-complex for damaged substrates cannot 
be asserted. Furthermore, such a small difference in the binding affinity of the two sub-
complexes might imply that XPD does not actively participate in the binding of TFIIH 
Core to the DNA. Further experiments would be required to confirm this last point.  
 
In contrast to the results published by Li and co-workers (Li et al., 2015), our anisotropy 
fluorescence assays show that TFIIH Core can bind dsDNA with an affinity in the nM 
range. The KDs shown in this work are approximately six times lower than the one 
observed by the Yang group for the binding of the sub-complex to ssDNA when our 
dsDNA substrate presents a mismatch, and only three times lower when our dsDNA 
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substrate presents a mismatch and a lesion at the mismatched site, when comparing 
their results with the ones obtained with our XPD-enriched TFIIH Core construct. 
 
We finally studied the binding of the Core sub-complex to substrates S7 and S8 in bulk 
FRET assays. Substrates S7 and S8 are 44-mer duplexes carrying a 3-nucleotide bubble 
with a lesion at its centre and a Cy3 dye at the left (S7) or the right (S8) side of the 
mismatch. Binding of the Core sub-complex offered a KD of 16 nM for substrate S7 and 
32 nM for S8 (table 6) (figure 93), very similar to the values obtained for substrates S1, 
S2, S3, S4, S5 and S6, thus further validating the results obtained in our fluorescence 
anisotropy experiments. Although there is a possibility that the difference in the KDs 
obtained for substrates S7 and S8 is due to the location of the Cy3 dye affecting the 
binding affinity of the Core sub-complex for substrate S8, the 2-fold difference is more 
likely negligible. A further analysis of the changes on the emitted fluorescence of both 
the fluorescein and Cy3 dyes present in the S7 and S8 substrates showed no changes 
in the ratio A, suggesting that the binding of the sub-complex does not significantly alter 
the conformation of the bubble in our substrates. Further experiments are needed to 
confirm this point.  
 
5.3.2. A fluorescence-based helicase assay shows TFIIH 
unwinding of dsDNA  
The fact that the TFIIH complex requires two helicases (enzymes known for their high 
processivity) to open a very small fragment of DNA has been a matter of intense 
discussion for a long time. The recent redefinition of the 3’ to 5’ helicase XPB as a 
translocase (Fishburn et al., 2015) (He et al., 2016) (Schilbach et al., 2017) has shed 
some light into the possible mechanism of action of the complex, defining different but 
complementary functions for both XPB and XPD, whose 5’ to 3’ helicase activity makes 
it the factor responsible for the actual unwinding of the damaged bubble to allow the 
subsequent repair factors access to the lesion.  
 
We verified the lack of 3’ to 5’ helicase activity in an ATP-dependent fluorescence-based 
unwinding assay using two different substrates: one with a 5’ overhang end (SD) and a 
second one with a 3’ overhang end (REV34) available.  As expected, the TFIIH Core 
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sub-complex was only able to open the SD substrate (figure 96). This result was further 
confirmed in a subsequent assay employing a different set of substrates: two asymmetric 
duplexes with a 5’ overhang (XPD12 and XPD34) and another two with a 3’ overhang 
(REV12 and REV34). XPD12 and REV12 present a majority of purine bases in their 
translocating strands, while XPD34 and REV34 have a majority of pyrimidine bases 
composing their translocating strands. The assay confirmed that TFIIH Core cannot open 
a substrate that doesn’t present a 5’ overhang end, and interestingly it also showed that 
the sub-complex opened the XPD12 substrate preferentially over XPD34 (figure 97). 
This preference had previously been observed by the Penedo group in experiments 
performed with the archaeal homologue of XPD from Thermoplasma acidophilum 
(unpublished data), and it was further verified by our lab in a second experiment that 
showed approximately 50% more unwound product for the XPD12 substrate compared 
to XPD34 (figure 98).  
 
Although our experiments showed that TFIIH Core could open a double-stranded 
substrate with a 5’ overhang efficiently, the amplitude of unwinding of the SD substrate 
by the sub-complex was 30% higher when compared to unwinding of the XPD12 
asymmetric duplex (figure 96). We next analysed the effect of TFIIH Core’s concentration 
on the opening of the SD substrate. The assay showed that unwinding was dependent 
on the concentration of the sub-complex, with 50% more unwound product at the 
maximum concentration tested (200 nM) compared to the minimum concentration tested 
(25 nM) (figure 99). This dependency on concentration has also been reported for the 
XPD homologue from T. acidophilum (Constantinescu-Aruxandei et al., 2016). Different 
ATP concentrations and temperatures were subsequently tested, showing about 30% 
more unwound product when the reaction was performed with 1 mM ATP, compared to 
a reaction performed with 0.5 mM ATP (figure 100 (A)). On the other hand, the assay 
showed only a 15% more unwound substrate when the reaction was run at 25 °C 
compared to the same reaction carried out at 37 °C (figure 100 (B)), hinting that within 
this range temperature doesn’t have a significant effect on TFIIH Core unwinding. Taking 
in consideration all these results, we decided to establish a concentration of 50 nM TFIIH 
Core and 1 mM ATP, in a reaction performed at 25 °C, as standard conditions to perform 
any future TFIIH Core unwinding fluorescence assays. 
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The arrival of TFIIH to the damaged DNA-XPC complex acts as a signal for the 
recruitment of repair factors RPA and XPA (Krasikova et al., 2010), which will cause a 
reorganization of the repair bubble (Tapias et al., 2004). RPA will protect the ssDNA 
portion of the bubble by binding to it (Krasikova et al., 2010), while XPA triggers the 
removal of the CAK sub-complex from TFIIH (Svejstrup et al., 1995) (Coin et al., 2008), 
thus allowing XPD to carry out its unwinding activity (Sandrock & Egly, 2001) 
(Abdulrahman et al., 2013), as well as promoting the recruitment of endonucleases XPG 
and XPF/ERCC1 to the repair bubble (Krasikova et al., 2010). 
 
As RPA and XPA are the next proteins to be recruited to ensure the progress of the NER 
reaction, we aimed to study the effect that the addition of these factors might have on 
TFIIH Core unwinding of the SD substrate. The addition of RPA on its own to an 
unwinding reaction already containing TFIIH Core caused an increment of approximately 
47% of the obtained unwound product, while addition of XPA or a combination of XPA 
and RPA to a similar reaction did not affect unwinding by TFIIH Core (figure 101). The 
increase caused by addition of RPA can probably be attributed to RPA’s ability to melt 
dsDNA in the presence of magnesium, as previously reported by the Seidel group 
(Kemmerich et al., 2016). This effect is not observable when the protein is added 
together with XPA, consistent with a previously reported coordinated action of both 
proteins (Krasikova et al., 2010). The next step in our research will be to investigate the 
progression of the repair bubble when endonuclease XPF/ERCC1 is added to the 
reaction. 
 
Having confirmed that TFIIH Core can efficiently unwind an undamaged splayed duplex 
substrate, we next investigated the effect a lesion placed in the non-translocating strand 
(substrate SD13) or in the translocating strand (substrate SD24) would have on 
unwinding by the sub-complex. Compared to the unwinding of the SD substrate, 
amplitude of the unwinding of SD13 was 58% lower, and unwinding of SD24 was 73% 
lower (figure 102). Interestingly, unwinding for both the SD13 and SD24 substrates was 
quite similar, with only a 15% difference between the two of them, suggesting that XPD 
can be stalled not only by a lesion present in the translocating strand, but also by damage 
located in the non-translocating strand, further supporting the observations of Mathieu 
and co-workers (Mathieu et al., 2010) and the Tessmer group  (Buechner et al., 2014) .  
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Unwinding of the three substrates fit to a bi-exponential model with a short burst phase 
(30% of the unwinding reaction for the SD substrate, 12% for SD13 and 9% for SD24) 
and a long slow phase (70% for SD, 88% for SD13 and 91% for SD24) (figure 103). This 
extended slow phase was also observed by Constantinescu-Aruxandei and co-workers 
in their study of the T. acidophilum XPD homologue (Constantinescu-Aruxandei et al., 
2016), proposing an unwinding mechanism through multiple repeated steps to explain 
the behaviour of the archaeal XPD. In the case of the TFIIH Core sub-complex, there is 
a possibility that this slow phase might be caused by the binding of a second TFIIH Core 
to the substrate, as there is an excess of sub-complex compared to the substrate 
concentration; this situation is consistent with previous observations made by the Yang 
group in their study of TFIIH Core (Li et al., 2015) and by the Spies group in their study 
of XPD’s archaeal homologue from Ferroplasma acidarmanus (Honda et al., 2009). 
Another possibility to consider given the difficulties experienced in obtaining active, Core-
bound XPD is that our sample might contain a mixed population of Core sub-complexes 
carrying XPD helicases with different levels of activity. The fact that substrates SD13 and 
SD24 present similar fast and slow components (similar kinetics) in their unwinding 
further supports our observation that a lesion in the non-translocating can stall XPD 
almost as effectively as damage in the translocating strand. 
 
5.4. Conclusions 
We have analyzed the binding affinity of the 10-subunit TFIIH complex, plus TFIIH Core 
with suboptimal amounts of XPD bound to it and an XPD-enriched TFIIH Core construct 
to a variety of DNA duplexes, both unmodified and carrying an 18-nucleotide or a 3-
nucleotide mismatch, by three different methods: EMSA, fluorescence anisotropy, and 
bulk FRET. We have also analyzed the unwinding activity of the XPD-enriched Core sub-
complex in a helicase fluorescence-based assay with a variety of asymmetric duplexes 
presenting a 5’ or a 3’ overhang, and a splayed duplex substrate either undamaged or 
presenting a bulky adduct in the translocating or the non-translocating strand. 
 
Although our EMSA assay seemed to initially support the Yang group’s observation that 
TFIIH Core binds dsDNA with low affinity (Li et al., 2015), further fluorescence anisotropy 
experiments showed similar binding affinities (in the low nM range) of the TFIIH Core 
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sub-complex to substrates that included unmodified duplexes, damaged and 
undamaged duplexes carrying an 18-nucleotide mismatch and damaged and 
undamaged duplexes carrying a 3-nucleotide mismatch. Although we consistently 
observed a 2 to 3-fold difference in the binding affinity of the Core sub-complex to 
mismatched substrates carrying a bulky adduct at the site of the bubble compared to 
similar mismatched substrates carrying the lesion at their 5’ end, this difference is not 
significant, and so we conclude that TFIIH Core does not show a binding preference for 
damaged DNA over undamaged DNA. Interestingly, the similarity of the results obtained 
for the binding to substrates carrying an 18-nucleotide mismatch and the ones carrying 
a 3-nucleotide mismatch suggest that the size of the bubble does not affect the binding 
of the Core sub-complex. Similarly, the analogous KD values obtained for the TFIIH Core 
and XPD-enriched TFIIH Core constructs might imply a passive role of XPD in the 
binding of the sub-complex to DNA. Further experiments are required to confirm this last 
point.  
 
The results observed in our fluorescence anisotropy assays were further confirmed in 
bulk FRET assays that analyzed the binding of the Core sub-complex to a damaged 
substrate carrying a 3-nucleotide mismatch. These assays showed that, although TFIIH 
Core can effectively bind a dsDNA substrate with high affinity, it doesn’t seem to modify 
the conformation of the substrate, although a more thorough investigation is required to 
validate this point.   
 
Our study of the unwinding activity of TFIIH Core showed that the sub-complex was only 
able to open an asymmetric duplex substrate when a 5’ overhang end was available, 
confirming the lack of helicase activity of subunit XPB. Furthermore, the sub-complex 
showed an evident preference for an asymmetric duplex with a 5’ overhang and a 
majority of purine bases in their translocating strands, compared to unwinding of a similar 
substrate whose translocating strand was primarily composed of pyrimidine bases. 
Analysis of the unwinding of an undamaged splayed duplex showed that the opening of 
the substrate was dependent on the concentration of the sub-complex and concentration 
of ATP in the reaction, but it was not significantly affected by changes in a temperature 
range of 25 °C to 37 °C. Similarly, the addition of the RPA and XPA proteins (the repair 
factors that follow the recruitment of TFIIH in NER) to the reaction did not affect the 
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unwinding of the splayed duplex by the Core sub-complex. Unsurprisingly, the helicase 
activity of the sub-complex was considerably reduced by a bulky adduct placed in the 
translocating strand of the splayed duplex, and, more interestingly, it was reduced almost 
as effectively by a lesion located in the non-translocating strand.  
 
Future work includes: 
 
• Anisotropy and unwinding experiments with a substrate carrying a cisplatin 
lesion. 
• Study of the effects of our site-directed variants XPD K46R (Coin et al., 1998), 
XPB K346R (Tirode et al., 1999), XPD Y192A and XPD K196R (Mathieu et al., 
2013) on the binding of the sub-complex to DNA and its unwinding activity. 
• Study of a complete repair bubble (XPC, TFIIH, RPA, XPA, XPF) by means of 
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6. Conclusions and further work 
6.1. Summary 
Protein XPC initiates the DNA repair reaction by detecting a mismatch in the double helix 
(Sugasawa et al., 1998), aided by partners HR23 (paralogs A or B) and CETN2 
(Sugasawa et al., 1996) (Nishi et al., 2005). This recognition of a distortion in the DNA  
rather than identification of actual damage (Maillard et al., 2007) is the basis for the 
extended range of lesions repaired by NER, and the reason why a damage-verification 
step is needed (Min & Pavletich, 2007) (Shell et al., 2013). The formation of a stable 
DNA-XPC complex will trigger the arrival of the TFIIH complex, recruited by XPC through 
interaction with its subunits XPB and p62 (Yokoi et al., 2000) (Uchida et al., 2002) 
(Bernardes de Jesus et al., 2008). The 10-subunit TFIIH complex will now open and 
extend the repair bubble through the coordinated actions of helicases XPB and XPD 
(Schilbach et al., 2017) (Constantinescu-Aruxandei et al., 2016), to allow the subsequent 
repair factors access to the damaged site. XPD has further been proposed as the factor 
responsible for the verification of the NER-triggering lesion (Kuper et al., 2012) 
(Sugasawa et al., 2009) (Li et al., 2015) so that the repair reaction can progress 
successfully.  
 
Our interest in the NER process led us to clone, express and purify both the damage-
detector protein XPC (in its monomeric and heterodimeric forms, as protein CETN2 is 
reportedly not required in in vitro experiments (Okuda et al., 2015)) and the TFIIH 
complex (sub-complexes CAK and TFIIH Core obtained individually first, and 10-subunit 
TFIIH complex later obtained by co-infection with a CAK- and TFIIH Core-recombinant 
virus) as a first step in our investigation to characterize the binding and opening of the 
repair bubble at a damaged site. All constructs were cloned using the MultiBacTM tool 
and obtained using Sf9 cells as an expression system. 
 
Monomeric XPC (reportedly sufficient to bind to the DNA and start a repair reaction 
(Sugasawa et al., 1996) (Reardon et al., 1996)) was initially purified  following a three-
step protocol consisting of IMAC, size exclusion and  cation exchange chromatography, 
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but the sample consistently presented two unspecific bands of about 110 kDa and 50 
kDa even after adding a fourth heparin chromatographic step to our purification process. 
As MS analysis identified the 110 kDa band as a degraded form of XPC and the 50 kDa 
band as the Spodoptera frugiperda homologue of HR23B, hinting at the importance of 
their partnership, we decided to clone and express the heterodimeric XPC-HR23B 
complex for future experiments. Fluorescence anisotropy experiments performed with 
this construct showed a high affinity for a dsDNA substrate with a simulated lesion inside 
its sequence (S1), but unexpectedly two duplex substrates presenting an 18-nucleotide 
bubble (S3 and S4, with S3 also carrying the damage-like fluorescein molecule at the 
site of the mismatch) presented a KD similar to the one obtained for an undamaged 
duplex substrate (S2) rather than a value closer to the KD obtained in the binding of 
monomeric XPC to substrate S1.  
 
Expression levels for the heterodimer XPC-HR23B were dramatically reduced after 
scaling-up our infections, and even after optimising our purification protocol (which was 
finally reduced to a two-step process, comprising only an IMAC and size exclusion 
chromatography) the amount of sample obtained for its biochemical characterization was 
seriously limited. This sample was tested for binding in both EMSA and bulk FRET 
assays. After our anisotropy assays with monomeric XPC showed that the protein bound 
to a substrate carrying an 18-nucleotide mismatch with an affinity similar to that for a 
DNA duplex substrate, we decided to perform our EMSA experiments with two 
substrates carrying a 3-nucleotide mismatch (S5 and S6, with S5 carrying a lesion-
mimicking molecule at the centre of the bubble, similarly to S3) in case the 18-nucleotide 
bubble had been too big to be identified by XPC as a mismatch. This assay showed that 
XPC-HR23B bound to both S5 and S6 with an affinity that was higher than that obtained 
for the duplex S2, and similar to each other, suggesting that the presence of lesion did 
not increase XPC’s binding affinity. Even more interestingly, the assay hinted the 
possibility that two XPC were bound to substrates S5 and S6, but not to S2, at higher 
concentrations of the heterodimer. Our bulk FRET experiments with substrates S7 and 
S8 (equivalent to S5, with S7 carrying a Cy3 dye to the left of the bubble and S8 carrying 
it to the right) confirmed that binding KD of XPC-HR23B is in the nM range and similar to 
the KD obtained for the binding of monomeric XPC to the substrates carrying an 18-
nucleotide bubble. They also confirmed the binding of two XPC molecules to substrates 
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S7 and S8, as seen for substrates S5 and S6 in our EMSA assay, with binding of the 
second XPC molecule aided by the binding of the first XPC and the structure of our 
substrates altered due to the binding of the protein, which seems to be positioned closer 
to the Cy3 dye in substrate S8 than in S7. Addition of the TFIIH Core sub-complex did 
not alter XPC’s binding.  
 
The TFIIH complex is composed of the 3-subunit CAK sub-complex and the 7-subunit 
TFIIH Core sub-complex. While all ten subunits are required in transcription, only TFIIH 
Core participates in NER (Svejstrup et al., 1995), and the binding of repair factor XPA 
will promote the removal of the CAK sub-complex (Coin et al., 2008) to eliminate its 
inhibitory action on XPD’s helicase activity (Sandrock & Egly, 2001). As our main interest 
in TFIIH focuses on its role as a repair factor, we initially aimed to clone the Core sub-
complex on its own. For this purpose, a short and versatile purification tag (including a 
6-residue His tag, a V5 epitope and a TEV cleavage site) was designed and cloned into 
several TFIIH Core subunits. Different combinations of tagged subunits were assembled 
using the multiplication module present in the MultiBacTM plasmids, which allowed the 
cloning of different multi-gene constructs (Bieniossek et al., 2013) that were analysed for 
expression in Sf9 insect cells. Infections for the successful constructs were scaled-up 
and a variety of chromatographic steps, buffers and conditions were tested until an easily 
reproducible three-step protocol (consisting of an IMAC step, a size exclusion step and 
a final cation exchange chromatography) was standardized. This protocol yielded up to 
1 mg of a pure TFIIH Core sub-complex (with subunits p62 and p52 carrying the 6xHis-
V5-TEV tag at their N-terminal end, simply referred to as TFIIH Core in this thesis) for 
every 2 L culture. Unfortunately, most of the XPD helicase was lost along the purification 
process, although its presence was confirmed by MS first and later by crosslinking 
assays that showed a tightly connected structure. Fluorescence anisotropy experiments 
performed with this construct confirmed that the TFIIH Core sub-complex can bind a 
dsDNA substrate with an affinity in the low nM range, and the presence of a lesion or a 
mismatch at the substrate did not alter that affinity significantly. These results were 
further supported by bulk FRET experiments, which also showed that the structure of the 
substrate was not altered by the binding of the sub-complex (further experiments are 
required to confirm this observation). 
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Attempts to increase the yield of XPD in our samples included the modification of our 
purification tag, increasing the number of His residues and introducing a spacer between 
the V5 epitope and the TEV cleavage site (8xHis-V5-spacer-TEV), the designing of a 
new, C-terminal tag exclusively for XPD (TEV-10xHis-V5), and the cloning and 
expression of the helicase individually to subsequently be combined with the a 6-subunit 
TFIIH Core construct. We also attempted the cloning and expression of the CAK sub-
complex, to later obtain the complete 10-subunit TFIIH complex in a co-infection 
experiment with a CAK- and a TFIIH Core-recombinant viruses, as a means to stabilize 
XPD within the Core sub-complex. Unfortunately, none of these approaches succeeded 
to improve the recovery of XPD; neither did a purification in anaerobic conditions or 
addition of different detergents to our extraction and purification buffers. The combined 
use of a Strep-Tactin®XT Superflow® resin with an affinity in the pM range for a matching 
Twin-Strep-tag®-encoding sequence cloned into XPD finally solved these issues and 
allowed us to obtain the helicase, and a TFIIH Core sub-complex in which subunits p62 
and p52 carrying the N-terminal 6xHis-V5-TEV tag and XPD carried a C-terminal Twin-
Strep-tag® (referred to as XPD-enriched TFIIH Core in this thesis) was purified following 
a protocol that included an ion affinity, a size exclusion and a Streptavidin affinity 
chromatography steps, with all seven subunits obtained in stoichiometric amounts. This 
construct was tested for binding to two dsDNA substrates carrying a 3-nucleotide bubble 
(one of them carrying a lesion-mimicking fluorescein molecule at the centre of the bubble 
(S5) and the other one carrying the probe at its 5’ end) in fluorescence anisotropy assays, 
showing an affinity only slightly higher than that observed for the binding of TFIIH Core 
to the same substrates. This suggests a possible passive role of XPD in the binding of 
the complex to DNA, although a more thorough investigation is required to confirm this 
point. The study of the unwinding activity of this sub-complex in fluorescence-based 
helicase assays showed that TFIIH Core can only open a substrate when a 5’ overhang 
end is available, and a preference for a substrate with a majority of purine bases in the 
translocating strand was further observed. Unwinding was dependent on TFIIH Core and 
ATP concentration in the reaction, but changes in temperature within a range of 25 °C – 
37 °C did not affect the opening of the substrate significantly, nor did the addition of the 
RPA and XPA repair factors. Lastly, our assays showed that the helicase activity of the 
TFIIH Core sub-complex was greatly reduced by a lesion-mimicking fluorescein 
molecule located in either the translocating or the non-translocating strands.  
                                                       CONCLUSIONS AND FURTHER WORK 
 
   181 
6.2. Conclusions 
This thesis described the development and optimization of a protocol for the cloning and 
expression of the ~ 500 kDa, 10-subunit TFIIH complex, and damage-detector XPC-
HR23B, following an efficient and simplified method and aided by powerful molecular 
biology tools. Both complex and heterodimer were cloned using the multiplication module 
present in the plasmids that integrate the MultiBacTM system, a BEV conceived for the 
production of multi-subunit eukaryotic complexes, with every individual subunit 
expressed in equimolar amounts (Berger et al., 2004).  
 
The design of the synthetic genes for subunits p52 and p8, p44 and p34 and cdk7 and 
cyclin H as single units, with each pair of genes separated by an autocleavable 2A-like 
peptide (Luke et al., 2009) (with an observed cleaving efficiency of approximately 90%) 
further simplified the cloning of the TFIIH complex by reducing the number of steps 
required to assemble the desired multi-gene construct.  
 
Purification of the complex was assisted by the introduction of the multi-function 6xHis-
V5-TEV tag (developed and successfully tested in our lab in a variety of constructs using 
both bacteria and insect cells as an expression system) into several Core subunits. 
Moreover, the versatility of the MultiBacTM system allowed the quick assembly of new, 
different multi-gene constructs by relocating the tag within the sub-complex without 
requiring the cloning of the whole complex de novo by using intermediate constructs 
obtained in previous cloning processes.  
 
Our most successful purification was achieved with a TFIIH Core sub-complex in which 
subunits p52 and p62 carried the 6xHis-V5-TEV tag at their N-terminal end, obtaining up 
to 1 mg of pure sub-complex from a 2 L culture after a 3-step protocol consisting of an 
IMAC, a size exclusion and a cation exchange chromatography. This yield was higher 
than any reported result until the publication of the work by the Yang group (Li et al., 
2015) two years after the start of this project. The obtaining of the TFIIH Core sub-
complex was further optimised to improve the recovery of helicase XPD, finally agreeing 
on a 3-step IMAC – size exclusion – streptavidin affinity chromatography purification 
protocol for a TFIIH Core sub-complex in which subunits p52 and p62 still carried the N-
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terminal 6xHis-V5-TEV tag and subunit XPD carried a C-terminal Twin-Strep-tag®.  
 
Analysis of the binding of monomeric XPC and heterodimeric XPC-HR23B to a variety 
of dsDNA substrates in EMSA, fluorescence anisotropy and bulk FRET assays led us to 
conclude that XPC binds preferentially to substrates carrying a mismatch, with an affinity 
in the low nM range. However, neither the size of that mismatch (18-nucleotide or 3-
nucleotide bubbles) nor the additional presence of a lesion at the bubble altered this 
binding affinity. The presence of partner HR23B in the sample didn’t increase the binding 
affinity of XPC either. Our bulk FRET experiments suggest that two molecules of XPC 
can bind a duplex substrate carrying a 3-nucleotide mismatch and a lesion-like 
fluorescein molecule at the centre of the bubble with high cooperativity, and this binding 
is able to change the conformation of our substrate. Addition of the TFIIH Core sub-
complex to this reaction did not alter the binding. Unfortunately, the experiments so far 
performed with both monomeric XPC and HR23B-XPC were severely limited by the 
amount of pure protein/heterodimer obtained in our purifications, and a more thorough 
research will be needed to confirm our preliminary observations.  
 
We also tested the TFIIH Core sub-complex for binding to the same range of substrates 
tested with XPC and XPC-HR23B in EMSA, fluorescence anisotropy and bulk FRET 
assays. Our research revealed that the sub-complex binds to duplex DNA with an affinity 
in the nM range; compared to the binding affinity observed for XPC, TFIIH Core binds to 
a duplex carrying a lesion-like fluorescein molecule at the centre of its sequence with an 
affinity at least three times lower. The presence of damage or a mismatch at the 
substrate did not alter the sub-complex binding affinity, and KD values obtained for an 
undamaged duplex and substrates carrying an 18-nucleotide bubble were similar for 
both the sub-complex and damage detector XPC. Bulk FRET assays further supported 
these observations, and also suggested that the binding of the sub-complex did not alter 
the structure of the substrates (further experiments are required to confirm this last 
observation).  
 
The unwinding activity of TFIIH Core was evaluated in a fluorescence-based helicase 
assay that confirmed that the sub-complex can only open a substrate when a 5’ overhang 
end (but not a 3’ end) is available. The opening of a splayed duplex substrate was 
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observed to be dependent on both TFIIH Core and ATP concentration, but it was not 
significantly altered by changes in temperature within a range of 25 °C – 37 °C. Addition 
of repair factors XPA and RPA did not modify the unwinding activity of the sub-complex 
either. Lastly, analysis of the opening of two splayed duplexes carrying a fluorescein 
molecule mimicking a bulky adduct in either the translocating or the non-translocating 
strand revealed that both lesions can successfully stall helicase XPD, showing a 
considerably reduced opening of the substrates compared to opening of the undamaged 
splayed duplex.  
 
6.3. Future work 
The results obtained in the course of this PhD offer interesting and challenging 
perspectives for the future of the project. A pressing issue to tackle is the low expression 
observed in our XPC-HR23B infections and consequent reduced yield in our 
purifications. A possible solution to this problem is the change of expression strain, from 
our current Sf9 cells to High FiveTM insect cells, which reportedly offer 5- to 10-fold higher 
expression in the case of secreted heterologous protein. This change will also require 
the optimization of our expression and purification protocols, adapting them to the 
amount of heterodimer obtained from our High FiveTM infections. The cloning of a gene 
encoding XPC’s partner HR23B into our TCP-tagged monomeric XPC will also be 
required before continuing our anisotropy and FRET assays with this construct.  
 
The publication of the cryoEM structure of TFIIH Core as part of the PIC complex 
(Schilbach et al., 2017) offered new, unprecedent insights about the sub-complex which, 
together with the structure of XPC’s yeast homologue (Min & Pavletich, 2007), allowed 
our group to develop a model describing the potential unravelling of the repair reaction 
at its initial stages (figures 104 and 105). A similar model, although offering less detail 
regarding the role of XPB, has very recently been published by the Schärer group (Mu 
et al.,  2018). 
 





Figure 104: Unravelling the repair bubble.  
Structures of TFIIH Core (5OQJ, (Schilbach et al., 2017)) and XPC (2QSG, (Min & Pavletich, 
2007)) engaged in a damaged dsDNA substrate are here brought together to model the initiation 
of NER. XPC’s interacting domain with subunit p62 is missing from the structure, but it will 
potentially extend towards the PH domain of p62. XPC locks XPB in place; as the enzyme will try 
to translocate in the 3’ to 5’ direction, the bubble will be extended until ssDNA is engaged by XPD, 
which will finally unwind the DNA to allow subsequent repair factors access to the lesion.  
 
Our group already possesses many of the tools that would allow the experimental 
validation of the theoretical model described in figures 104 and 105. We already have 
not only a TCP-tagged monomeric XPC, but also a TCP-tagged TFIIH Core sub-
complex, which have been successfully labelled in our lab. Both TCP-tagged XPC and 
TFIIH Core could be employed in fluorescence anisotropy and FRET assays with 
unmodified and mismatched duplex substrates to further characterize the binding of XPC 
and TFIIH Core. In this sense, it would be very interesting to continue our study of the 
binding of TFIIH Core to a DNA-bound XPC-HR23B complex, ideally using a 
cisplatinated substrate, as this lesion is one of the natural targets of NER. Single 
molecule experiments such as TIRF and FCS would further help us characterize this 
binding and the changes undergone by the substrate as a consequence of it. 
Fluorescence-based and radioactive helicase activity assays performed with the 
cisplatinated substrate would also help us to advance in our characterization of the 
unwinding activity of the TFIIH Core sub-complex, particularly in the study of the ability 
of a lesion located in the non-translocating strand to stall helicase XPD almost as 
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efficiently as a lesion located in the translocating strand. Ideally, these studies would 
lead to the observation and characterization of the changes taking place in a damaged 
substrate as a full repair reaction takes place, including mismatch-detection and DNA 
binding by XPC-HR23B, substrate-opening and potential damage verification by TFIIH 
Core, reorganization of the bubble caused by addition of XPA and RPA and 5’ damaged 
strand nicking by endonuclease XPF (our lab already has access to all these factors). A 
very interesting complement to this research would be to investigate the effect on DNA 
binding and unwinding of TFIIH Core mutant variants affecting the Walker A domain 
(XPD K46R (Coin et al., 1998) and XPB K346R (Tirode et al., 1999)) and affecting XPD’s 
DNA binding pocket (XPD Y192A and XPD K196R (Mathieu et al., 2013)) (cloning of 




Figure 105: Hypothetical model describing the first stages of a GGR reaction.  
The distortion caused in the DNA by the appearance of a lesion (1) will be detected by XPC, 
which will bind to the damaged site (2) and will recruit the TFIIH complex through interactions with 
subunits p62 and XPB (3). TFIIH subunit XPB will now engage dsDNA (4) and translocate in the 
3’ to 5’ direction in an ATP-dependent manner, but as the enzyme is locked by XPC this will cause 
an initial opening of the bubble, with XPB spooling DNA towards XPC (5). The spooled ssDNA 
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4FeS domains opens temporarily to allow ssDNA to pass through the channel formed by Arch, 
4FeS and HD1 (Constantinescu-Aruxandei et al., 2016). ssDNA is finally engaged by XPD’s HD1, 
and the helicase will unwind the dsDNA until it becomes stalled by the lesion, potentially acting 
as a damage-verification factor (Sugasawa et al., 2009) (Li et al., 2015).
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APPENDIX A: Synthetic gene sequences 

































































  APPENDIX A  
 






































































  APPENDIX A  
 







































































  APPENDIX A  
 






































































  APPENDIX A  
 
   213 





































































  APPENDIX A  
 
















                     APPENDIX B 
 
   217 
APPENDIX B: Plasmids and bacmids 
Table B1: Plasmids employed in the cloning of the different TFIIH constructs described 
in this thesis. Purification tags (highlighted in red) are indicated in brackets before the 
subunit they were attached to. 

































Subunit XPD (tagged with N-terminal 8xHis-V5-spacer-TEV) 
pACEBac2-(8xHis)XPD 











Subunit XPD (tagged with C-terminal TEV-10xHis-V5) 
pACEBac2-(10xHis)XPD 













Sub-complex TFIIH Core (subunits p52, XPD tagged with N-terminal 6xHis-V5-
TEV and subunit XPD tagged with a C-terminal Twin-Strep-tag®) 
pACEBac2-(6xHis)p52-F2A-p8 
pACEBac2-p44-T2A-p34 
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Monomeric XPC (tagged with N-terminal 8xHis-V5-spacer-TEV) 
pACEBac2-(8xHis)XPC 




Monomeric XPC (tagged with N-terminal 8xHis-V5-spacer-TEV, TCP) 
pACEBac2-(8xHis)(TCP)XPC 
Sub-complex TFIIH Core (subunits p52, p62 tagged with N-terminal 6xHis-V5-






















Table B2: Recombinant bacmids employed to transfect Sf9 insect cells for the 
expression of the different proteins, complexes and sub-complexes described in this 
thesis. Purification tags (highlighted in red) are indicated in brackets before the subunit 




Bacmid Genes transposed  
TFIIH Core AcMNPV (6xHis)p52-F2A-p8-p44-T2A-p34-p62-XPB-(6xHis)XPD 
TFIIH Core AcMNPV (6xHis)p52-F2A-p8-p44-T2A-p34-(6xHis)p62-XPB-XPD 
TFIIH Core AcMNPV (8xHis)p52-F2A-p8-p44-T2A-p34-p62-XPB 
TFIIH Core AcMNPV (8xHis)p52-F2A-p8-p44-T2A-p34-p62-XPB-(8xHis)XPD 





XPD AcMNPV (8xHis)XPD 
XPD AcMNPV (10xHis)XPD 
CAK AcMNPV (8xHis)MAT1-cdk7-T2A-cyclin H 
CAK AcMNPV MAT1-(8xHis)cdk7-T2A-cyclin H 
CAK AcMNPV (8xHis)MAT1-(8xHis)cdk7-T2A-cyclin H 
XPC AcMNPV (8xHis)XPD 
XPC AcMNPV (8xHis)(TCP)XPC 
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APPENDIX C: PCR oligonucleotides 
Table C1: TFIIH Core sub-complex PCR primers   
Oligonucleotide Sequence 5' to 3' 
XPD Fwd TACATGCGGGAGCTCAAACGC 
XPD Rev TCTGCTCTATCCTCTTCAGC 
XPB Fwd GGCCATATCTTCTTGGAAGC 
XPB Rev GCCAGGACTTTCTGTAAGAGC 
p62 Fwd CCTCATCTGAAGTTTTGC 
p62 Rev CGTTTTCTTCATCAGACGCCG 
p52-p8 Fwd GGATCTGGCACACACAGCTGC 
p52-p8 Rev CTTGAATGATGAACTTCTTCC 
p44-p34 Fwd TTAGAGTATCTGTTATTGG 
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APPENDIX D: DNA substrates 
Table D1: Oligonucleotides used in this thesis 


































Table D2: DNA substrates used in this thesis  
Substrate Constituent oligonucleotides 
S1 A, C 
S2 B, C 
S3 A, D 
S4 B, D 
S5 A, E 
S6 B, E 
S7 A, F 
S8 A, G 
SD SD-Dab, SD-Cy3 
SD13 SD1, SD3 
SD24 SD2, SD4 
XPD12 XPD1, XPD2 
XPD34 XPD3, XPD4 
REV12 REV1, REV2 
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